[{"text": "What Are Analysts Talking About Cytokinetics (CYTK)? Jabran Kundi Tue, Jan 28, 2025, 12:50 AM 3 min read In This Article: CYTK -2.01% We recently published a list of 10 Stocks That Analysts Are Talking About . In this article, we are going to take a look at where Cytokinetics, Incorporated (NASDAQ:CYTK) stands against other stocks that analysts are talking about. Like any other informed investor, we are always on the hunt for stocks that analysts are talking about. Analysts use their in-depth research expertise, industry knowledge, and industry connections to figure out how well companies are doing every quarter. Once they stumble upon something that could change the course of that company\u2019s stock, they come out with analyst updates. These are usually in the form of an upgrade or downgrade, or simply an update on a previously assigned rating. For retail investors, going through these reports saves a lot of time. This is why we came up with 10 stocks that analysts are talking about this week. To come up with the list of 10 stocks that analysts are talking about, we considered companies that received an analyst upgrade or coverage in the last 5 days. Are Analysts Talking About Cytokinetics Incorporated (CYTK)? A lab technician using a microscope to examine the biopharmaceutical company's molecules. Cytokinetics, Incorporated (NASDAQ:CYTK) Cytokinetics, Incorporated (NASDAQ:CYTK) is a late-stage pharmaceutical company committed to developing, commercializing, and discovering inhibitors and muscle activators. The financial research firm Stifel started analyst coverage of CYTK with a Buy rating due to its new promising drug, aficamten, promising an exciting couple of years ahead. According to Stifel, aficamten is an extraordinary drug with a high competitive bar. Even outside the US, the drug is set to bring in millions of dollars of revenue for the company. In December, one of the company\u2019s partners transferred the rights for the drug in China, Taiwan, and Hong Kong to Sanofi. Cytokinetics (NASDAQ:CYTK) is set to receive $150 million in a one-time payment and somewhere between $10-$20 million in sales. In Japan, the company has struck a similar deal with Bayer. In this way, Cytokinetics (NASDAQ:CYTK)can now focus on marketing the drug in the US while leaving its international operations to companies that have a better global presence. The stock is down 43% in the last year, though that has a lot to do with Novartis walking away from an M&A deal. Apart from the promise of aficamten, new M&A activity cannot be ruled out and forms one of the components of Stifel\u2019s bullish thesis on the stock. Overall, CYTK ranks 10th on our list of stocks that analysts are talking about. While we acknowledge the potential of CYTK as a leading AI investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns, and doing so within a shorter time frame. If you are looking for an AI stock that is as promising as CYTK but that trades at less than 5 times its earnings, check out our report about the cheapest AI stock . Story Continues READ NEXT: 20 Best AI Stocks To Buy Now and Complete List of 59 AI Companies Under $2 Billion in Market Cap Disclosure: None. This article is originally published at Insider Monkey . View Comments Terms and Privacy Policy Privacy Dashboard Recommended Stories", "symbol": "CYTK", "date": "2025-01-27T21:50:38+00:00", "sentiment": {"score": 0.1460300013422966, "confidence": 0.15797802805900574, "probabilities": {"positive": 0.15797802805900574, "negative": 0.011948026716709137, "neutral": 0.8300739526748657}}, "embedding": [-0.13155172765254974, -0.07831592857837677, -0.04959690198302269, -0.05133461579680443, -0.014091912657022476, 0.01422511413693428, 0.049555689096450806, 0.27374035120010376, 0.1349761039018631, 0.05108002573251724, -0.09728871285915375, 0.07591774314641953, 0.07507208734750748, 0.029711853712797165, -0.12842805683612823, 0.021483656018972397, 0.09393319487571716, 0.12859569489955902, -0.10202844440937042, -0.020202547311782837, -0.16930736601352692, -0.08312959969043732, 0.08390579372644424, 0.025462143123149872, 0.0585859939455986, 0.019818846136331558, -0.07095810770988464, -0.05147567763924599, -0.2047576606273651, 0.06575863808393478, -0.08945836126804352, 0.18720073997974396, 0.1415417641401291, 0.0197991244494915, -0.06121106445789337, 0.024926181882619858, -0.11783833801746368, 0.06387938559055328, 0.04639647901058197, 0.0232484620064497, 0.035048216581344604, 0.0016079312190413475, -0.12045326828956604, 0.06940877437591553, 0.08509582281112671, -0.026220383122563362, 0.028510339558124542, 0.009912588633596897, -0.010407526046037674, 0.016665440052747726, -0.1852957010269165, -0.14143119752407074, 0.047136057168245316, 0.06180447340011597, -0.061407677829265594, -0.005692627746611834, -0.2445085644721985, -0.003812869545072317, 0.06826625764369965, 0.04191601276397705, 0.029200777411460876, 0.024449415504932404, 0.057729918509721756, 0.07150176167488098, 0.1527823507785797, -0.003441559849306941, -0.07523252069950104, 0.10580375045537949, 0.021321671083569527, -0.0563165619969368, 0.033945247530937195, -0.10127099603414536, -0.06210974603891373, 0.09014441072940826, -0.17319734394550323, 0.13559851050376892, 0.14200221002101898, 0.12434697151184082, 0.0736510381102562, -0.16805410385131836, 0.1275569200515747, -0.0371674969792366, 0.12125587463378906, -0.061134856194257736, -0.05299212038516998, -0.04851735383272171, 0.014145726338028908, 0.14523887634277344, 0.022898489609360695, 0.11230279505252838, 0.10544247925281525, 0.047805555164813995, 0.03882565721869469, -0.043438997119665146, -0.0029155798256397247, -0.03531841188669205, -0.08623038977384567, 0.04727082699537277, 0.036073967814445496, 0.07710219919681549, 0.06070827692747116, 0.06680427491664886, 0.0012027602642774582, -0.030224034562706947, -0.15836599469184875, -0.20321115851402283, 0.0391998365521431, -0.08871980756521225, 0.08591820299625397, 0.06284715235233307, -0.13454905152320862, 0.026676911860704422, -0.1902480572462082, -0.056734271347522736, -0.08027424663305283, 0.20042452216148376, 0.023525530472397804, 0.055809058248996735, 0.13210433721542358, 0.047186464071273804, 0.08398336917161942, -0.04594258591532707, -0.006461838260293007, -0.0768282413482666, 0.024422768503427505, 0.18852022290229797, -0.21601562201976776, 7.627997370204849e-33, -0.09721632301807404, 0.03952312842011452, 0.11697667837142944, 0.027388088405132294, -0.15050610899925232, -0.031215505674481392, 0.09501439332962036, -0.07570339739322662, 0.0047986991703510284, -0.11215537786483765, -0.11982974410057068, 0.1480773687362671, -0.017066355794668198, 0.029905827715992928, -0.02195294015109539, -0.05298679322004318, -0.14013805985450745, 0.013077013194561005, -0.005541060585528612, -0.0901193767786026, 0.03623905032873154, 0.028568925336003304, -0.09353634715080261, 0.0490371473133564, -0.050019025802612305, -0.08334324508905411, -0.02025061845779419, 0.014083633199334145, -0.03684080019593239, 0.044177647680044174, -0.11452740430831909, 0.036939527839422226, -0.004727987572550774, -0.029203670099377632, -0.007112053222954273, -0.08096277713775635, -0.03314259648323059, -0.17163580656051636, 0.11768291890621185, -0.03239654749631882, -0.16262884438037872, -0.12295427918434143, -0.0744888037443161, -0.07887326180934906, 0.06611369550228119, 0.03382062911987305, -0.2750003933906555, -0.0500970296561718, -0.0502033606171608, -0.03264772891998291, 0.0051645999774336815, 0.05472015589475632, 0.007115826476365328, -0.05722074955701828, 0.021060561761260033, 0.14684107899665833, -0.04563130438327789, -0.13829654455184937, -0.017609890550374985, 0.0937047153711319, -0.03601555526256561, 0.0703551396727562, -0.058069273829460144, 0.059487003833055496, -0.1231188029050827, 0.21602463722229004, -0.14675691723823547, 0.02628181502223015, -0.1357574313879013, 0.2292184978723526, 0.004975436255335808, -0.030646830797195435, 0.1593591570854187, -0.02919573336839676, 0.12434285879135132, -0.03252386301755905, -0.09292814135551453, 0.14856429398059845, -0.0880051851272583, 0.04138369858264923, 0.07662522047758102, -0.08143243938684464, -0.07108793407678604, 0.023411404341459274, 0.03169437497854233, -0.087538942694664, 0.020529281347990036, 0.013343972153961658, -0.04644398391246796, -0.023850079625844955, 0.07389210164546967, -0.07181128859519958, -0.11421692371368408, 0.21956875920295715, -0.028704114258289337, -8.902339040987782e-33, -0.10894756764173508, 0.04726845398545265, -0.08276300877332687, -0.020916268229484558, -0.018696635961532593, 0.028744522482156754, 0.045588161796331406, -0.049792006611824036, 0.0826592892408371, -0.04974950850009918, -0.03531219810247421, -0.026288561522960663, -0.07429231703281403, 0.04101463779807091, -0.1499989628791809, 0.018553150817751884, 0.02583710476756096, -0.030213359743356705, -0.12076748162508011, 0.02251073718070984, 0.0504031777381897, 0.02201138064265251, -0.05228827893733978, 0.08316096663475037, 0.07310198247432709, 0.07177771627902985, 0.039166465401649475, 0.121905118227005, 0.036295581609010696, 0.008531888946890831, -0.10860571265220642, -0.01045336201786995, -0.13499759137630463, 0.056468263268470764, 0.07651366293430328, 0.011115510016679764, 0.03047298640012741, -0.22349193692207336, -0.0019329283386468887, -0.06814226508140564, 0.0044596134684979916, -0.09378276020288467, 0.010141415521502495, 0.04712437838315964, 0.07969525456428528, 0.07356539368629456, 0.08092588186264038, -0.0054930755868554115, 0.10359899699687958, 0.01826321892440319, 0.05717288702726364, 0.12388505786657333, 0.09808829426765442, 0.11480690538883209, -0.15112903714179993, 0.09510832279920578, 0.06251539289951324, 0.03441493213176727, -0.020216066390275955, 0.031203290447592735, 0.0915345549583435, -0.008685294538736343, 0.07026846706867218, 0.022065313532948494, -0.0014582611620426178, -0.013875845819711685, 0.10871396958827972, 0.09510762989521027, 0.02676713839173317, -0.05070515722036362, 0.0578477680683136, -0.08131582289934158, 0.027716241776943207, -0.09220965206623077, -0.009021937847137451, 0.12518006563186646, -0.005326629616320133, -0.14902612566947937, -0.155252605676651, -0.025016291067004204, 0.02115851826965809, -0.025526495650410652, 0.07323767989873886, 0.039388224482536316, 0.010784728452563286, -0.04170466214418411, 0.029872272163629532, 0.09021280705928802, 0.011974268592894077, -0.06293828040361404, -0.018619995564222336, -0.14221185445785522, -0.11729881912469864, 0.1302044540643692, 0.036936987191438675, -1.0042429465784153e-07, 0.06046072021126747, -0.1104162186384201, -0.027257706969976425, -0.10727973282337189, 0.19472602009773254, -0.1469893455505371, -0.08426012098789215, 0.016915950924158096, 0.03333207219839096, 0.08179878443479538, 0.08266354352235794, 0.11668495833873749, -0.15525448322296143, 0.044196173548698425, -0.0041422294452786446, 0.0039166659116744995, -0.10072925686836243, 0.0006441730074584484, -0.006268897093832493, 0.047301944345235825, -0.020990723744034767, 0.07327333837747574, 0.003757212311029434, -0.026831358671188354, 0.03859291970729828, -0.09198078513145447, -0.07745606452226639, 0.0617775022983551, 0.030703432857990265, -0.012894339859485626, 0.02661941945552826, 0.04227849841117859, 0.09313813596963882, 0.049342140555381775, -0.1356762796640396, 0.006719037890434265, 0.04889136925339699, -0.011316562071442604, 0.003672072198241949, 0.06336130946874619, -0.1834416687488556, -0.1005159318447113, 0.007437040098011494, 0.05628824234008789, -0.044737376272678375, -0.07690903544425964, -0.129482701420784, 0.01551549881696701, 0.12642985582351685, -0.15624189376831055, 0.00469829561188817, 0.013416018337011337, -0.04926586151123047, -0.04665295407176018, 0.01493777334690094, 0.07440818846225739, -0.07510567456483841, -0.06349129974842072, -0.07898148894309998, -0.07595989108085632, -0.0707327276468277, -0.1814827024936676, 0.1718810498714447, 0.18284495174884796], "changes": {"1wk": -2.9435271254085964}}, {"text": "CYTK Stock Rises as Enrollment Begins in Phase II Heart Failure Study Zacks Equity Research Thu, Jan 23, 2025, 7:19 PM 4 min read In This Article: CYTK -2.01% Shares of Cytokinetics CYTK gained 2.2% on Wednesday after the company began enrolling patients in its mid-stage study of CK-4021586 (CK-586), a cardiac myosin inhibitor, for treating heart failure patients. The intended patient population includes those with symptomatic heart failure with preserved ejection fraction (HFpEF) with left ventricular ejection fraction (LVEF) \u226560%. The primary goal of the phase II AMBER-HFpEF study is to evaluate the safety and tolerability profile of CK-586 compared to placebo in HFpEF patients. As secondary objectives, the study will also assess the effect of CK-586 on LVEF and NT-proBNP, and determine the candidate\u2019s pharmacokinetics\u00a0and pharmacokinetic/pharmacodynamic relationship. Other exploratory endpoints of the study include evaluating the effect of CK-586 on patient function, symptoms and measures of cardiac function. Cytokinetics plans to enroll approximately 60 HFpEF patients in the phase II AMBER-HFpEF study who will receive CK-586 or placebo in three dose escalation cohorts. In the past three months, CYTK shares have lost 10.6% compared with the industry\u2019s 8.7% decline. Zacks Investment Research Image Source: Zacks Investment Research CYTK\u2019s Other Pipeline Developmental Programs Cytokinetics is developing its lead investigational candidate, aficamten, a novel, oral and small-molecule cardiac myosin inhibitor, to reduce the hypercontractility associated with\u00a0hypertrophic cardiomyopathy (HCM). A regulatory filing for aficamten to treat obstructive HCM is currently under review by the FDA. A final decision from the regulatory body is expected on Sept. 26, 2025. The FDA also informed the company that it is not planning to hold an advisory committee meeting to discuss the application. Similar regulatory filings seeking approval for aficamten to treat obstructive HCM are also currently under review in other geographies, including the EU. Cytokinetics is also evaluating aficamten monotherapy in its phase III MAPLE-HCM study compared to metoprolol monotherapy in patients with obstructive HCM (enrollment completed) and ACACIA-HCM, a phase III study of aficamten in patients with non-obstructive HCM (enrolment ongoing). Other studies include CEDAR-HCM, a clinical study of aficamten in a pediatric population with obstructive HCM. Enrollment is ongoing in CEDAR-HCM. Another pipeline candidate is omecamtiv mecarbil, a cardiac muscle activator, which is being developed for patients with heart failure. Last month, Cytokinetics initiated COMET-HF, a confirmatory phase III study to assess the efficacy and safety of the candidate in patients with symptomatic heart failure with severely reduced ejection fraction. Story Continues Cytokinetics, Incorporated Price and Consensus Cytokinetics, Incorporated Price and Consensus Cytokinetics, Incorporated price-consensus-chart | Cytokinetics, Incorporated Quote CYTK\u2019 Zacks Rank & Stocks to Consider Cytokinetics currently carries a Zacks Rank #3 (Hold). Some better-ranked stocks from the sector are Castle Biosciences CSTL, BioMarin Pharmaceutical BMRN and CytomX Therapeutics CTMX. While CSTL and BMRN currently sport a Zacks Rank #1 (Strong Buy) each, CTMX carries a Zacks Rank #2 (Buy) at present. You can see the complete list of today\u2019s Zacks #1 Rank stocks here . In the past 30 days, Castle Biosciences\u2019 earnings estimates for 2024 have increased from 34 cents to 39 cents per share. During the same timeframe, loss per share for 2025 has remained constant at $1.84. In the past three months, shares of Castle Biosciences have plunged 16.3%. CSTL\u2019s earnings beat estimates in each of the trailing four quarters, delivering an average surprise of 172.72%. In the past 30 days, estimates for BioMarin Pharmaceutical\u2019s 2024 earnings per share have Improved from $3.28 to $3.29. Estimates for 2025 earnings per share have decreased from $4.05 to $4.02 during the same timeframe. In the past three months, BioMarin Pharmaceutical shares have lost 11.9%. BMRN\u2019s earnings beat estimates in each of the trailing four quarters, delivering an average surprise of 28.7%. In the past 30 days, estimates for CytomX Therapeutics\u2019 2024 loss per share have remained constant at 5 cents. Estimates for 2025 loss per share have remained constant at 35 cents during the same timeframe. In the past three months, shares of CytomX Therapeutics have lost 22.4%. CTMX\u2019s earnings beat estimates in two of the trailing four quarters and missed the mark in the other two, delivering an average surprise of 115.70%. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report BioMarin Pharmaceutical Inc. (BMRN) : Free Stock Analysis Report Cytokinetics, Incorporated (CYTK) : Free Stock Analysis Report CytomX Therapeutics, Inc. (CTMX) : Free Stock Analysis Report Castle Biosciences, Inc. (CSTL) : Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research View Comments Terms and Privacy Policy Privacy Dashboard Recommended Stories", "symbol": "CYTK", "date": "2025-01-23T16:19:00+00:00", "sentiment": {"score": 0.4275383949279785, "confidence": 0.5761318206787109, "probabilities": {"positive": 0.5761318206787109, "negative": 0.14859342575073242, "neutral": 0.27527475357055664}}, "embedding": [-0.06593118607997894, -0.04532856494188309, -0.010380471125245094, -0.07221843302249908, 0.017437588423490524, -0.034834641963243484, -0.146497905254364, 0.30026185512542725, 0.0770333856344223, -0.005706056021153927, -0.04951607808470726, -0.016365280374884605, 0.09657905995845795, 0.033622317016124725, -0.035750146955251694, -0.03081287257373333, 0.11760632693767548, 0.13099542260169983, -0.13457977771759033, 0.11533640325069427, -0.05721329152584076, -0.009046501480042934, 0.037791356444358826, 0.08616189658641815, -0.12076733261346817, 0.015560832805931568, -0.174166738986969, 0.03404688835144043, -0.13032229244709015, 0.043732430785894394, 0.00886203721165657, 0.10509276390075684, 0.09077562391757965, 0.09399862587451935, 0.02204795368015766, 0.05845009535551071, -0.14523369073867798, -0.046862080693244934, -0.1749987006187439, -0.03821524977684021, 0.025075599551200867, -0.07257198542356491, -0.13611473143100739, 0.05940622091293335, 0.18960775434970856, -0.06370677798986435, -0.07412727177143097, 0.003447785973548889, -0.0963391661643982, 0.17091865837574005, -0.1243855208158493, -0.03970174863934517, 0.04347006231546402, 0.1468888819217682, -0.07264341413974762, -0.009760403074324131, -0.28255078196525574, -0.031876809895038605, 0.10371999442577362, 0.004426200874149799, -0.10241873562335968, 0.048464298248291016, -0.060138039290905, -0.035731032490730286, 0.09842464327812195, 0.025785785168409348, -0.037246670573949814, 0.012669207528233528, 0.04974669963121414, -0.03930013254284859, 0.0655876025557518, -0.13425037264823914, -0.05299726128578186, 0.11855369061231613, -0.0160366240888834, 0.14237472414970398, 0.0909212976694107, 0.05004020780324936, -0.033659979701042175, -0.2263716459274292, 0.0912792906165123, 0.042336881160736084, 0.030313873663544655, 0.0008550863713026047, -0.04975200444459915, 0.037051185965538025, 0.013793842867016792, 0.1717321127653122, -0.03014529123902321, 0.08496399223804474, 0.18811042606830597, 0.08097457885742188, 0.0705505833029747, -0.027226123958826065, 0.048887647688388824, -0.05638926848769188, -0.05096288025379181, 0.07673698663711548, 0.008976318873465061, -0.020173553377389908, 0.09279847145080566, 0.018166808411478996, -0.15857450664043427, -0.147507905960083, 0.021740611642599106, -0.13514727354049683, 0.08120764791965485, -0.06091861426830292, 0.12018679082393646, 0.008464044891297817, -0.019995957612991333, -0.03865249827504158, -0.050161704421043396, -0.09527992457151413, 0.10734766721725464, 0.31137681007385254, 0.011747753247618675, -0.007661512121558189, 0.28381651639938354, 0.07289405912160873, 0.07854609191417694, -0.1226557046175003, 0.05559180676937103, -0.1012226939201355, -0.09118899703025818, 0.13194367289543152, -0.1301664113998413, 1.3879796484128013e-32, -0.0051997946575284, 0.03833046928048134, 0.12008177489042282, 0.004618734121322632, 0.03905510529875755, -0.14210423827171326, 0.10904235392808914, -0.09432058036327362, -0.05124623328447342, -0.14263707399368286, -0.14271482825279236, 0.015609508380293846, -0.035619571805000305, -0.02786586806178093, -0.2346135377883911, -0.10478726774454117, -0.11830765008926392, -0.015356507152318954, -0.04760037735104561, 0.09401514381170273, 0.07523941993713379, -0.06431274116039276, -0.058598123490810394, -0.00541405426338315, -0.02999228611588478, 0.0748034119606018, -0.048977818340063095, 0.14801642298698425, -0.04403636232018471, 0.06346117705106735, -0.10273781418800354, 0.027259349822998047, -0.05463540554046631, -0.15524612367153168, -0.09427924454212189, -0.173774853348732, -0.06451630592346191, -0.04990723356604576, 0.025541219860315323, 0.010621817782521248, -0.12418610602617264, -0.018742412328720093, -0.07928647100925446, -0.07739433646202087, 0.1990131139755249, -0.0950232446193695, -0.01766200363636017, 0.004366549663245678, -0.07296306639909744, -0.003461184911429882, 0.08261141180992126, -0.08825592696666718, 0.010279593989253044, -0.06753337383270264, -0.05737348273396492, 0.06823166459798813, -0.10389585793018341, -0.06047225743532181, 0.019714457914233208, 0.06256479769945145, -0.00023895315825939178, 0.04154043644666672, 0.020857704803347588, 0.07849544286727905, -0.073310986161232, 0.09245432913303375, -0.14878466725349426, -0.10067176818847656, -0.2192651629447937, 0.0984470471739769, -0.0021552415564656258, -0.05107572674751282, 0.15456144511699677, -0.045831430703401566, 0.21009762585163116, -0.03215574473142624, -0.0038178032264113426, 0.245301753282547, -0.0759086161851883, -0.03560139238834381, -0.006547882221639156, 0.010356420651078224, -0.11775219440460205, 0.06225217506289482, 0.028032079339027405, -0.13606566190719604, 0.08101990073919296, -0.01619013398885727, -0.1899661272764206, -0.0836397185921669, 0.11919460445642471, -0.10842391848564148, 0.016983581706881523, 0.14627565443515778, 0.030274176970124245, -1.4258067627486748e-32, -0.0522952526807785, 0.10905726253986359, 0.021377326920628548, -0.08602681756019592, 0.011593693867325783, 0.08836572617292404, 0.14550963044166565, -0.12571042776107788, 0.24864569306373596, -0.03362150117754936, 0.1331017166376114, 0.014921926893293858, -0.03974518924951553, 0.009813034906983376, -0.16007643938064575, 0.09535413235425949, -0.13831663131713867, -0.024137752130627632, -0.09585326910018921, 0.16265162825584412, 0.05514370650053024, -0.04272904992103577, -0.06690290570259094, 0.2448771595954895, 0.0813552662730217, 0.09537485241889954, 0.04311851039528847, 0.10045797377824783, 0.11032092571258545, -0.11967248469591141, 0.07883420586585999, -0.015403086319565773, -0.21475130319595337, 0.025327663868665695, 0.03485056757926941, -0.09236747026443481, -0.04821326583623886, -0.07557148486375809, -0.048181816935539246, -0.1056557297706604, -0.016771692782640457, 0.006434004753828049, 0.02713354304432869, 0.0028915414586663246, -0.017404694110155106, 0.09225883334875107, 0.24836048483848572, -0.18156611919403076, 0.053963553160429, 0.029147852212190628, -0.016193479299545288, 0.05343346670269966, 0.02101496420800686, 0.2255019247531891, -0.0686366856098175, 0.09550460427999496, 0.16270795464515686, 0.18027637898921967, -0.12175990641117096, 0.06748935580253601, -0.0028901053592562675, 0.007545219734311104, 0.10186970233917236, 0.011290904134511948, 0.11205461621284485, -0.01944679021835327, 0.08860962092876434, 0.10519132018089294, 0.08077654242515564, -0.029813170433044434, -0.0056817978620529175, 0.00999823771417141, 0.06333251297473907, -0.10384973883628845, 0.029672538861632347, 0.12407178431749344, 0.062250711023807526, -0.12626856565475464, -0.19257304072380066, -0.057618558406829834, 0.0011101551353931427, -0.07591269910335541, -0.09559288620948792, -0.04102377966046333, -0.067786805331707, -0.031131545081734657, 0.13631263375282288, -0.02591569349169731, -0.02346557006239891, 0.013664823956787586, -0.07600469142198563, -0.03658425807952881, -0.07264483720064163, 0.15023818612098694, 0.05018836259841919, -1.005478438287355e-07, 0.07043441385030746, -0.10532199591398239, -0.09315770864486694, -0.13702696561813354, -0.03724300488829613, -0.1029013842344284, -0.035953786224126816, -0.007486026734113693, -0.1428602933883667, 0.0798858106136322, 0.04801471158862114, 0.13888034224510193, -0.04924356937408447, -0.15547442436218262, -0.044790007174015045, -0.14119480550289154, 0.013874208554625511, 0.025300247594714165, 0.026685509830713272, 0.060386937111616135, 0.012021387927234173, -0.04480741173028946, 0.06433379650115967, -0.08114359527826309, 0.07906176149845123, -0.0545736625790596, 0.07772229611873627, 0.11266961693763733, 0.04576529562473297, -0.04815969616174698, 0.09438014030456543, -0.005309123545885086, 0.04143638163805008, 0.09458381682634354, -0.055415548384189606, -0.04931219294667244, -0.036419518291950226, 0.01929597742855549, -0.011529582552611828, 0.12224417924880981, -0.007575556635856628, -0.15411147475242615, -0.0537940189242363, -0.020794574171304703, 0.0162767693400383, -0.04237579554319382, -0.0067381830886006355, -0.02831438183784485, 0.05961466580629349, -0.03414024040102959, -0.02757144719362259, 0.05033225938677788, -0.08677228540182114, -0.12514778971672058, 0.05310235172510147, 0.11073842644691467, -0.12414167821407318, -0.0027133990079164505, -0.0036381958052515984, -0.14415717124938965, 0.011043133214116096, -0.07662792503833771, 0.06215210631489754, 0.05327757075428963], "changes": {"1wk": 4.408693237448881}}, {"text": "Cytokinetics Heart Drug's Future Sparks Optimism Despite M&A Hurdles and Royalty Deal Concerns: Analyst Vandana Singh Wed, Jan 22, 2025, 11:43 PM 2 min read In This Article: CYTK -2.01% Cytokinetics Heart Drug's Future Sparks Optimism Despite M&A Hurdles and Royalty Deal Concerns: Analyst Stifel initiated coverage on Cytokinetics Incorporated (NASDAQ: CYTK ), noting the company\u2019s catalyst rich one to two years. The M&A speculation ramped up in early 2024 after the company released SEQUOIA-HCM Phase 3 trial data of\u00a0aficamten in December 2023. However, last year, Novartis AG (NYSE: NVS ) decided to step back from pursuing the\u00a0Cytokinetics deal . Amgen Inc (NASDAQ: AMGN ), AstraZeneca Plc (NASDAQ: AZN ), and Johnson & Johnson (NYSE: JNJ ) also all popped up as potential suitors, though the stock faded from there as a deal never materialized. Also Read: Cytokinetics Sets Stage For Mid-Stage Study For Heart Failure Drug After Encouraging Data From Phase 1 Study Cytokinetics has fallen out of favor with investors after a turbulent start to 2024, marked by a controversial Royalty Pharma Plc (NASDAQ: RPRX ) deal and no mergers or acquisitions . Investors poorly received the structure of the Royalty Pharma deal at the time, and it continues to be a concern for many even today. Stifel has initiated coverage with a Buy rating and a price forecast of $80 . However, the outlook appears promising, with its valuation adjusted and several catalysts expected over the next 12+ months. Stifel analyst James Condulis writes Cytokinetics\u2019 aficamten is an exceptional drug as it sets a strong competitive standard for a multi-billion-dollar obstructive hypertrophic cardiomyopathy (oHCM) market. As the rollout of Bristol Myers Squibb Co\u2019s (NYSE: BMY ) Camzyos mavacamten continues, some concerns remain about its potential in treating obstructive hypertrophic cardiomyopathy (oHCM). While the initial launch is not seen as a negative sign for mavacamten\u2019s potential, its Risk Evaluation and Mitigation Strategy (REMS) is a barrier to fully unlocking the market. Cytokinetics appears well-positioned to capitalize on Bristol Myers\u2019 groundwork with its second-to-market drug, aficamten, which is expected to have a best-in-class profile. There is a strong case for aficamten to secure a differentiated REMS, potentially including six-month echocardiograms (Q6M echos) as a standard. Under conservative assumptions, aficamten could drive the U.S. oHCM market to approximately $3 billion. Looking ahead to 2025 and 2026, Phase 3 nHCM data and early findings for HFpEF could present new opportunities. Although mergers and acquisitions are not a key focus, potential strategic interest could bring unexpected benefits. Price Action: CYTK stock is up 3.45% at $47.40 at last check Wednesday. Read Next: Halliburton Faces Mixed Q4 With North American Weakness, But Global Gains And Cash Flow Bolster Optimism Story Continues Latest Ratings for CYTK Date Firm Action From To Dec 2021 Oppenheimer Initiates Coverage On Outperform Dec 2021 HC Wainwright & Co. Maintains Buy Dec 2021 JP Morgan Initiates Coverage On Overweight View More Analyst Ratings for CYTK View the Latest Analyst Ratings UNLOCKED: 5 NEW TRADES EVERY WEEK. Click now to get top trade ideas daily , plus unlimited access to cutting-edge tools and strategies to gain an edge in the markets. Get the latest stock analysis from Benzinga? CYTOKINETICS (CYTK): Free Stock Analysis Report This article Cytokinetics Heart Drug's Future Sparks Optimism Despite M&A Hurdles and Royalty Deal Concerns: Analyst originally appeared on Benzinga.com \u00a9 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved. View Comments Terms and Privacy Policy Privacy Dashboard Recommended Stories", "symbol": "CYTK", "date": "2025-01-22T20:43:50+00:00", "sentiment": {"score": 0.674386702477932, "confidence": 0.7550502419471741, "probabilities": {"positive": 0.7550502419471741, "negative": 0.0806635394692421, "neutral": 0.16428624093532562}}, "embedding": [-0.06067802384495735, -0.10173866897821426, -0.024209972470998764, -0.0042687575332820415, 0.022105440497398376, 0.004905619192868471, -0.08626142144203186, 0.27444887161254883, 0.12208455055952072, 0.008008383214473724, -0.14288808405399323, 0.10628874599933624, 0.04753910377621651, 0.022573336958885193, -0.04041988402605057, 0.02712271362543106, 0.13878381252288818, 0.06589920818805695, -0.05789043754339218, 0.18974295258522034, -0.05208723992109299, -0.026472706347703934, 0.02999032661318779, 0.06881261616945267, -0.013366999104619026, 0.03558460623025894, -0.08325455337762833, -0.01902364194393158, -0.14495640993118286, -0.030013885349035263, 0.037722621113061905, 0.13345786929130554, 0.11953187733888626, 0.0810600221157074, 0.007875993847846985, 0.024145517498254776, -0.09001176059246063, -0.012861719354987144, -0.1361776441335678, -0.025244027376174927, 0.010933908633887768, -0.02245035581290722, -0.14461620151996613, 0.11657194793224335, 0.0816425234079361, -0.12429285049438477, 0.009925647638738155, -0.04407283291220665, 0.011156855151057243, 0.11281883716583252, -0.1574631631374359, -0.16259759664535522, -0.029543420299887657, 0.01209481991827488, -0.06500501930713654, 0.04636676609516144, -0.34027546644210815, -0.058693401515483856, 0.10398264974355698, -0.026209328323602676, 0.04977266490459442, 0.017728766426444054, 0.0054925307631492615, -0.007856752723455429, 0.08833146840333939, 0.03300945460796356, 0.02459537237882614, 0.1041877418756485, 0.07605120539665222, -0.035570837557315826, 0.17007037997245789, -0.13804149627685547, -0.00789027102291584, 0.04275762289762497, -0.11738156527280807, 0.2427055835723877, 0.1602952480316162, 0.01284162700176239, 0.1112024337053299, -0.08499748259782791, 0.08021530508995056, 0.0015683970414102077, 0.038512829691171646, -0.04758274555206299, 0.028037257492542267, 0.05774182453751564, 0.01435830444097519, 0.1530211865901947, 0.1185024082660675, 0.005499842576682568, 0.172785684466362, 0.045549094676971436, 0.060610316693782806, 0.0347306951880455, 0.02876579575240612, -0.05172891169786453, 0.0010487115941941738, 0.0038052890449762344, 0.043101366609334946, 0.003697287291288376, 0.09794613718986511, 0.15625473856925964, -0.12841366231441498, -0.04153599217534065, 0.0014601591974496841, -0.14347687363624573, 0.0811849981546402, -0.07898879051208496, 0.13186456263065338, 0.009812064468860626, -0.07870376110076904, 0.0013956660404801369, -0.10392215847969055, -0.13204699754714966, -0.06343001872301102, 0.27928411960601807, -0.036916717886924744, -0.007306277751922607, 0.17382748425006866, 0.048353664577007294, 0.047660477459430695, -0.06906689703464508, -0.025482654571533203, -0.10911357402801514, 0.03438427299261093, 0.1552729457616806, -0.24372830986976624, 1.31511045973174e-32, -0.07951641082763672, 0.1276346743106842, 0.10207973420619965, 0.04600682109594345, 0.005180055275559425, 0.0030194090213626623, 0.10587415844202042, -0.10030845552682877, -0.1303219199180603, -0.10596795380115509, -0.2405308485031128, 0.08826941251754761, -0.05365139991044998, -0.037300847470760345, -0.12327226996421814, -0.19886502623558044, -0.12197672575712204, -0.04993826895952225, 0.03951512649655342, -0.042531825602054596, -0.01516165491193533, 0.009491557255387306, -0.07833290100097656, 0.028985412791371346, -0.14163975417613983, 0.04746466875076294, 0.010141436010599136, 0.08110594749450684, 0.12135427445173264, 0.059488728642463684, -0.06968227028846741, -0.010491302236914635, -0.04213032126426697, -0.04272792115807533, -0.07035985589027405, -0.047066543251276016, -0.18694782257080078, -0.13554489612579346, 0.030181610956788063, -0.036885347217321396, -0.19585588574409485, 0.08119480311870575, -0.10407906770706177, -0.12694139778614044, 0.10989882051944733, -0.1214742362499237, -0.11946552991867065, -0.048133064061403275, -0.04459475725889206, -0.06677446514368057, 0.02258225530385971, 0.03856338933110237, -0.010563084855675697, -0.04581230878829956, -0.06366150826215744, 0.024176761507987976, -0.13017940521240234, -0.0024537276476621628, -0.010667548514902592, 0.119185671210289, -0.0047880904749035835, 0.03876502811908722, 0.008892256766557693, 0.057179536670446396, -0.10779611766338348, 0.24474072456359863, -0.12392669916152954, -0.034987498074769974, -0.2252528965473175, 0.20811183750629425, 0.12006591260433197, -0.04333928972482681, 0.09847759455442429, -0.057181499898433685, 0.1440258026123047, 0.0027994103729724884, 0.04176218807697296, 0.1979561746120453, 0.0067769004963338375, -0.06974238157272339, 0.005815020762383938, 0.010507956147193909, -0.05621833726763725, 0.12658677995204926, 0.007427293807268143, -0.1267642378807068, 0.08176274597644806, -0.020685384050011635, -0.13357122242450714, 0.04595639929175377, 0.159245103597641, -0.08361190557479858, 0.0028644241392612457, 0.1781020164489746, -0.026621460914611816, -1.1907959077237351e-32, -0.07100391387939453, 0.06650955975055695, -0.0011801193468272686, -0.13440248370170593, -0.08106294274330139, 0.03201798349618912, 0.12964637577533722, -0.06261321157217026, 0.08616278320550919, -0.12125223129987717, 0.08393078297376633, 0.03342592343688011, -0.05681958794593811, 0.12099580466747284, -0.15439672768115997, 0.010798845440149307, 0.0674658939242363, -0.15917465090751648, -0.0353899821639061, -0.0018829654436558485, 0.02101694606244564, 0.11708830296993256, -0.12719690799713135, 0.22699785232543945, 0.007460668217390776, 0.11585143208503723, 0.07954093813896179, 0.03888311982154846, -0.03016328439116478, -0.0837131142616272, 0.03937442600727081, 0.0004425155930221081, -0.2168164998292923, 0.030739113688468933, 0.01438091229647398, 0.09002697467803955, -0.03824000060558319, -0.04332781583070755, -0.06864593923091888, -0.12790390849113464, 0.011753791943192482, 0.03332457318902016, 0.02850927971303463, 0.041553739458322525, 0.05577867478132248, 0.05610888451337814, 0.19723477959632874, -0.04456666111946106, 0.25638025999069214, 0.02027789130806923, -0.08882483839988708, 0.00848936103284359, 0.033543460071086884, 0.08638550341129303, -0.06607330590486526, 0.044930871576070786, 0.09552096575498581, 0.04352469742298126, -0.12625816464424133, -0.00017223553732037544, 0.014048868790268898, 0.04078243672847748, 0.11329467594623566, -0.13784091174602509, 0.10083919763565063, 0.10379267483949661, 0.17259714007377625, -0.016071444377303123, 0.03176990896463394, -0.1315731555223465, 0.05381105840206146, 0.0225213672965765, -0.10585599392652512, -0.045662544667720795, -0.01185669470578432, 0.10350429266691208, -0.004143205471336842, -0.16120341420173645, -0.2079683542251587, -0.12604928016662598, 0.04977528005838394, -0.07936125993728638, -0.021429628133773804, -0.04129793494939804, 0.03364366292953491, 0.01181863248348236, 0.13964474201202393, -0.003414271865040064, -0.049013711512088776, 0.02677581086754799, -0.08734825253486633, -0.13108840584754944, -0.10436506569385529, 0.1632256805896759, 0.0498485192656517, -9.999573080676782e-08, 0.05999124050140381, -0.05651656538248062, -0.017398951575160027, -0.1806524395942688, 0.09088066220283508, -0.05009801685810089, -0.042029138654470444, -0.004978537559509277, 0.010440600104629993, 0.1859048753976822, 0.07757364213466644, 0.13492324948310852, -0.11452951282262802, -0.04439648240804672, -0.06997737288475037, 0.004153032321482897, -0.12754052877426147, 0.008572477847337723, 0.005004175007343292, -0.018273798748850822, -0.09807334840297699, 0.06685508787631989, 0.019381863996386528, -0.05904107913374901, 0.09600585699081421, -0.09998133778572083, 0.037129584699869156, 0.09913668036460876, 0.08198796212673187, -0.01858336851000786, 0.06165577098727226, 0.000317305326461792, 0.18547192215919495, 0.07886335253715515, -0.1484616994857788, -0.16294771432876587, 0.07167305052280426, 0.10300345718860626, 0.045567966997623444, 0.06215686351060867, -0.030358271673321724, -0.03275085240602493, -0.050075843930244446, 0.029517540708184242, -0.11119215190410614, -0.09666144102811813, -0.07684358209371567, -0.0242453683167696, 0.07368864119052887, -0.079508475959301, 0.03512461110949516, -0.014077131636440754, -0.031091222539544106, -0.05476158857345581, -0.003296135924756527, -0.006975636351853609, -0.16860844194889069, 0.05628223344683647, -0.028637506067752838, -0.05597129091620445, -0.024857528507709503, -0.30271321535110474, 0.09089705348014832, 0.09646131098270416], "changes": {"1wk": 3.9085900106423694}}, {"text": "Cytokinetics Announces Start of AMBER-HFpEF, a Phase 2 Clinical Trial of CK-586 in Patients With Symptomatic Heart Failure With Preserved Ejection Fraction Cytokinetics, Incorporated Tue, Jan 21, 2025, 3:30 PM 8 min read In This Article: CYTK -2.01% Cytokinetics, Incorporated SOUTH SAN FRANCISCO, Calif., Jan. 21, 2025 (GLOBE NEWSWIRE) -- \u00a0Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that AMBER-HFpEF ( A ssessment of CK-586 in a M ulti-Center, B linded E valuation of Safety and Tolerability R esults in HFpEF ) is open to enrollment. AMBER-HFpEF is a Phase 2 randomized, placebo-controlled, double-blind, multi-center, dose-finding clinical trial of CK-4021586 (CK-586) in patients with symptomatic heart failure with preserved ejection fraction (HFpEF) with left ventricular ejection fraction (LVEF) \u226560%. CK-586 is a cardiac myosin inhibitor in development for the potential treatment of a subgroup of with symptomatic HFpEF patients with hypercontractility and ventricular hypertrophy. \u201cWe are pleased to be advancing CK-586 into a Phase 2 trial in a subset of patients with symptomatic HFpEF,\u201d said Stuart Kupfer, M.D., Senior Vice President, Chief Medical Officer. \u201cDespite recent advances in available treatments, patients with heart failure with supranormal ejection fraction continue to have a poor prognosis following hospitalization. Evaluating CK-586 in this Phase 2 trial further extends the potential of our cardiac myosin directed development platform focused to specialty cardiology indications.\u201d Approximately half of patients with heart failure have HFpEF, characterized by an ejection fraction of at least 50%, impaired diastolic function and elevated NTpro-BNP, which can lead to poor ventricular compliance and reduced cardiac output. A subset of patients with HFpEF resemble patients with non-obstructive hypertrophic cardiomyopathy (nHCM) in that those patients have higher ejection fractions and thickened walls of their heart in association with elevated cardiac biomarkers and symptoms of heart failure. The evaluation of CK-586 in HFpEF builds on the similarity of these conditions and the data accumulated to date with aficamten in nHCM. About AMBER-HFpEF AMBER-HFpEF is a Phase 2 randomized, placebo-controlled, double-blind, multi-center, dose-finding clinical trial in patients with symptomatic HFpEF with LVEF \u226560%. The primary objective is to evaluate the safety and tolerability profile of CK-586 compared to placebo. The secondary objectives include assessing the effect of CK-586 on LVEF and NT-proBNP, and determining both its pharmacokinetics and its pharmacokinetic/pharmacodynamic relationship. A number of exploratory endpoints will evaluate the effect of CK-586 on patient function, symptoms, and measures of cardiac function. AMBER-HFpEF is planned to enroll approximately 60 patients randomized on a 3:1 basis to receive CK-586 or placebo in three dose escalation cohorts. Patients will receive up to two escalating doses of CK-586 over 12 weeks or placebo. An echocardiogram at Week 6 will determine whether patients will be up-titrated to the higher dose. Once-daily doses of 150 mg and 300 mg are planned in Cohort 1, 300 mg and 450 mg in Cohort 2 and 450 mg and 600 mg in Cohort 3. At screening, patients enrolled in AMBER-HFpEF must have LVEF \u226560%, NT-proBNP \u2265300 pg/mL for participants in sinus rhythm and \u2265900 pg/mL for participants with atrial fibrillation or flutter (AFF), and be New York Heart Association (NYHA) Functional Class II or III. Additional information can be found on www.clinicaltrials.gov . Story Continues About CK-4021586 (CK-586) CK-4021586 (CK-586) is designed to be a novel, selective, oral, small molecule cardiac myosin inhibitor designed to reduce the hypercontractility associated with heart failure with preserved ejection fraction (HFpEF). CK-586 was designed to selectively inhibit the ATPase of intact cardiac myosin but does not inhibit the ATPase of subfragment-1 of myosin (S1). The inhibitory effect of CK-586 requires the presence of the regulatory light chain (RLC) of myosin in the context of the intact myosin dimer (heavy meromyosin or HMM). In preclinical models, CK-586 reduced cardiac hypercontractility by decreasing the number of active myosin cross-bridges during cardiac contraction thereby reducing the contractile force, without effect on calcium transients. In engineered human HCM heart tissues, CK-586 demonstrated shallow force-concentration response and improved lusitropy. A subset of patients with HFpEF resemble patients with non-obstructive hypertrophic cardiomyopathy (nHCM) in that those patients have higher ejection fractions, thickened walls of their heart, elevated biomarkers, and symptoms of heart failure.\u00a0Data from a Phase 2 clinical trial of aficamten, another investigational cardiac myosin inhibitor being developed by Cytokinetics, showed that in patients with nHCM aficamten was well tolerated, improved patient reported outcomes (Kansas City Cardiomyopathy Questionnaire (KCCQ) and New York Heart Association (NYHA) Functional Class) and biomarkers, measures that are also relevant to HFpEF. Aficamten was also well-tolerated with no drug discontinuations due to adverse events and no adverse events of heart failure. These data provide support for investigating this mechanism of action in HFpEF. About Heart Failure with Preserved Ejection Fraction Heart failure is a grievous condition that affects more than 64 million people worldwide. 1 Approximately 6.7 million Americans have heart failure, which is expected to increase to over 8.5 million Americans by 2030. 2 Approximately half of patients with heart failure have heart failure with preserved ejection fraction (HFpEF) 3 , and the prevalence of HFpEF is increasing. 2,4 Approximately 75% of patients with HFpEF will die within five years of initial hospitalization, and 84% will be rehospitalized. 2 Despite broad use of standard treatments and advances in care, the prognosis for patients with heart failure is poor. 5 A subset of HFpEF patients with hypercontractility, ventricular hypertrophy, elevated biomarkers and symptoms of heart failure may benefit from treatment with a cardiac sarcomere inhibitor. About Cytokinetics Cytokinetics is a late-stage, muscle biology specialty biopharmaceutical company focused on discovering, developing and commercializing muscle biology-directed drug candidates as potential treatments for debilitating diseases in which muscle performance is compromised. As a leader in muscle biology and the mechanics of muscle performance, Cytokinetics is intent on meaningfully improving the lives of patients through global access to innovative\u00a0medicines. Cytokinetics is readying for potential regulatory approvals and commercialization of aficamten, a potential next-in-class cardiac myosin inhibitor following positive results from SEQUOIA-HCM, the pivotal Phase 3 clinical trial in patients with obstructive hypertrophic cardiomyopathy (HCM). Aficamten is also being evaluated in additional clinical trials enrolling patients with obstructive and non-obstructive HCM. Cytokinetics is also developing omecamtiv mecarbil , a cardiac myosin activator, in patients with heart failure with severely reduced ejection fraction (HFrEF), CK-586, a cardiac myosin inhibitor with a mechanism of action distinct from aficamten, for the potential treatment of heart failure with preserved ejection fraction (HFpEF) and CK-089, a fast skeletal muscle troponin activator with potential therapeutic application to a specific type of muscular dystrophy and other conditions of impaired skeletal muscle function. For additional information about Cytokinetics, visit www.cytokinetics.com and follow us on X , LinkedIn , Facebook and YouTube . Forward-Looking Statements This press release contains forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995 (the \"Act\"). Cytokinetics disclaims any intent or obligation to update these forward-looking statements and claims the protection of the Act's Safe Harbor for forward-looking statements. Examples of such statements include, but are not limited to, statements, express or implied, relating to the Company\u2019s development plans for CK-586 in the United States, including its ability to full enroll AMBER-HFpEF by any particular date, if at all. Such statements are based on management's current expectations, but actual results may differ materially due to various risks and uncertainties, including, but not limited to, potential difficulties or delays in the development, testing, regulatory approvals for trial commencement, progression or product sale or manufacturing, or production of Cytokinetics' drug candidates that could slow or prevent clinical development or product approval; Cytokinetics' drug candidates may have adverse side effects or inadequate therapeutic efficacy; the FDA or foreign regulatory agencies may delay or limit Cytokinetics' ability to conduct clinical trials; Cytokinetics may be unable to obtain or maintain patent or trade secret protection for its intellectual property; standards of care may change, rendering Cytokinetics' drug candidates obsolete; and competitive products or alternative therapies may be developed by others for the treatment of indications Cytokinetics' drug candidates and potential drug candidates may target. For further information regarding these and other risks related to Cytokinetics' business, investors should consult Cytokinetics' filings with the Securities and Exchange Commission. CYTOKINETICS \u00ae and the C-shaped logo are registered trademarks of Cytokinetics in the U.S. and certain other countries. References: James et al. GBD 2017 Disease and Injury Incidence and Prevalence Collaborators. Lancet 2018; 392: 1789\u2013858. Bozkurt B, Ahmad T, Alexander KM, Baker WL, Bosak K, Breathett K, Fonarow GC, Heidenreich P, Ho JE, Hsich E, Ibrahim NE, Jones LM, Khan SS, Khazanie P, Koelling T, Krumholz HM, Khush KK, Lee C, Morris AA, Page RL 2nd, Pandey A, Piano MR, Stehlik J, Stevenson LW, Teerlink JR, Vaduganathan M, Ziaeian B; Writing Committee Members. Heart Failure Epidemiology and Outcomes Statistics: A Report of the Heart Failure Society of America. J Card Fail. 2023 Oct;29(10):1412-1451. doi: 10.1016/j.cardfail.2023.07.006. Epub 2023 Sep 26. PMID: 37797885; PMCID: PMC10864030. Dunlay SM, Roger VL, Weston SA, Jiang R, Redfield MM. Longitudinal changes in ejection fraction in heart failure patients with preserved and reduced ejection fraction. Circ Heart Fail. 2012 Nov;5(6):720-6. doi: 10.1161/CIRCHEARTFAILURE.111.966366. Epub 2012 Aug 30. PMID: 22936826; PMCID: PMC3661289. Yancy CW, Jessup M, Bozkurt B, et al. 2013 ACCF/AHA Guideline for the Management of Heart failure: A Report of the\u00a0American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines.\u00a0Circulation. 2013;128:e240-e327. Jhund PS, MacIntyre K, Simpson CR, et al. Long-Term Trends in First Hospitalization for Heart Failure and Subsequent Survival Between 1986 and 2003.\u00a0Circulation. 2009;119:515-523. Contact: Cytokinetics Diane Weiser Senior Vice President, Corporate Affairs (415) 290-7757 View Comments Terms and Privacy Policy Privacy Dashboard Recommended Stories", "symbol": "CYTK", "date": "2025-01-21T12:30:00+00:00", "sentiment": {"score": 0.2323281317949295, "confidence": 0.3004748523235321, "probabilities": {"positive": 0.3004748523235321, "negative": 0.0681467205286026, "neutral": 0.6313783526420593}}, "embedding": [-0.0232155229896307, -0.050973840057849884, 0.05701644346117973, -0.05069781839847565, 0.08148513734340668, -0.016537664458155632, -0.17917698621749878, 0.20317846536636353, 0.021355830132961273, -0.011931976303458214, -0.01400526612997055, -0.05990099161863327, 0.07605750858783722, 0.048779409378767014, -0.010304146446287632, -0.025419801473617554, 0.12707635760307312, 0.18664629757404327, -0.1909841001033783, 0.10977781563997269, -0.008704819716513157, 0.023551765829324722, 0.015660513192415237, 0.08592811226844788, -0.05269274488091469, 0.024234391748905182, -0.27788880467414856, -0.01132968533784151, -0.10796089470386505, 0.004213778767734766, 0.05554290860891342, 0.029241900891065598, 0.029139336198568344, 0.19240984320640564, -0.018908938392996788, 0.07648087292909622, -0.11967648565769196, -0.05173908919095993, -0.19256189465522766, -0.04102953150868416, 0.004767453297972679, -0.057349786162376404, -0.14182507991790771, 0.028917064890265465, 0.1676989197731018, -0.07299631834030151, -0.06925368309020996, -0.009433610364794731, -0.08549591898918152, 0.2018028050661087, -0.1017201766371727, -0.016756396740674973, 0.03336188942193985, 0.08324184268712997, -0.0065812766551971436, -0.02754596620798111, -0.20149895548820496, -0.1268528252840042, 0.12862908840179443, -0.018275227397680283, -0.10156398266553879, -0.039452504366636276, -0.03276875615119934, -0.07652930915355682, 0.07461538910865784, -0.008864449337124825, -0.03269060701131821, -0.0621626041829586, 0.0420498251914978, 0.023231878876686096, 0.08180457353591919, -0.09012751281261444, -0.0901305228471756, 0.19427302479743958, 0.09103472530841827, 0.1369898021221161, 0.02567550539970398, -0.01582825556397438, -0.06377749145030975, -0.11404356360435486, 0.11666485667228699, 0.08080621808767319, -0.008520533330738544, -0.041988126933574677, 0.0012764325365424156, 0.03704740107059479, -0.026717958971858025, 0.14812153577804565, -0.023381691426038742, 0.034776829183101654, 0.220210462808609, 0.06580653041601181, 0.1311483085155487, -0.02029310166835785, 0.1435030996799469, -0.10414336621761322, -0.015580612234771252, 0.06733183562755585, -0.022594884037971497, -0.02003275416791439, 0.0860636830329895, 0.01967259868979454, -0.2007288932800293, -0.17151017487049103, 0.13199427723884583, -0.11889854818582535, 0.005114411935210228, -0.029245004057884216, 0.09232629835605621, 0.0014303335919976234, 0.10025712102651596, -0.04774600639939308, 0.02000579796731472, -0.02015528455376625, 0.10740898549556732, 0.2546067535877228, -0.06057252734899521, -0.00651458278298378, 0.19218051433563232, 0.09122307598590851, 0.12196947634220123, -0.12685585021972656, 0.02535076066851616, -0.09125292301177979, -0.06147008016705513, 0.15144607424736023, -0.10610529780387878, 9.382803255103192e-33, 0.09185105562210083, 0.06558689475059509, 0.06331084668636322, 0.0771401971578598, 0.11359803378582001, -0.21333813667297363, 0.021244611591100693, -0.10830289870500565, -0.09075742214918137, -0.07855626940727234, -0.12562696635723114, 0.059000492095947266, -0.01476683747023344, -0.03327897936105728, -0.2280082106590271, -0.06869834661483765, -0.0887453705072403, -0.03746761381626129, -0.027497250586748123, 0.10259079933166504, 0.11240485310554504, -0.02891671285033226, -0.045522987842559814, -0.12126976251602173, -0.09442625939846039, 0.12062126398086548, 0.008232289925217628, 0.2071731835603714, -0.01875433698296547, 0.005805810913443565, -0.09529906511306763, -0.029126286506652832, 0.016409127041697502, -0.10471351444721222, -0.0780060663819313, -0.2156940996646881, -0.03474775329232216, -0.021705232560634613, -0.03552067279815674, 0.004069262184202671, -0.10629422217607498, 0.0356016606092453, -0.13719259202480316, -0.06636272370815277, 0.22832083702087402, -0.21782207489013672, 0.05187824368476868, -0.08276534080505371, -0.12615475058555603, 0.04282601550221443, 0.09930063784122467, -0.06948640942573547, 0.08379845321178436, -0.01997210644185543, -0.024215012788772583, 0.02953173778951168, -0.0296950526535511, -0.013970248401165009, 0.04868118092417717, 0.025652609765529633, -0.0439685583114624, 0.06609536707401276, 0.0005974322557449341, 0.09071056544780731, -0.05406902730464935, 0.025512803345918655, -0.08294275403022766, -0.08715024590492249, -0.20117950439453125, 0.060571156442165375, 0.0871264860033989, -0.15602590143680573, 0.112251415848732, 0.03020048886537552, 0.11506790667772293, -0.009437916800379753, -0.042420923709869385, 0.19077476859092712, -0.11865672469139099, -0.086850106716156, -0.13268783688545227, 0.07133868336677551, -0.16778147220611572, 0.13038355112075806, 0.044513583183288574, -0.13801082968711853, 0.05048292875289917, -0.0067449756897985935, -0.2647971212863922, -0.17007231712341309, 0.14819253981113434, -0.10508280992507935, 0.0702943354845047, 0.0894690454006195, -0.024197623133659363, -1.0778727775959613e-32, -0.027951214462518692, 0.005013837944716215, 0.0029655499383807182, -0.11378642916679382, -0.013551358133554459, 0.12885619699954987, 0.1624772548675537, -0.16756249964237213, 0.17131438851356506, -0.09045054018497467, 0.1428976058959961, -0.046569257974624634, -0.006617830600589514, 0.0550750270485878, -0.15046393871307373, 0.08001803606748581, -0.15269994735717773, -0.013961405493319035, -0.09608553349971771, 0.2451220005750656, 0.09061978757381439, -0.023317430168390274, -0.08299178630113602, 0.22777995467185974, 0.08690754324197769, 0.16999971866607666, 0.11714686453342438, 0.1698715090751648, 0.09077291935682297, -0.2096310257911682, 0.12539945542812347, -0.1221441924571991, -0.1520189344882965, -0.09299936890602112, 0.03841055929660797, -0.08828820288181305, -0.005786031950265169, 0.0243084579706192, -0.026378346607089043, -0.04681883752346039, -0.01240807119756937, 0.05654381960630417, -0.024441104382276535, 0.05727069452404976, -0.03555391728878021, 0.0993926003575325, 0.20748673379421234, -0.1242666244506836, 0.05845768004655838, 0.043614186346530914, -0.08546556532382965, 0.03875451162457466, -0.029217185452580452, 0.21522274613380432, -0.11833132058382034, 0.0539853498339653, 0.13076326251029968, 0.23291932046413422, -0.14902248978614807, 0.09719035029411316, -0.029501376673579216, 0.026055173948407173, 0.11061535775661469, 0.020515697076916695, 0.17211733758449554, 0.05571341514587402, 0.057550545781850815, 0.11628691852092743, 0.03514508530497551, -0.04175880178809166, -0.024738408625125885, 0.040488630533218384, 0.025395283475518227, -0.09794814884662628, 0.09684737026691437, 0.07547768950462341, -0.030488204210996628, -0.060358092188835144, -0.1532050222158432, -0.07668175548315048, -0.02352447435259819, -0.10796462744474411, -0.14563146233558655, -0.025716885924339294, -0.028271928429603577, -0.023351985961198807, 0.1820608675479889, -0.0806017816066742, 0.06432973593473434, 0.0016675656661391258, -0.0065726637840271, -0.018935400992631912, -0.12864536046981812, 0.15188929438591003, -0.04724518582224846, -1.0025590313489374e-07, 0.051837991923093796, -0.05094040557742119, -0.0948110818862915, -0.2639525532722473, -0.07554745674133301, -0.11897315829992294, -0.029962124302983284, -0.057179540395736694, -0.20420493185520172, 0.0639454573392868, 0.08998085558414459, 0.09749516099691391, -0.03333108872175217, -0.22465497255325317, 0.01069677621126175, -0.1450187861919403, -0.01112430915236473, 0.06685309112071991, 0.018244920298457146, 0.011358155868947506, 0.07456482201814651, -0.06193745881319046, 0.08057881891727448, -0.1265750229358673, 0.06584294140338898, -0.014930058270692825, 0.14932578802108765, 0.10608331859111786, 0.05332406610250473, -0.11311513930559158, 0.004114209674298763, -0.02913637086749077, 0.11326315253973007, 0.12009148299694061, -0.019652295857667923, -0.06965850293636322, 0.010228712111711502, -0.043800707906484604, -0.016992362216114998, 0.07387371361255646, 0.0008044536225497723, -0.12816086411476135, -0.07938488572835922, -0.03912591561675072, -0.004606615751981735, -0.005855550989508629, 0.05724531412124634, 0.06436282396316528, 0.14474010467529297, -0.02818560227751732, -0.02275617979466915, 0.022678494453430176, -0.0621696338057518, -0.15359637141227722, 0.008072255179286003, 0.07348351925611496, -0.10541030764579773, 0.033365603536367416, 0.06012982130050659, -0.0611812025308609, 0.08986802399158478, -0.06899119913578033, 0.029994837939739227, 0.030117934569716454], "changes": {"1wk": 8.991704407082649}}, {"text": "Netflix upgraded, Reddit downgraded: Wall Street's top analyst calls The Fly Wed, Jan 22, 2025, 5:36 PM 4 min read In This Article: NFLX +0.22% RDDT +1.38% Netflix upgraded, Reddit downgraded: Wall Street's top analyst calls The most talked about and market moving research calls around Wall Street are now in one place. Here are today's research calls that investors need to know, as compiled by The Fly. Top 5 Upgrades: Rosenblatt upgraded Netflix (NFLX) to Buy from Neutral with a price target of $1,494, up from $680, after the company \"delivered on so many levels\" in Q4. Canaccord also upgraded Netflix to Buy from Hold with a price target of $1,150, up from $940, after the company reported strong Q4 results, with paid memberships, revenue, and profitability all coming in ahead of expectations. Meanwhile, Barclays upgraded Netflix to Equal Weight from Underweight with a price target of $900, up from $715, and Benchmark upgraded Netflix to Hold from Sell with no price target. Bernstein upgraded Darden (DRI) to Outperform from Market Perform with a price target of $215, up from $180. After a \"dismal 2024, the restaurants sector looks relatively inexpensive,\" the firm tells investors in a research note, adding that Darden has upside from improvements in its core middle-income consumer cohort, rollout of UberDirect with marketing support, and efficiency measures supporting margin expansion. Wells Fargo upgraded 3M (MMM) to Overweight from Equal Weight with a price target of $170, up from $140. The company is in the \"early days of significant margin expansion\" at a time of uncertainty about the trajectory of an industrial recovery, which is attractive, the firm tells investors in a research note. Summit Insights upgraded Seagate (STX) to Buy from Hold. The firm is positive on the company's HAMR HDD technology transition driving upside to its gross margin in the second half of FY25, also noting that the current favorable pricing environment and product mix at Seagate will continue. Barclays upgraded Hormel Foods (HRL) to Overweight from Equal Weight with a price target of $36, up from $35. The firm sees the company's investments into its \"Transform and Modernize\" initiative materializing into a higher long-term margin structure. Top 5 Downgrades: Roth MKM downgraded Reddit (RDDT) to Neutral from Buy with a price target of $195, up from $116. Given the rise in the share price, the firm believes the near-term risk/reward is fairly balanced at current levels. Barclays downgraded Ford (F) to Equal Weight from Overweight with a price target of $11, down from $13. The firm says that while it appreciates Ford's transformation efforts, it believes elevated volume headwinds in 2025 due to inventory destocking and continued modest price normalization will drive downside on earnings estimates. Stephens downgraded Elevance Health (ELV) to Equal Weight from Overweight with a price target of $440, down from $520. Despite the company having previously cut expectations in conjunction with its Q3 earnings report, the firm sees a \"formidable set of percolating risks\" to the current Street 2025 adjusted EPS forecast. Bernstein downgraded Yum! Brands (YUM) to Market Perform from Outperform with a price target of $135, down from $140. Yum may witness pressures in reaching its long-term growth algorithm in 2025, resulting in a range-bound stock, the firm tells investors in a research note. TD Cowen downgraded Celsius Holdings (CELH) to Hold from Buy with a price target of $29, down from $40. Celsius shares are already well below their highs, but the valuation multiple could contract even further if the company goes \"ex-growth,\" the firm tells investors in a research note. Story Continues Top 5 Initiations: Citi resumed coverage of Disney (DIS) with a Buy rating and $125 price target. While consensus earnings estimates \"look a touch high,\" the stock's risk/reward is attractive at prevailing levels, the firm tells investors in a research note. Stifel initiated coverage of Cytokinetics (CYTK) with a Buy rating and $80 price target. Cytokinetics \"is an out-of-favor stock\" following the \"controversial\" Royalty Pharma deal, but Stifel believes the stock's valuation has largely reset and with a catalyst-rich 12-months ahead. Goldman Sachs initiated coverage of Viking Holdings (VIK) with a Neutral rating and $49 price target. The firm sees a \"lot to like\" about Viking's business model, but with the stock up 73% since the initial public offering in May 2024, Goldman would look for a more favorable entry point at these levels. Truist initiated coverage of APi Group (APG) with a Buy rating and $45 price target. The firm says APi is an \"underappreciated name\" as it \"quietly\" holds the leading market position in U.S. fire protection. Craig-Hallum initiated coverage of Daktronics (DAKT) with a Buy rating and $26 price target. The firm sees a significant stock opportunity and the potential for a $35-$40 stock over time. View Comments Terms and Privacy Policy Privacy Dashboard Recommended Stories", "symbol": "CYTK", "date": "2025-01-22T14:36:09+00:00", "sentiment": {"score": 0.9312058733776212, "confidence": 0.945905864238739, "probabilities": {"positive": 0.945905864238739, "negative": 0.01469999086111784, "neutral": 0.039394255727529526}}, "embedding": [-0.0800449475646019, -0.2351164072751999, -0.08102613687515259, 0.03355798125267029, 0.09831523150205612, -0.024612098932266235, -0.005788707174360752, 0.10251130163669586, 0.14881734549999237, 0.023064935579895973, -0.07991160452365875, 0.12822559475898743, -0.004263145849108696, -0.06047770380973816, 0.04994140565395355, -0.10896436870098114, 0.1670723855495453, -0.10361087322235107, -0.22840045392513275, 0.03905228152871132, -0.013494569808244705, -0.15250718593597412, -0.05429396405816078, -0.07389439642429352, 0.06698986887931824, 0.008243678137660027, -0.08297738432884216, -0.02479979582130909, -0.18293286859989166, -0.11552146077156067, -0.017785146832466125, 0.19799324870109558, 0.019624345004558563, -0.06116810441017151, -0.03693325072526932, -0.08221393823623657, -0.03285602852702141, 0.0017233856488019228, 0.047798044979572296, -0.04599083587527275, -0.07666867971420288, -0.03692048043012619, -0.10022595524787903, 0.04158132150769234, 0.04398482292890549, -0.1580512523651123, -0.023767877370119095, 0.11319389194250107, 0.08504553884267807, 0.002653254196047783, -0.17006249725818634, 0.09753035008907318, 0.0008337981998920441, -0.03222501650452614, -0.02048490196466446, 0.15159831941127777, -0.014196943491697311, 0.003482781583443284, 0.05792390555143356, -0.03109162300825119, 0.04548169672489166, -0.15107640624046326, 0.0694054514169693, 0.04121740907430649, 0.13599729537963867, -0.05023043975234032, -0.07240834832191467, -0.11056622862815857, -0.11887399852275848, 0.018816810101270676, 0.04450050741434097, -0.018697315827012062, -0.0642828643321991, -0.07807941734790802, 0.12443441152572632, 0.06893296539783478, 0.19543686509132385, -0.03495202586054802, 0.031267937272787094, -0.04247497767210007, 0.03381861746311188, -0.030577898025512695, 0.006852330639958382, -0.008096418343484402, -0.006795207038521767, -0.086196169257164, 0.08650016784667969, -0.04018120840191841, 0.021681275218725204, 0.013231301680207253, 0.05712916702032089, -0.005825132131576538, -0.07078493386507034, 0.025486186146736145, -0.02445213869214058, 0.01820431835949421, -0.12216857075691223, -0.05546704679727554, -0.0317513681948185, 0.046262502670288086, 0.15594178438186646, 0.0524238646030426, -0.046509966254234314, -0.04047681391239166, -0.04606492072343826, -0.16209807991981506, 0.11877533048391342, 0.1677035689353943, 0.041886549443006516, -0.049831971526145935, -0.0708046555519104, 0.06778901070356369, 0.006041103042662144, -0.02184867486357689, -0.1574743092060089, 0.007285581901669502, -0.009493375197052956, -0.11445770412683487, 0.13661301136016846, 0.06959657371044159, 0.06547094881534576, 0.1444428265094757, 0.0006472403183579445, 0.002696748822927475, -0.12148243188858032, 0.010420739650726318, -0.14499373733997345, 1.2550381433641116e-32, -0.09799899905920029, 0.010909771546721458, -0.0594710037112236, -0.24752551317214966, -0.0291910357773304, -0.019635550677776337, 0.11851866543292999, 0.1624586582183838, -0.118607297539711, -0.017379194498062134, -0.0722830519080162, 0.07221980392932892, -0.08468268811702728, -0.02597026154398918, 0.061966463923454285, -0.12506842613220215, -0.04637286812067032, 0.019705835729837418, 0.03869577497243881, -0.06376849859952927, 0.07369904965162277, 0.06569804251194, -0.008227351121604443, -0.01775391213595867, -0.03268953785300255, -0.10079163312911987, -0.021221887320280075, 0.06702297180891037, 0.09763485193252563, 0.07092709839344025, -0.06649237871170044, -0.04210673272609711, 0.023200098425149918, -0.10710708796977997, -0.04546729475259781, -0.06995324045419693, -0.10247303545475006, -0.104946568608284, 0.009761318564414978, -0.009121472015976906, -0.24494561553001404, 0.20109650492668152, -0.14997932314872742, -0.0717373788356781, -0.0651579424738884, 0.04271877184510231, 0.022054173052310944, 0.044790416955947876, -0.1555425524711609, 0.05479490011930466, -0.1076640635728836, 0.04575584456324577, 0.016306348145008087, -0.033582206815481186, -0.11520877480506897, -0.0014480352401733398, 0.022695615887641907, -0.06960824131965637, 0.02472774311900139, 0.08462370932102203, 0.08310829102993011, 0.0802425667643547, -0.0968560203909874, -0.005000049713999033, -0.15901902318000793, 0.2234063744544983, 0.1561654955148697, 0.07967283576726913, -0.0866817981004715, 0.17833620309829712, 0.04895498603582382, 0.03918544575572014, 0.12649454176425934, 0.00942927971482277, 0.13989894092082977, -0.0876232236623764, -0.05593197047710419, 0.03795883432030678, 0.12646394968032837, -0.07584240287542343, 0.07172902673482895, 0.07692798227071762, 0.07722242921590805, 0.017085257917642593, -0.17959317564964294, 0.030205905437469482, -0.010063555091619492, -0.036769505590200424, -0.02642086148262024, -0.011809288524091244, -0.022663481533527374, -0.007781057618558407, -0.024037856608629227, 0.04588615894317627, 0.10256610065698624, -1.1402121817559443e-32, -0.10158178210258484, -0.03719574585556984, -0.099864661693573, 0.04063263535499573, -0.0927039086818695, 0.003802298568189144, -0.0380980409681797, -0.07070174068212509, 0.08220203965902328, -0.05209611728787422, -0.10525092482566833, 0.08856379240751266, -0.0740102156996727, 0.0163034126162529, -0.09537284076213837, -0.05654975771903992, -0.07228920608758926, -0.1413632333278656, -0.02428669109940529, -0.021765410900115967, 0.0602673664689064, 0.18130093812942505, -0.11409436166286469, 0.13824068009853363, 0.0575813427567482, 0.07572834193706512, -0.005424391478300095, 0.23962420225143433, 0.02573966607451439, -0.06582076847553253, -0.030347593128681183, -0.0913643091917038, -0.09523381292819977, 0.040404077619314194, -0.038438864052295685, 0.11995998024940491, -0.009761255234479904, -0.048312265425920486, -0.06777894496917725, 0.05436980351805687, 0.15837746858596802, -0.017133202403783798, 0.10998351871967316, -0.07433663308620453, 0.20617249608039856, -0.007218345068395138, -0.07740403711795807, -0.1336568295955658, 0.16840860247612, 0.026932191103696823, 0.006623446941375732, 0.052458036690950394, 0.016645489260554314, 0.2122456133365631, -0.13004028797149658, 0.042762305587530136, 0.10461641848087311, 0.06238093599677086, 0.021750379353761673, -0.039095692336559296, -0.008857257664203644, 0.08566761016845703, 0.023159150034189224, 0.03167152404785156, 0.08704748749732971, -0.014800149016082287, 0.07460781186819077, -0.15425831079483032, -0.01075328141450882, -0.05588734894990921, -0.018651507794857025, -0.09150585532188416, 0.11892946064472198, -0.024899227544665337, -0.08023165911436081, 0.1667940467596054, 0.02335512451827526, 0.011236569844186306, -0.08726619184017181, 0.01628585159778595, -0.07351355999708176, 0.04557126760482788, 0.07051868736743927, 0.005914626177400351, 0.014406591653823853, -0.020134322345256805, 0.11847707629203796, 0.018476424738764763, -0.12199155986309052, 0.04964449256658554, -0.04082236438989639, -0.1457735300064087, -0.08720715343952179, -0.010192562825977802, 0.02424454316496849, -1.0058280963676225e-07, 0.018201328814029694, -0.053074952214956284, -0.05682462826371193, 0.16810211539268494, 0.13331365585327148, -0.04715673252940178, 0.07517167925834656, 0.10547885298728943, 0.12718427181243896, 0.05295640975236893, 0.10402635484933853, 0.026231862604618073, -0.10983867943286896, 0.057327985763549805, -0.029716838151216507, 0.1061738133430481, -0.06574398279190063, -0.08219954371452332, 0.039709653705358505, 0.018349938094615936, 0.0023912619799375534, 0.07478156685829163, 0.018399663269519806, -0.07695899903774261, 0.06443412601947784, -0.017157843336462975, 0.0030040107667446136, 0.016159851104021072, 0.07331247627735138, 0.009960747323930264, -0.07870253175497055, -0.016084594652056694, 0.06342950463294983, -0.060763757675886154, 0.05587278679013252, -0.030158374458551407, -0.0644846111536026, 0.035229094326496124, 0.01117607019841671, 0.1622411608695984, 0.04991866275668144, 0.02500295080244541, -0.04895418882369995, -0.059921592473983765, 0.12311997264623642, -0.04684389382600784, -0.2664334774017334, 0.05513429269194603, 0.0996369794011116, -0.10291463136672974, 0.07421314716339111, 0.00773940933868289, -0.0014982782304286957, 0.0652221217751503, 0.06413619220256805, -0.08546647429466248, -0.046012505888938904, -0.0435551218688488, -0.17323066294193268, 0.10148276388645172, 0.13532958924770355, -0.18806031346321106, -0.03007781319320202, 0.12516604363918304], "changes": {"1wk": 3.9085900106423694}}, {"text": "Cytokinetics Announces 2025 Corporate Milestones and Vision 2030 Cytokinetics, Incorporated Mon, Jan 13, 2025, 3:30 PM 6 min read In This Article: CYTK -2.01% Cytokinetics, Incorporated PDUFA Target Action Date for Aficamten Set for\u00a0September 26, 2025; Commercial Launch Preparations Underway for First Potential Approval Five-Year Aspirations Outline Corporate Strategies to Becoming Leading Muscle Biology Specialty Biopharma Company SOUTH SAN FRANCISCO, Calif., Jan. 13, 2025 (GLOBE NEWSWIRE) -- \u00a0Cytokinetics, Inc. (Nasdaq: CYTK) today provided guidance for corporate milestones expected to occur in 2025 and outlined its aspirational Vision 2030, five-year strategic objectives designed to propel Cytokinetics to becoming the leading muscle-focused specialty biopharmaceutical company intent on meaningfully improving the lives of patients through global access to innovative\u00a0medicines. \u201cIn 2025 we are poised for a defining year with principal focus to the potential approval and commercial launch of aficamten for obstructive HCM in the United States. At the same time, we are executing on a robust clinical trials development program for aficamten inclusive of MAPLE-HCM, with results expected in the first half of this year as may potentially support the use of aficamten as monotherapy,\u201d said Robert I. Blum, Cytokinetics\u2019 President and Chief Executive Officer. \u201cIn addition, we are advancing our later-stage development programs for omecamtiv mecarbil and CK-586 in adjacent specialty cardiology indications with intention to further augment our pipeline over time. Cytokinetics is well positioned to prudently and meaningfully deliver increased shareholder value as we continue to execute well on key milestones and position the company to achieve longer-term aspirations defining of our Vision 2030.\u201d Expected 2025 Milestones Cardiac Muscle Programs Aficamten (cardiac myosin inhibitor) Advance go-to-market strategies and prepare to commercially launch aficamten in the U.S. in 2H 2025, subject to approval by the U.S. Food & Drug Administration (FDA). Continue go-to-market plans in Germany and expand commercial readiness activities in Europe in 2025, in preparation for potential approval by the European Medicines Agency (EMA) in 1H 2026. Coordinate with Sanofi to support the potential approval of aficamten in China in 2H 2025, pending approval by the National Medical Products Administration (NMPA). Report topline results from MAPLE-HCM ( M etoprolol vs A ficamten in P atients with L VOT Obstruction on E xercise Capacity in HCM) , the Phase 3 clinical trial comparing aficamten as monotherapy to metoprolol as monotherapy in patients with symptomatic obstructive HCM, in 1H 2025. Complete patient enrollment of ACACIA-HCM ( A ssessment C omparing A ficamten to Placebo on C ardiac Endpoints I n A dults with Non-Obstructive HCM ), the pivotal Phase 3 clinical trial of aficamten in patients with non-obstructive HCM, in 2H 2025. Complete enrollment of the adolescent cohort in CEDAR-HCM ( C linical E valuation of D osing with A ficamten to R educe Obstruction in a Pediatric Population in HCM ), a clinical trial of aficamten in a pediatric population with symptomatic obstructive HCM, in 2H 2025. Story Continues Omecamtiv mecarbil (cardiac myosin activator) Continue patient enrollment in COMET-HF ( C onfirmation of O mecamtiv M ecarbil E fficacy T rial in H eart F ailure), a confirmatory Phase 3 clinical of omecamtiv mecarbil in patients with symptomatic heart failure with severely reduced ejection fraction (HFrEF) through 2025 to enable completion of enrollment in 2026. CK-586 (cardiac myosin inhibitor) Complete enrollment of the first two patient cohorts in AMBER-HFpEF, ( A ssessment of CK-586 in a M ulti-Center, B linded E valuation of Safety and Tolerability R esults in HFpEF ), a Phase 2 clinical trial of CK-586 in patients with symptomatic heart failure with preserved ejection fraction (HFpEF) in 2H 2025. Skeletal Muscle Program CK-089 (fast skeletal muscle troponin activator) Complete the Phase 1 study of CK-089 in healthy human participants in 2025. Ongoing Research Continue ongoing pre-clinical development and research activities directed to additional muscle biology focused programs. Vision 2030 The Company also outlined its Vision 2030: \u201cEmpowering Muscle, Empowering Lives\u201d with the following objectives: Innovation : Advance two approved products across three indications and ten novel molecular entities (NMEs) in our pipeline. Ignition : Achieve broad access and rapid use of our medicines in >15 countries throughout North America and Europe. Impact : Reach >100,000 patients globally with our medicines. Inspiration : Foster a patient-centric culture with emphasis on equitable access. Ingenuity : Extend our leadership in muscle biology deploying multiple therapeutic modalities. \u201cOur Vision 2030 provides the aspirational roadmap, aligned with our corporate five-year strategic plan, that will propel us forward as a fully integrated and leading specialty biopharma company intent on delivering innovative medicines to patients around the world,\u201d said Mr. Blum. \u201cVision 2030 articulates ambitious company goals to deliver product approvals, achieve broad access to our medicines, promote equitable access and advance our pioneering research to benefit patients, shareholders and employees.\u201d About Cytokinetics Cytokinetics is a late-stage, muscle biology specialty biopharmaceutical company focused on discovering, developing and commercializing muscle biology-directed drug candidates as potential treatments for debilitating diseases in which muscle performance is compromised. As a leader in muscle biology and the mechanics of muscle performance, Cytokinetics is intent on meaningfully improving the lives of patients through global access to innovative\u00a0medicines. Cytokinetics is readying for potential regulatory approvals and commercialization of aficamten, a next-in-class cardiac myosin inhibitor following positive results from SEQUOIA-HCM, the pivotal Phase 3 clinical trial in patients with obstructive hypertrophic cardiomyopathy (HCM). Aficamten is also being evaluated in additional clinical trials enrolling patients with obstructive and non-obstructive HCM. Cytokinetics is also developing omecamtiv mecarbil , a cardiac myosin activator, in patients with heart failure with severely reduced ejection fraction (HFrEF), CK-586, a cardiac myosin inhibitor with a mechanism of action distinct from aficamten, for the potential treatment of heart failure with preserved ejection fraction (HFpEF) and CK-089, a fast skeletal muscle troponin activator with potential therapeutic application to a specific type of muscular dystrophy and other conditions of impaired skeletal muscle function. For additional information about Cytokinetics, visit www.cytokinetics.com and follow us on X , LinkedIn , Facebook and YouTube . Forward-Looking Statements This press release contains forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995 (the \u201cAct\u201d). Cytokinetics disclaims any intent or obligation to update these forward-looking statements and claims the protection of the Act\u2019s Safe Harbor for forward-looking statements. Examples of such statements include, but are not limited to, statements express or implied relating to the properties or potential benefits of aficamten or any of our other drug candidates, our ability to obtain regulatory approval for aficamten for the treatment of obstructive hypertrophic cardiomyopathy or any other indication from FDA or any other regulatory body in the United States or abroad on a timely basis, or at all, the labeling or post-marketing conditions that FDA or another regulatory body may require in connection with the approval of aficamten, our ability to timely enroll and complete the ACACIA-HCM, AMBER-HFpEF, CEDAR-HCM, COMET-HF or CK-089 clinical trials, our ability to timely report the results of the MAPLE-HCM trial, and our ability achieve any element of our Vision 2030. Such statements are based on management\u2019s current expectations, but actual results may differ materially due to various risks and uncertainties, including, but not limited to the risks related to Cytokinetics\u2019 business outlines in Cytokinetics\u2019 filings with the Securities and Exchange Commission. Forward-looking statements are not guarantees of future performance, and Cytokinetics\u2019 actual results of operations, financial condition and liquidity, and the development of the industry in which it operates, may differ materially from the forward-looking statements contained in this press release. Any forward-looking statements that Cytokinetics makes in this press release speak only as of the date of this press release. Cytokinetics assumes no obligation to update its forward-looking statements whether as a result of new information, future events or otherwise, after the date of this press release. CYTOKINETICS\u00ae and the CYTOKINETICS and C-shaped logo are registered trademarks of Cytokinetics in the U.S. and certain other countries. Contact: Cytokinetics Diane Weiser Senior Vice President, Corporate Affairs (415) 290-7757 View Comments Terms and Privacy Policy Privacy Dashboard Recommended Stories", "symbol": "CYTK", "date": "2025-01-13T12:30:00+00:00", "sentiment": {"score": 0.87333062896505, "confidence": 0.8807958364486694, "probabilities": {"positive": 0.8807958364486694, "negative": 0.0074652074836194515, "neutral": 0.11173895001411438}}, "embedding": [-0.128730908036232, -0.10494136065244675, 0.06510217487812042, -0.16711583733558655, -0.0680980533361435, -0.05387187749147415, -0.14464648067951202, 0.23798596858978271, 0.03134946897625923, 0.00765308178961277, -0.0843823254108429, 0.01042746938765049, 0.03704400360584259, 0.12917765974998474, 0.013202306814491749, 0.02799198403954506, 0.09787677973508835, 0.05564333125948906, -0.07397876679897308, 0.06343187391757965, 0.004466058686375618, -0.04840777814388275, 0.027846775949001312, 0.11404731869697571, -0.09060177206993103, -0.017764316871762276, -0.1204940602183342, -0.06981496512889862, -0.14668989181518555, 0.02767810970544815, -0.017095286399126053, 0.11680255085229874, 0.11316008865833282, 0.027720823884010315, 0.020381376147270203, 0.025142578408122063, -0.07982628047466278, -0.024276118725538254, -0.11069950461387634, -0.05223088338971138, 0.007833937183022499, -0.11341925710439682, -0.1072225496172905, 0.08573871850967407, 0.15310515463352203, -0.04752914234995842, -0.014022870920598507, 0.009647931903600693, -0.09473592042922974, 0.18812867999076843, -0.14697585999965668, -0.21492131054401398, 0.05575978755950928, 0.01297750510275364, -0.08292987942695618, -0.0033277608454227448, -0.24635529518127441, -0.0753403753042221, 0.05237727612257004, -0.05773714929819107, -0.07227535545825958, -0.08269083499908447, -0.05279044806957245, -0.011263484135270119, -0.005484789609909058, -0.028713461011648178, 0.044248662889003754, 0.05805381387472153, 0.12052657455205917, -0.040196385234594345, 0.0984230637550354, -0.1346149742603302, -0.03109150379896164, 0.13193827867507935, -0.046639833599328995, 0.192854642868042, 0.17216232419013977, 0.13884000480175018, 0.08395296335220337, -0.19824355840682983, 0.13274407386779785, 0.07965933531522751, 0.0616130605340004, 0.0017981715500354767, -0.06414152681827545, 0.07188200205564499, -0.03723568469285965, 0.19685307145118713, -0.02960602380335331, 0.07118632644414902, 0.10580914467573166, 0.027766156941652298, 0.013252566568553448, -0.0009451780933886766, -0.06296218931674957, -0.03771878406405449, -0.033416248857975006, 0.014874020591378212, 0.057192109525203705, -0.0028585027903318405, 0.07105252891778946, 0.06317228078842163, -0.09213464707136154, -0.06691473722457886, -0.054522838443517685, -0.126152902841568, 0.039939336478710175, -0.03577669709920883, 0.1498432159423828, -0.03230374678969383, -0.0006492189131677151, -0.07455267012119293, -0.07583051919937134, -0.1253202110528946, -0.036772146821022034, 0.31434696912765503, -0.02852996252477169, 0.004297914914786816, 0.21934717893600464, 0.009324808605015278, 0.06916988641023636, -0.061396799981594086, -0.0038679447025060654, -0.052166104316711426, -0.05264662206172943, 0.1254054456949234, -0.14141112565994263, 1.0733690913959765e-32, -0.0518040657043457, 0.005724230781197548, 0.10113859176635742, 0.11971046775579453, -0.08157441020011902, -0.06285428255796432, 0.09071986377239227, -0.027596384286880493, -0.09522220492362976, -0.19089925289154053, -0.1281338632106781, 0.03618478402495384, 0.009303577244281769, 0.09429848194122314, -0.06800424307584763, -0.2289513647556305, -0.04509519040584564, 0.00843554176390171, -0.0008941544219851494, 0.03428260236978531, 0.11355555057525635, -0.06089124083518982, -0.08658022433519363, 0.03055413067340851, 0.04088721424341202, 0.11502949893474579, -0.0066890534944832325, 0.04929697513580322, 0.08508875966072083, 0.07694908231496811, -0.11753809452056885, 0.019767513498663902, -0.00513320229947567, -0.10345793515443802, 0.0030457405373454094, -0.07738303393125534, -0.11596973240375519, -0.12873373925685883, 0.03098670020699501, 0.025310680270195007, -0.02920602634549141, 0.02329411171376705, -0.10807924717664719, -0.13476932048797607, 0.18600553274154663, -0.1101362556219101, -0.041526928544044495, 0.0261886864900589, -0.016470788046717644, -0.09376949071884155, 0.1292349100112915, -0.00558167789131403, -0.010302841663360596, -0.07565204799175262, -0.005179509520530701, 0.08581440150737762, -0.15923863649368286, -0.034108586609363556, -0.009183789603412151, 0.026874616742134094, 0.05008593946695328, 0.041016045957803726, -0.05452345684170723, 0.05777781456708908, -0.10727998614311218, 0.1402353048324585, -0.10272283107042313, -0.00962670799344778, -0.15120407938957214, 0.19365841150283813, -0.003149394877254963, -0.09963653981685638, 0.04902813211083412, -0.07556271553039551, 0.18629500269889832, 0.058866437524557114, 0.0481855683028698, 0.18038159608840942, -0.05197599530220032, 0.04883955791592598, -0.026937389746308327, 0.09883993864059448, -0.10786746442317963, 0.1596902310848236, 0.129903644323349, -0.14528469741344452, 0.14820607006549835, -0.04552508890628815, -0.14081910252571106, -0.00922098383307457, 0.10678388178348541, -0.05480086803436279, 0.033754073083400726, 0.28278523683547974, -0.05673541873693466, -1.3648872088276913e-32, 0.011084642261266708, 0.08969816565513611, -0.011821256950497627, -0.129074826836586, -0.030749114230275154, 0.10003812611103058, 0.04532554745674133, -0.1027926579117775, 0.14657598733901978, -0.0541982501745224, 0.05765952914953232, 9.091384708881378e-05, -0.05646897479891777, 0.07519002258777618, -0.1824958473443985, 0.02451356127858162, -0.04180010035634041, -0.036968398839235306, -0.1929110884666443, 0.1190357357263565, 0.06290106475353241, 0.044321127235889435, -0.0501222088932991, 0.12033817917108536, 0.11293812096118927, 0.06562576442956924, 0.07651890814304352, 0.03997058793902397, 0.1345193088054657, -0.09135664999485016, -0.07703635841608047, -0.0364973247051239, -0.18150106072425842, -0.0443926565349102, 0.01916465163230896, 0.01812356524169445, 0.015113684348762035, -0.10884016007184982, 0.03784532472491264, -0.05799204483628273, -0.010637791827321053, -0.10347156971693039, -0.04567733779549599, 0.08488737791776657, -0.010392716154456139, -0.0231044739484787, 0.15358856320381165, -0.04178202897310257, 0.07305993139743805, 0.030742332339286804, -0.06091039627790451, 0.03899344056844711, -0.010864629410207272, 0.09931748360395432, -0.10046204924583435, 0.01849573850631714, 0.11293604224920273, 0.053506262600421906, -0.04786865785717964, -0.05694158002734184, -0.0032097590155899525, 0.03288101777434349, 0.10840936750173569, -0.024990705773234367, 0.10811656713485718, 0.04997492954134941, 0.13232046365737915, 0.0951998382806778, -0.04068755358457565, -0.09109941124916077, -0.008659664541482925, 0.018513454124331474, -0.13575243949890137, -0.03901677951216698, 0.033407486975193024, 0.013313096016645432, 0.07940967381000519, -0.23585376143455505, -0.1741771250963211, -0.04856887832283974, -0.001965045928955078, -0.03660466521978378, -0.029750412330031395, 0.027547724545001984, 0.058892954140901566, -0.020483558997511864, 0.14625191688537598, 0.03100287914276123, -0.0341682955622673, 0.05367475375533104, -0.06899502128362656, -0.06949566304683685, -0.06482242047786713, 0.2087143212556839, 0.033899445086717606, -1.0120189841700267e-07, 0.10082893818616867, 0.010280839167535305, -0.10575795918703079, -0.05984994396567345, -0.03851889818906784, -0.08523782342672348, -0.15793603658676147, -0.03367684781551361, -0.016695760190486908, 0.08630351722240448, 0.06586238741874695, 0.184513121843338, -0.03922930732369423, -0.07040975987911224, -0.012330524623394012, -0.00814816728234291, -0.09103019535541534, 0.012066470459103584, -0.04713936895132065, 0.008935876190662384, -0.13379234075546265, 0.003031384199857712, 0.02067599445581436, -0.07736817747354507, -0.023614972829818726, -0.23338112235069275, -0.024028757587075233, 0.1526753306388855, 0.07571396231651306, -0.07066553086042404, 0.055599287152290344, 0.016717664897441864, 0.01713123358786106, 0.04513804614543915, -0.1246735155582428, -0.12953677773475647, -0.06917756795883179, 0.03832218796014786, 0.03674344718456268, 0.07941562682390213, -0.031398311257362366, -0.029178764671087265, 0.0005073817446827888, 0.04474819451570511, -0.037006836384534836, -0.18093359470367432, -0.030469004064798355, -0.06782408058643341, 0.005521952174603939, -0.007055722177028656, -0.10740835964679718, 0.01891055330634117, 0.004697468131780624, -0.06548367440700531, 0.036825135350227356, 0.15119442343711853, -0.08844016492366791, -0.12605226039886475, 0.011504187248647213, -0.042354434728622437, 0.001245100051164627, -0.15587064623832703, 0.12461084127426147, 0.051203642040491104], "changes": {"1wk": -2.076637604406004}}, {"text": "Cytokinetics to Present at the 43rd Annual J.P. Morgan Healthcare Conference Cytokinetics, Incorporated Tue, Jan 7, 2025, 12:00 AM 3 min read In This Article: CYTK -2.01% Cytokinetics, Incorporated SOUTH SAN FRANCISCO, Calif., Jan. 06, 2025 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that Robert I. Blum, President and Chief Executive Officer, is scheduled to present at the 43 rd Annual J.P. Morgan Healthcare Conference on Monday, January 13, 2025 at 9:00 AM Pacific Time in the Borgia Room of the Westin St. Francis Hotel in San Francisco, CA. Interested parties may access the live webcast of the presentation by visiting the Investors & Media section of the Cytokinetics website at http://www.cytokinetics.com . The webcast replay will be archived on the Cytokinetics website for 90 days following the conclusion of the event. About Cytokinetics Cytokinetics is a late-stage, specialty cardiovascular biopharmaceutical company focused on discovering, developing and commercializing muscle biology-directed drug candidates as potential treatments for debilitating diseases in which cardiac muscle performance is compromised. As a leader in muscle biology and the mechanics of muscle performance, the company is developing small molecule drug candidates specifically engineered to impact myocardial muscle function and contractility. Cytokinetics is readying for the potential commercialization of aficamten, a next-in-class cardiac myosin inhibitor following positive results from SEQUOIA-HCM, the pivotal Phase 3 clinical trial in patients with obstructive hypertrophic cardiomyopathy (HCM). Aficamten is also being evaluated in additional clinical trials enrolling patients with obstructive and non-obstructive HCM. Cytokinetics is also developing omecamtiv mecarbil , a cardiac myosin activator, in patients with heart failure with severely reduced ejection fraction (HFrEF), CK-586, a cardiac myosin inhibitor with a mechanism of action distinct from aficamten, for the potential treatment of heart failure with preserved ejection fraction (HFpEF) and CK-089, a fast skeletal muscle troponin activator with potential therapeutic application to a specific type of muscular dystrophy and other conditions of impaired skeletal muscle function. For additional information about Cytokinetics, visit www.cytokinetics.com and follow us on X , LinkedIn , Facebook and YouTube . Forward-Looking Statements This press release contains forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995 (the \"Act\"). Cytokinetics disclaims any intent or obligation to update these forward-looking statements and claims the protection of the Act's Safe Harbor for forward-looking statements. Examples of such statements include, but are not limited to, statements relating to Cytokinetics' and its partners' research and development activities of Cytokinetics\u2019 product candidates. Such statements are based on management's current expectations, but actual results may differ materially due to various risks and uncertainties, including, but not limited to the risks related to Cytokinetics' business outlined in Cytokinetics' filings with the Securities and Exchange Commission. Forward-looking statements are not guarantees of future performance, and Cytokinetics' actual results of operations, financial condition and liquidity, and the development of the industry in which it operates, may differ materially from the forward-looking statements contained in this press release. Any forward-looking statements that Cytokinetics makes in this press release speak only as of the date of this press release. Cytokinetics assumes no obligation to update its forward-looking statements whether as a result of new information, future events or otherwise, after the date of this press release. Story Continues CYTOKINETICS\u00ae and the CYTOKINETICS and C-shaped logo are registered trademarks of Cytokinetics in the U.S. and certain other countries. Contact: Cytokinetics Diane Weiser Senior Vice President, Corporate Affairs (415) 290-7757 View Comments Terms and Privacy Policy Privacy Dashboard Recommended Stories", "symbol": "CYTK", "date": "2025-01-06T21:00:00+00:00", "sentiment": {"score": 0.13280820474028587, "confidence": 0.1422482430934906, "probabilities": {"positive": 0.1422482430934906, "negative": 0.009440038353204727, "neutral": 0.8483117818832397}}, "embedding": [-0.08657943457365036, -0.10698840767145157, 0.025325609371066093, -0.10661709308624268, -0.020341886207461357, -0.05062178149819374, -0.07887531816959381, 0.22719714045524597, 0.03676415607333183, -0.0042243232019245625, -0.06253302097320557, 0.005775736644864082, 0.10918991267681122, 0.13054658472537994, 0.03853578865528107, 0.033101700246334076, 0.12805676460266113, 0.25659051537513733, -0.10755898058414459, 0.15483519434928894, 0.032924581319093704, 0.06710359454154968, -0.022674724459648132, 0.19126957654953003, -0.12007385492324829, -0.025795578956604004, -0.1009175032377243, 0.014938280917704105, -0.21608498692512512, 0.029110796749591827, -0.14342409372329712, 0.039435386657714844, 0.19269204139709473, 0.10904915630817413, 0.04076331481337547, 0.12663421034812927, -0.0739428699016571, -0.07869520783424377, -0.052586767822504044, -0.0598498210310936, -0.0015499163419008255, -0.07310032099485397, -0.030448684468865395, 0.02615954540669918, 0.20040680468082428, 0.006026014685630798, -0.009425899013876915, 0.010832206346094608, -0.0685940608382225, 0.19428130984306335, -0.20158526301383972, -0.013105101883411407, 0.056026630103588104, 0.06291666626930237, -0.04750873148441315, -0.003505113534629345, -0.2933145761489868, -0.020512808114290237, -0.0403565913438797, -0.07824932038784027, -0.019039805978536606, -0.019152488559484482, 0.018997542560100555, -0.011556878685951233, 0.004934235941618681, 0.006354759447276592, 0.01574324257671833, 0.11948144435882568, 0.11896152794361115, -0.01811128854751587, 0.10304185748100281, -0.11744613945484161, -0.045908086001873016, 0.14016465842723846, -0.036952193826436996, 0.15339581668376923, 0.12517747282981873, 0.05842910334467888, -0.00038742460310459137, -0.16123345494270325, 0.12044674903154373, 0.015250052325427532, 0.1293884962797165, 0.012960807420313358, -0.03339141234755516, 0.0783655047416687, -0.03445323929190636, 0.12824629247188568, -0.014223238453269005, 0.1323733925819397, 0.118567556142807, 0.11927752196788788, 0.057443030178546906, -0.017333243042230606, 0.03326372802257538, -0.08689133822917938, -0.02768862061202526, 0.08338800072669983, 0.087563157081604, -0.01839904859662056, 0.13510450720787048, 0.04935096204280853, -0.08594062179327011, -0.07748489081859589, 0.09636056423187256, -0.07513564825057983, 0.0746125653386116, -0.027915632352232933, 0.1681339591741562, 0.05856635794043541, 0.013551559299230576, -0.05828127637505531, -0.11674432456493378, -0.11893819272518158, 0.05591452866792679, 0.36842578649520874, 0.012127574533224106, 0.040432073175907135, 0.11785511672496796, 0.05753779038786888, 0.09607402980327606, -0.16506825387477875, -0.009663267061114311, -0.0904478207230568, -0.13396957516670227, 0.15199658274650574, -0.19817142188549042, 9.556946865705759e-33, 0.003503597341477871, -0.06265824288129807, 0.14458522200584412, 0.05335812643170357, 0.06805042177438736, -0.13625696301460266, 0.010945343412458897, -0.07190011441707611, -0.11444798111915588, -0.20676368474960327, -0.15438425540924072, -0.002157849259674549, 0.11950954794883728, 0.02606559358537197, -0.14175060391426086, -0.13491597771644592, -0.13026684522628784, -0.026498842984437943, 0.04865943640470505, -0.023915842175483704, 0.11446089297533035, 0.0022986531257629395, -0.06128470599651337, 0.012625454925000668, -0.0498742014169693, 0.099399134516716, 0.013255869969725609, 0.0859595537185669, 0.03494521975517273, 0.0020234007388353348, -0.15074077248573303, -0.051445167511701584, -0.021707424893975258, -0.12188407778739929, 0.040137000381946564, -0.17282435297966003, -0.11548306047916412, -0.10913023352622986, 0.012096108868718147, -0.01300223171710968, -0.1589992642402649, -0.06267398595809937, -0.11473612487316132, -0.13604439795017242, 0.18024471402168274, -0.11646153032779694, 0.01680147275328636, -0.0227399542927742, -0.06896723806858063, -0.01088122557848692, 0.16278760135173798, -0.04353754222393036, 0.05910339206457138, -0.11453642696142197, -0.019592532888054848, -0.006556835025548935, -0.1091582179069519, 0.05456789582967758, -0.02915768139064312, 0.07179000973701477, 0.03726762533187866, 0.023311862722039223, -0.00231922697275877, 0.09003086388111115, -0.11906400322914124, 0.08481787890195847, -0.1946241706609726, -0.04774422571063042, -0.1654393970966339, 0.10546202957630157, 0.07959520071744919, -0.1173446774482727, 0.04450967162847519, -0.062025971710681915, 0.16361738741397858, 0.0066818539053201675, -0.005408463533967733, 0.18917909264564514, -0.1784004271030426, -0.07691140472888947, -0.037399303168058395, 0.049313340336084366, -0.10294994711875916, 0.16727763414382935, 0.001433705911040306, -0.08910903334617615, 0.20103028416633606, -0.086988165974617, -0.07399000227451324, -0.04821097478270531, 0.11979325115680695, -0.13077464699745178, -0.014018449001014233, 0.2024204134941101, -0.09534353017807007, -1.0517726887774786e-32, -0.042667437344789505, 0.05326437950134277, 0.06048623472452164, -0.08859594166278839, -0.07275956869125366, 0.14989441633224487, 0.06926009058952332, -0.1654263436794281, 0.17031648755073547, -0.12028314918279648, 0.06516747921705246, -0.047393444925546646, -0.06123344600200653, 0.061342302709817886, -0.16667301952838898, 0.12216228991746902, -0.09275422990322113, -0.09103058278560638, -0.23476079106330872, 0.1912657916545868, 0.0903407633304596, 0.05079563707113266, -0.012942848727107048, 0.1409679651260376, 0.07154655456542969, 0.096180260181427, 0.062309473752975464, 0.10093961656093597, 0.1488371193408966, -0.0802193209528923, 0.003846392035484314, 0.001182757318019867, -0.23077011108398438, -0.06156087666749954, 0.02931424230337143, 0.060377608984708786, -0.07327646017074585, -0.0031955093145370483, 0.038666244596242905, -0.10594595968723297, 0.010957298800349236, -0.0781618058681488, 0.02605881169438362, 0.07033482193946838, -0.015107207000255585, 0.021480794996023178, 0.16109566390514374, -0.07258477807044983, -0.07558857649564743, 0.11890259385108948, -0.03835195302963257, -0.009012898430228233, 0.03438377007842064, 0.09473150223493576, -0.012355961836874485, 0.05786653235554695, 0.08004899322986603, 0.1197083368897438, -0.08053626120090485, -0.0029090335592627525, -0.05436769872903824, -0.04955391585826874, 0.10288587957620621, -0.008418399840593338, 0.17628547549247742, 0.05845801159739494, 0.11558350920677185, 0.1239205151796341, 0.0256954338401556, -0.017179859802126884, 0.03425319865345955, 0.11618877947330475, 0.02645132690668106, 0.06646601110696793, 0.014064114540815353, 0.062221698462963104, 0.040778301656246185, -0.14152315258979797, -0.23253923654556274, -0.06126857548952103, 0.08121232688426971, -0.1142839789390564, -0.03611200302839279, -0.04599948227405548, -0.04050346463918686, 0.008006769232451916, 0.21114814281463623, 0.10369819402694702, -0.013984763994812965, 0.04198587313294411, 0.03248114138841629, -0.030620073899626732, -0.05076383426785469, 0.1611410528421402, -0.005232257768511772, -9.999466499266418e-08, 0.07856935262680054, -0.09557776153087616, -0.12492014467716217, -0.20853106677532196, -0.08191095292568207, -0.07250092178583145, -0.03452378138899803, -0.06796318292617798, -0.06170966476202011, 0.039092227816581726, 0.10165351629257202, 0.10028624534606934, 0.041433386504650116, -0.17005760967731476, -0.05129638686776161, -0.08634322136640549, -0.13890299201011658, -0.04222332686185837, -0.029293451458215714, 0.03198104351758957, -0.0820162296295166, -0.05333467572927475, -0.06352119892835617, -0.037665076553821564, 0.1236686259508133, -0.1793391853570938, 0.0015881825238466263, 0.1151602566242218, 0.07701969146728516, -0.13381236791610718, -0.003180504310876131, 0.008381262421607971, 0.06574610620737076, 0.0712742805480957, -0.10512292385101318, -0.09935362637042999, -0.04895897954702377, -0.02086494117975235, -0.08685079216957092, 0.08999265730381012, -0.07212384790182114, -0.10225291550159454, -0.0037345802411437035, -0.006330914795398712, 0.006551288068294525, -0.11422917246818542, -0.001058223657310009, 0.010555248707532883, 0.13725706934928894, -0.0211816243827343, -0.09148497879505157, 0.015574870631098747, 0.019083496183156967, -0.11362873017787933, -0.032943058758974075, 0.15002694725990295, -0.10996827483177185, 0.026197906583547592, 0.05749556049704552, -0.05561260133981705, -0.03803417831659317, -0.0745106190443039, 0.04202387109398842, 0.02236582338809967], "changes": {"1wk": -5.041674347373834}}, {"text": "Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) Cytokinetics, Incorporated Sat, Jan 4, 2025, 12:00 AM 5 min read In This Article: CYTK -2.01% Cytokinetics, Incorporated SOUTH SAN FRANCISCO, Calif., Jan. 03, 2025 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that on December 31, 2024 it granted stock options to purchase an aggregate of 52,188 shares of common stock, 33,885 restricted stock units (RSUs) that will be settled in shares of common stock upon vesting\u00a0and 3,189 performance stock units (PSUs) that, if earned, will be settled in shares of common stock upon vesting to 9 employees, whose employment commenced in December 2024, as a material inducement to their employment. The RSUs will vest over 3 years, with 40% of the RSUs vesting on the first anniversary of the applicable grant date, an additional 40% of the RSUs vesting on the second anniversary of the grant date and the final 20% vesting on the third anniversary of the grant date, in each case, subject to each respective employee\u2019s continued service with the Company. The stock options that were granted are subject to an exercise price of $47.04 per share, which is equal to the closing price of the Company\u2019s common stock on December 31, 2024, and will vest over 4 years, with 1/4 th of the shares underlying the employee\u2019s option vesting on the one-year anniversary of the grant date and the remaining shares thereafter vesting in monthly installments at a rate of 1/48th of the shares underlying such stock options over the subsequent 36 months, subject to each respective employee\u2019s continued service with the Company. The stock options have a 10-year term. The PSU\u00a0award is subject to two performance goals and will be earned as to up to 50% of the number of shares subject to the PSU award upon the certification by Compensation and Talent Committee of the Company\u2019s Board of Directors (Committee) that the Company has achieved the first performance goal and as to up to 50% of the number of shares subject to the PSU award upon the certification by the Committee that the Company has achieved the second performance goal. The earned shares will vest as to 50% of the earned shares on applicable Committee certification date and as to 50% of the earned shares following the\u00a0one-year\u00a0anniversary of the applicable Committee certification date, subject to the respective employee\u2019s continued service with the Company. These awards are subject to the terms and conditions of the Company's Amended and Restated 2004 Equity Incentive Plan and the applicable award agreements pursuant to which the awards were granted. The stock options, RSUs and PSUs were granted as material inducements to employment in accordance with Nasdaq Listing Rule 5635(c)(4). Story Continues About Cytokinetics Cytokinetics is a late-stage, specialty cardiovascular biopharmaceutical company focused on discovering, developing and commercializing muscle biology-directed drug candidates as potential treatments for debilitating diseases in which cardiac muscle performance is compromised. As a leader in muscle biology and the mechanics of muscle performance, the company is developing small molecule drug candidates specifically engineered to impact myocardial muscle function and contractility. Cytokinetics is readying for the potential commercialization of aficamten, a next-in-class cardiac myosin inhibitor following positive results from SEQUOIA-HCM, the pivotal Phase 3 clinical trial in patients with obstructive hypertrophic cardiomyopathy (HCM). Aficamten is also being evaluated in additional clinical trials enrolling patients with obstructive and non-obstructive HCM. Cytokinetics is also developing omecamtiv mecarbil , a cardiac myosin activator, in patients with heart failure with severely reduced ejection fraction (HFrEF), CK-586, a cardiac myosin inhibitor with a mechanism of action distinct from aficamten, for the potential treatment of heart failure with preserved ejection fraction (HFpEF) and CK-089, a fast skeletal muscle troponin activator with potential therapeutic application to a specific type of muscular dystrophy and other conditions of impaired skeletal muscle function. For additional information about Cytokinetics, visit www.cytokinetics.com and follow us on X , LinkedIn , Facebook and YouTube . Forward-Looking Statements This press release contains forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995 (the \"Act\").\u00a0Cytokinetics\u00a0disclaims any intent or obligation to update these forward-looking statements and claims the protection of the Act's\u00a0Safe Harbor\u00a0for forward-looking statements. Examples of such statements include, but are not limited to, statements relating to\u00a0Cytokinetics'\u00a0and its partners' research and development activities of Cytokinetics\u2019 product candidates. Such statements are based on management's current expectations, but actual results may differ materially due to various risks and uncertainties, including, but not limited to the risks related to\u00a0Cytokinetics'\u00a0business outlined in\u00a0Cytokinetics'\u00a0filings with the\u00a0Securities and Exchange Commission particularly under the caption \u201cRisk Factors\u201d in Cytokinetics\u2019 latest Annual Report on Form 10-K. Forward-looking statements are not guarantees of future performance, and\u00a0Cytokinetics'\u00a0actual results of operations, financial condition and liquidity, and the development of the industry in which it operates, may differ materially from the forward-looking statements contained in this press release. Any forward-looking statements that\u00a0Cytokinetics\u00a0makes in this press release speak only as of the date of this press release.\u00a0Cytokinetics\u00a0assumes no obligation to update its forward-looking statements whether as a result of new information, future events or otherwise, after the date of this press release. CYTOKINETICS\u00ae and the CYTOKINETICS and C-shaped logo are registered trademarks of Cytokinetics in the U.S. and certain other countries. Contact: Cytokinetics Diane Weiser Senior Vice President, Corporate Affairs (415) 290-7757 View Comments Terms and Privacy Policy Privacy Dashboard Recommended Stories", "symbol": "CYTK", "date": "2025-01-03T21:00:00+00:00", "sentiment": {"score": 0.01921086013317108, "confidence": 0.03447098657488823, "probabilities": {"positive": 0.03447098657488823, "negative": 0.015260126441717148, "neutral": 0.9502689242362976}}, "embedding": [-0.12222270667552948, 0.007966144010424614, 0.03196953982114792, -0.055299267172813416, -0.16286781430244446, 0.15490736067295074, 0.028062716126441956, 0.1184196025133133, 0.03923971578478813, -0.001956904772669077, 0.04475267231464386, 0.07306624948978424, 0.09524883329868317, 0.013257231563329697, -0.012782932259142399, 0.016979752108454704, -0.011441757902503014, 0.0508924201130867, -0.14351189136505127, -0.016926776617765427, -0.03434403985738754, -0.18820026516914368, -0.14136475324630737, -0.10810504853725433, 0.14054885506629944, -0.028739523142576218, -0.04290125146508217, 0.10217133164405823, -0.024428073316812515, 0.06105658411979675, -0.00904542300850153, 0.08727231621742249, 0.07960398495197296, -0.03389407694339752, -0.08194851875305176, -0.022143732756376266, -0.09623421728610992, 0.073598712682724, 0.09023047238588333, -0.005468924529850483, 0.007077494636178017, 0.009649712592363358, -0.08468402922153473, 0.019922897219657898, 0.004153059329837561, 0.03433326259255409, -0.0010867493692785501, 0.017585746943950653, -0.0668107122182846, -0.035746462643146515, -0.02709253877401352, 0.000640717800706625, 0.04147389903664589, 0.10577833652496338, -0.15137910842895508, -0.04018530994653702, -0.19192065298557281, -0.02516404539346695, 0.05802407115697861, -0.028405722230672836, -0.0359356552362442, -0.04731599986553192, -0.08915701508522034, 0.0461614653468132, 0.16154111921787262, -0.020797060802578926, -0.008564298041164875, 0.044012539088726044, 0.01858808845281601, 0.015225626528263092, 0.1002463847398758, -0.016428660601377487, -0.19444304704666138, -0.04894427955150604, -0.13970546424388885, 0.2970099449157715, 0.07602006942033768, 0.05999094247817993, -0.00944984145462513, -0.2815873324871063, -0.012091685086488724, 0.05871571600437164, 0.011224945075809956, -0.0821981281042099, -0.022780083119869232, -0.0069242240861058235, 0.04543176293373108, 0.13846325874328613, 0.09743324667215347, 0.014347466640174389, 0.09524337202310562, -0.01866181194782257, -0.02614213526248932, -0.10342864692211151, -0.0027486011385917664, -0.026595033705234528, -0.09202395379543304, -0.03924410045146942, 0.0026404932141304016, 0.08440906554460526, 0.0677458643913269, 0.05365346744656563, -0.1133471354842186, -0.07509028911590576, -0.06036321818828583, -0.004410584457218647, -0.03146032989025116, -0.06542687118053436, 0.0036696214228868484, 0.0003383453004062176, -0.15903538465499878, 0.006245651748031378, -0.15113690495491028, -0.0714818611741066, -0.1716253161430359, 0.1810826063156128, 0.02021998167037964, 0.0730334222316742, 0.14515841007232666, -0.0846705436706543, 0.08825697004795074, 0.022778581827878952, -0.05676115304231644, -0.0372452512383461, -0.09171996265649796, -0.08265401422977448, -0.16846834123134613, 1.1767697621929297e-32, -0.11045338958501816, -0.06898786127567291, 0.06251603364944458, -0.032000716775655746, -0.006785827223211527, -0.05337638780474663, 0.05732099711894989, -0.04581504315137863, -0.07652713358402252, 0.10475510358810425, -0.1553015112876892, 0.1487588882446289, 0.0823325365781784, -0.10391920804977417, 0.04115958511829376, -0.09395771473646164, -0.017516203224658966, 0.10234782099723816, 0.10529471933841705, -0.018370451405644417, 0.10066075623035431, 0.04944846034049988, -0.04098723456263542, 0.06732650101184845, 0.14634406566619873, -0.06398816406726837, 0.013129806146025658, -0.05494701862335205, -0.07351547479629517, 0.042821336537599564, 0.048154789954423904, 0.05637133866548538, -0.08645618706941605, -0.028162265196442604, 0.03374280408024788, -0.01145850121974945, 0.018327433615922928, -0.0689440369606018, 0.0653921440243721, -0.0617687851190567, -0.05433952435851097, -0.028751149773597717, 0.021807847544550896, -0.09028686583042145, -0.08487599343061447, 0.02648857980966568, -0.01881411485373974, 0.024989526718854904, 0.06766830384731293, 0.1275779753923416, -0.016244813799858093, 0.05587814375758171, -0.05140703544020653, -0.09536823630332947, 0.0074602290987968445, -0.05564842000603676, -0.09410808980464935, 0.033854059875011444, 0.07702646404504776, 0.10052712261676788, 0.057636458426713943, 0.08414899557828903, -0.07388794422149658, 0.06925737857818604, -0.1452769637107849, 0.15956701338291168, -0.13187935948371887, -0.13330765068531036, 0.03931337222456932, 0.0634111613035202, -0.03826465457677841, 0.04361511766910553, 0.11015207320451736, -0.12395096570253372, 0.07658647745847702, -0.10855066031217575, 0.06655994057655334, 0.060808487236499786, 0.04220189154148102, 0.06959210336208344, -0.06293578445911407, -0.05057358741760254, -0.10753272473812103, 0.030257482081651688, 0.13222673535346985, -0.01138791348785162, 0.09092570096254349, 0.028950970619916916, -0.11048927158117294, -0.03509025648236275, 0.125358447432518, -0.07629003375768661, 0.05180623382329941, 0.24715018272399902, -0.004599431529641151, -1.0740076052336638e-32, -0.1274040937423706, 0.020408976823091507, -0.015360267832875252, -0.011395237408578396, 0.08199198544025421, 0.06941652297973633, 0.049663517624139786, -0.017583826556801796, -0.10296183079481125, 0.041779775172472, -0.04152798652648926, 0.04460067301988602, 0.019826024770736694, 0.07877057045698166, -0.19850361347198486, 0.036557551473379135, 0.034032564610242844, 0.06806734204292297, -0.030748773366212845, 0.06342080980539322, 0.0289897583425045, 0.20282244682312012, 0.06213601678609848, 0.21695441007614136, 0.11811605840921402, 0.07594320178031921, 0.08913002163171768, 0.09841671586036682, 0.012950185686349869, 0.015215297229588032, -0.05032791942358017, -0.07888942956924438, -0.25907841324806213, 0.04339294880628586, 0.005811702460050583, -0.20160797238349915, 0.14685143530368805, -0.057275183498859406, 0.10668106377124786, 0.07569112628698349, 0.03024407848715782, -0.07006212323904037, 0.08079639077186584, 0.17869582772254944, 0.07747498154640198, -0.07481841742992401, 0.14550387859344482, -0.12368530035018921, 0.10292954742908478, 0.0006626695394515991, 0.04133804515004158, 0.0008601495064795017, 0.009496672078967094, 0.18032190203666687, 0.04034877195954323, 0.05637732893228531, 0.046148065477609634, -0.03299668803811073, -0.013749110512435436, -0.028909940272569656, 0.15428426861763, 0.029848378151655197, 0.0007787663489580154, 0.011324310675263405, 0.09927209466695786, -0.05584309250116348, -0.0035726577043533325, -0.013290071859955788, -0.07279501110315323, -0.006784010678529739, -0.04248042404651642, -0.17763984203338623, 0.05125359445810318, -0.16036421060562134, 0.060857921838760376, 0.09139616787433624, 0.1548459231853485, -0.15722529590129852, -0.04142876714468002, 0.028679504990577698, -0.19852590560913086, 0.0020882543176412582, -0.007991623133420944, 0.10537784546613693, -0.016402289271354675, -0.007030827924609184, 0.07951051741838455, 0.06389380991458893, 0.07984231412410736, -0.005720516666769981, -0.04490111395716667, -0.05531134083867073, 0.12083663046360016, 0.11294275522232056, -0.04567525163292885, -9.992918847956389e-08, 0.03474137559533119, -0.09917938709259033, -0.07946066558361053, -0.03560175001621246, 0.12907534837722778, -0.0657137930393219, 0.005987181328237057, -0.0748022049665451, -0.01368629653006792, 0.02561219222843647, 0.15326866507530212, 0.06075998395681381, -0.12485760450363159, -0.03638938441872597, -0.0843711644411087, -0.05633042752742767, -0.09225153923034668, 0.06575397402048111, -0.08007009327411652, -0.08431479334831238, 0.006596918683499098, -0.03132558614015579, 0.029392817988991737, 0.0028499793261289597, -0.07633465528488159, -0.011488418094813824, 0.04064801707863808, 0.07913584262132645, 0.031055735424160957, 0.08945111930370331, 0.014940014109015465, -0.031094824895262718, 0.02147551253437996, -0.0624319463968277, -0.11930373311042786, -0.048163700848817825, 0.04391128569841385, 0.09139544516801834, 0.05994340032339096, 0.07354175299406052, -0.048471979796886444, -0.08851895481348038, 0.019148940220475197, 0.11109806597232819, 0.049979180097579956, -0.018114831298589706, -0.2856207489967346, -0.07042275369167328, -0.02411852590739727, -0.1802140176296234, 0.06417199969291687, -0.016908835619688034, -0.03792146220803261, 0.07175508141517639, 0.0711296871304512, 0.048004575073719025, -0.053646087646484375, -0.039634376764297485, -0.035834554582834244, -0.058809299021959305, -0.05992893874645233, -0.09769530594348907, -0.07551007717847824, 0.07199249416589737], "changes": {"1wk": -5.55105681642187, "1mo": 0.2025900990368353}}, {"text": "PREMIUM Cytokinetics Says European Regulator Validated its Application for Cardiomyopathy Drug Candidate MT Newswires Mon, Dec 23, 2024, 4:03 PM 1 min read In This Article: CYTK -2.01% Cytokinetics (CYTK) said Monday that the European Medicines Agency has validated its marketing autho PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premium news articles. Upgrade Already have a subscription? Sign in Terms and Privacy Policy Privacy Dashboard Recommended Stories", "symbol": "CYTK", "date": "2024-12-23T13:03:56+00:00", "sentiment": {"score": 0.07207620982080698, "confidence": 0.08330146968364716, "probabilities": {"positive": 0.08330146968364716, "negative": 0.011225259862840176, "neutral": 0.9054732918739319}}, "embedding": [-0.14160284399986267, -0.005521279759705067, -0.04276091977953911, -0.016431085765361786, 0.18518874049186707, -0.017673462629318237, -0.052547723054885864, 0.19615495204925537, -0.0013674485962837934, -0.08471907675266266, 0.0012642067158594728, 0.09153095632791519, 0.12557433545589447, 0.11630867421627045, -0.03755127266049385, -0.05454152449965477, 0.11749642342329025, 0.07906989008188248, -0.05000627413392067, 0.09044093638658524, -0.1460510641336441, -0.03024004027247429, 0.05380845069885254, 0.13811933994293213, -0.029507717117667198, -0.05246393755078316, -0.1499483734369278, -0.037086453288793564, 0.002222108654677868, 0.11040910333395004, -0.07627271115779877, 0.016392860561609268, 0.15753430128097534, -0.02170460671186447, 0.05742846056818962, -0.03672558814287186, -0.04930845648050308, -0.04164210334420204, -0.2242402285337448, 0.04318463057279587, 0.1449296921491623, -0.23513564467430115, -0.11950386315584183, 0.15048952400684357, 0.15221811830997467, 0.0367034450173378, -0.050028134137392044, 0.04266690835356712, -0.19587577879428864, 0.17466208338737488, -0.05640874058008194, -0.14426879584789276, 0.09705818444490433, -0.059245966374874115, -0.052577514201402664, -0.03378178924322128, -0.37220850586891174, -0.06535717099905014, 0.03837331756949425, -0.11284767091274261, -0.025027602910995483, 0.011415950953960419, -0.16091227531433105, 0.13749726116657257, -0.046556003391742706, 0.04098821431398392, -0.1083642989397049, 0.06606122106313705, 0.06831547617912292, -0.16943708062171936, 0.020542647689580917, -0.1726357489824295, 0.030468281358480453, 0.1450386941432953, 0.027962159365415573, 0.2988295555114746, 0.016387609764933586, -0.03310807794332504, 0.04281139373779297, -0.19348253309726715, 0.1042722761631012, -0.006131979636847973, 0.0836372822523117, 0.003852525260299444, 0.09819648414850235, 0.02156679704785347, -0.03370529040694237, 0.07215666025876999, -0.12638172507286072, 0.03702312335371971, 0.3094111382961273, 0.07439889758825302, 0.07272673398256302, 0.047000255435705185, -0.19064286351203918, -0.09778620302677155, -0.10086318105459213, 0.027735186740756035, -0.13115918636322021, 0.08676820248365402, -0.018328629434108734, 0.09532549232244492, -0.09322498738765717, -0.029275652021169662, 0.04808482900261879, -0.15213806927204132, 0.06026767939329147, 0.025646250694990158, 0.10600614547729492, 0.11725766211748123, 0.021984746679663658, -0.046218544244766235, -0.0554211400449276, -0.2670052647590637, -0.03259545937180519, 0.2783436179161072, -0.1589449942111969, -0.010064058937132359, 0.1684620976448059, 0.08829560875892639, 0.030737552791833878, -0.1236053854227066, -0.02741614729166031, -0.08399958908557892, 0.038404710590839386, 0.15167571604251862, -0.13026054203510284, 1.2483341521445783e-32, -0.15230707824230194, 0.09861645102500916, 0.18186238408088684, -0.07118089497089386, -0.027647152543067932, 0.013599858619272709, 0.013135983608663082, -0.22924798727035522, -0.0578136071562767, -0.18403853476047516, -0.1978863775730133, 0.18551665544509888, 0.02785511501133442, 0.07083094865083694, -0.2048082798719406, -0.08348052203655243, -0.10557714849710464, 0.025132687762379646, 0.09144946187734604, 0.1357419490814209, 0.22938527166843414, -0.12257644534111023, -0.009597712196409702, -0.02181597426533699, -0.11275756359100342, 0.11594100296497345, 0.08656349778175354, 0.02513047866523266, 0.21469265222549438, 0.11511557549238205, -0.19769755005836487, -0.017678266391158104, 0.047235485166311264, -0.0714949518442154, -0.0595029816031456, 0.07480509579181671, 0.015507138334214687, -0.1789371520280838, -0.011340347118675709, -0.0925922691822052, -0.0560150183737278, -0.142188161611557, -0.09315823763608932, -0.04316999763250351, 0.11150775104761124, -0.050999242812395096, -0.14341683685779572, -0.07357286661863327, -0.032258041203022, -0.10169099271297455, 0.04930712655186653, -0.010070220567286015, -0.14954155683517456, -0.002124504651874304, -0.03368744999170303, 0.06630817800760269, -0.1378902792930603, 0.04697990417480469, 0.07980333268642426, -0.14549227058887482, 0.1350172758102417, 0.02580632083117962, -0.008171451278030872, -0.0682719275355339, -0.04230593889951706, 0.08862759917974472, -0.1869114488363266, -0.21861831843852997, -0.3106093406677246, 0.124623142182827, 0.16021588444709778, -0.01325590256601572, 0.022883251309394836, 0.0461110919713974, -0.052908364683389664, 0.01153695397078991, -0.004149483982473612, 0.20586392283439636, 0.04242348298430443, 0.06248483806848526, -0.08265898376703262, -0.04411155730485916, 0.029425477609038353, 0.16536957025527954, 0.09383128583431244, -0.034218791872262955, 0.07627396285533905, 0.03952695429325104, -0.04463625326752663, 0.023239655420184135, 0.02975289896130562, 0.015999294817447662, -0.004956592805683613, 0.2514350712299347, -0.09217372536659241, -1.4353880702654334e-32, -0.06287669390439987, 0.10269603133201599, 0.06499097496271133, -0.06235208734869957, -0.06667131185531616, 0.060937944799661636, -0.19154949486255646, 0.07271437346935272, 0.34132257103919983, 0.06690841168165207, 0.15551099181175232, -0.02784554660320282, -0.059913717210292816, 0.08506405353546143, -0.010588320903480053, 0.005661776755005121, -0.05320417508482933, 0.018526863306760788, -0.12559910118579865, 0.12407918274402618, -0.050539035350084305, 0.012063257396221161, -0.09056942164897919, 0.2841697633266449, 0.08991845697164536, -0.03147666156291962, 0.09431971609592438, 0.15847048163414001, -0.0726756751537323, -0.14250637590885162, -0.07595306634902954, 0.0581451952457428, -0.2184285968542099, -0.002541458001360297, -0.02004755660891533, 0.023994768038392067, 0.03989814594388008, 0.07889270037412643, 0.03549695014953613, 0.02168477512896061, -0.06689190119504929, -0.16705119609832764, -0.10624361038208008, 0.0033840241376310587, 0.08263175189495087, 0.02418280579149723, 0.21862773597240448, -0.12855759263038635, 0.17334800958633423, -0.09127184003591537, 0.06712442636489868, -0.010583550669252872, 0.14798055589199066, 0.1619291752576828, -0.10215987265110016, 0.1216735690832138, 0.11152228713035583, 0.09995537996292114, 0.021392853930592537, -0.10148608684539795, 0.07224853336811066, 0.07149845361709595, -0.06381922215223312, -0.0790041908621788, 0.1262563169002533, 0.05414601415395737, 0.1377178132534027, 0.005996453110128641, 0.045296844094991684, 0.03399088606238365, -0.02671842835843563, 0.005458290688693523, -0.175844207406044, 0.003506995039060712, -0.026542089879512787, 0.07135577499866486, 0.0017565195448696613, -0.0759255662560463, -0.14370791614055634, -0.1632085144519806, 0.0818345919251442, -0.10743512958288193, 0.013072393834590912, -0.04132888466119766, -0.05812576785683632, -0.1546965390443802, 0.19273684918880463, -0.06797388195991516, -0.07218372821807861, 0.0676831528544426, -0.0981689915060997, -0.06750641763210297, -0.1932869404554367, 0.12589742243289948, 0.020818328484892845, -1.0054571220052821e-07, 0.06097275763750076, -0.0598452053964138, -0.12417756766080856, 0.028727030381560326, 0.015469463542103767, -0.03296591341495514, -0.09512998163700104, -0.018168898299336433, -0.03583696484565735, 0.045121096074581146, 0.0239099208265543, 0.06508393585681915, -0.02221975475549698, -0.14999598264694214, 0.04503873363137245, 0.019781554117798805, -0.009352627210319042, 0.0903090164065361, 0.012289818376302719, 0.06517859548330307, 0.06720136106014252, 0.10665267705917358, 0.20103423297405243, -0.13582439720630646, -0.04131640866398811, -0.09260036796331406, 0.05839906632900238, 0.0707549899816513, 0.04491686448454857, -0.18375755846500397, 0.04069415479898453, 0.011540329083800316, 0.016167014837265015, 0.07109497487545013, -0.09972939640283585, 0.053333647549152374, -0.022564159706234932, -0.01978977769613266, 0.04972924664616585, -0.008381806313991547, -0.08084431290626526, -0.11182434111833572, 0.007132155820727348, -0.009371195919811726, -0.12173492461442947, -0.10383768379688263, -0.03487250208854675, -0.12208137661218643, 0.09983958303928375, -0.06938470155000687, 0.040971286594867706, 0.009240836836397648, 0.1122937873005867, -0.17711102962493896, -0.01229611411690712, -0.0010753176175057888, -0.050655268132686615, -0.029560500755906105, -0.011895807459950447, -0.05931204557418823, -0.010621990077197552, -0.14619316160678864, 0.18413181602954865, 0.04104845970869064], "changes": {"1wk": -3.248212722790591, "1mo": -6.39428195981764}}, {"text": "PREMIUM Cytokinetics Says Sanofi Acquiring Rights for Aficamten in Greater China MT Newswires Fri, Dec 20, 2024, 11:58 AM 1 min read In This Article: CYTK -2.01% SNY -1.82% Cytokinetics (CYTK) said Friday that Sanofi (SNY) will acquire exclusive rights to develop and comme PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premium news articles. Upgrade Already have a subscription? Sign in Terms and Privacy Policy Privacy Dashboard Recommended Stories", "symbol": "CYTK", "date": "2024-12-20T08:58:16+00:00", "sentiment": {"score": 0.05866927281022072, "confidence": 0.0691748857498169, "probabilities": {"positive": 0.0691748857498169, "negative": 0.010505612939596176, "neutral": 0.9203194975852966}}, "embedding": [-0.04498733952641487, -0.018948568031191826, 0.019961213693022728, -0.10894127190113068, 0.2619277536869049, 0.1079590767621994, 0.015310638584196568, 0.07769052684307098, 0.001710394280962646, -0.0013260080013424158, 0.12775994837284088, 0.07314480096101761, 0.06950807571411133, 0.10044484585523605, 0.19567245244979858, -0.03274939954280853, 0.08384351432323456, -0.049320586025714874, -0.018687739968299866, -0.04050297290086746, -0.06647475063800812, -0.14756830036640167, 0.020099492743611336, 0.021022694185376167, -0.003191509749740362, -0.20533351600170135, -0.23156310617923737, 0.06368599086999893, 0.03930731490254402, 0.09606675803661346, -0.08666344732046127, 0.1322290152311325, 0.2622038722038269, -0.049693625420331955, 0.09210943430662155, -0.12238079309463501, 0.134832963347435, -0.15175852179527283, -0.12064116448163986, 0.05021686479449272, 0.09465872496366501, -0.17001712322235107, -0.10450013726949692, 0.00040941443876363337, 0.041797786951065063, 0.06672589480876923, 0.056778572499752045, 0.07436295598745346, -0.08862709254026413, 0.028992854058742523, 0.016708509996533394, -0.10305780172348022, 0.0775594711303711, 0.022030817344784737, -0.09697418659925461, 0.021960997954010963, -0.2358141988515854, 0.008969297632575035, 0.024702535942196846, -0.007209067698568106, -0.010854638181626797, -0.048920679837465286, -0.09557085484266281, 0.14116382598876953, -0.06245671957731247, 0.11408853530883789, -0.026174472644925117, 0.15378184616565704, 0.09505946189165115, -0.2096208781003952, -0.12965308129787445, -0.018438437953591347, -0.024309301748871803, 0.20621748268604279, -0.052545707672834396, 0.23692922294139862, 0.16232942044734955, 0.021950971335172653, -0.027191486209630966, -0.24801139533519745, 0.03089721128344536, 0.06099415570497513, 0.2479287087917328, -0.07779622077941895, 0.04427092894911766, 0.028441840782761574, -0.035773783922195435, 0.09320550411939621, -0.001435146783478558, 0.034670714288949966, 0.09839954972267151, -0.01912900060415268, 0.058404628187417984, 0.053669508546590805, -0.009836411103606224, -0.11234694719314575, -0.03614950552582741, -0.1362532079219818, -0.1676778644323349, 0.010499910451471806, -0.05810025334358215, -0.04929737374186516, 0.005127118434756994, -0.07782471179962158, 0.029170170426368713, -0.104844830930233, -0.11262859404087067, 0.11077871173620224, 0.054344065487384796, 0.08281583338975906, -0.050815239548683167, 0.016675593331456184, -0.02428615465760231, -0.29165294766426086, -0.03659076616168022, 0.28226426243782043, -0.231926828622818, 0.06693189591169357, 0.08626080304384232, -0.13151270151138306, 0.02653978206217289, -0.02164740487933159, -0.22287669777870178, 0.00632260600104928, 0.00508909672498703, -0.002972668968141079, -0.07288845628499985, 1.2042052860623434e-32, -0.08895239979028702, 0.2602878510951996, 0.08539362996816635, -0.04132965952157974, -0.050199203193187714, 0.01883029378950596, 0.18185482919216156, -0.027203552424907684, -0.1804037094116211, -0.10054101794958115, -0.1703449934720993, 0.1084667295217514, -0.07901326566934586, -0.026786180213093758, 0.06952311843633652, -0.16181087493896484, -0.11364150047302246, -0.02093370258808136, 0.2587083876132965, -0.031445614993572235, 0.11154959350824356, -0.061678119003772736, -0.07287018746137619, -0.06717518717050552, 0.000636325974483043, 0.00749325193464756, 0.20133812725543976, -0.0261536855250597, 0.19659748673439026, 0.14313358068466187, -0.18232361972332, 0.028197329491376877, 0.08320365101099014, -0.0009555809665471315, 0.09971832484006882, 0.05753941461443901, -0.05883367732167244, -0.14257310330867767, -0.04676596447825432, -0.08645808696746826, 0.0525222048163414, -0.032794803380966187, -0.2004048079252243, 0.0025154356844723225, 0.04341302067041397, -0.022787176072597504, -0.2147681713104248, -0.17879179120063782, 0.14354102313518524, -0.016585905104875565, -0.05345747992396355, 0.15284542739391327, -0.30440258979797363, 0.10100621730089188, -0.010477815754711628, -0.004104555584490299, 0.020404592156410217, -0.07190810889005661, -0.04869794473052025, -0.14989252388477325, 0.09912710636854172, 0.006691562943160534, 0.015343580394983292, 0.03798678517341614, -0.08778592199087143, 0.1202155351638794, -0.03133193403482437, -0.12963956594467163, -0.18870505690574646, 0.056314002722501755, 0.05787251517176628, 0.04915645718574524, 0.10660868138074875, -0.053942885249853134, -0.0806717574596405, 0.050869956612586975, -0.20077665150165558, 0.11857138574123383, 0.18146663904190063, 0.15361377596855164, -0.04102034866809845, -0.017104610800743103, -0.0033190406393259764, 0.12429668754339218, 0.025268858298659325, -0.02765972539782524, 0.10363048315048218, 0.13535058498382568, -0.08593513071537018, 0.010461004450917244, 0.10136479139328003, -0.035527102649211884, 0.05481519550085068, 0.17679712176322937, -0.10697262734174728, -1.3224280590024025e-32, -0.1996445506811142, -0.0018791547045111656, -0.08421246707439423, -0.14524954557418823, -0.19618135690689087, -0.0435931421816349, -0.056666746735572815, 0.1308683454990387, 0.12307743728160858, 0.07238925248384476, -0.017074720934033394, -0.10033512115478516, -0.11904798448085785, 0.057980187237262726, -0.14973238110542297, 0.05863030254840851, 0.05421601980924606, 0.017329761758446693, -0.17066694796085358, 0.09542103111743927, -0.06359606981277466, 0.00010435115109430626, 0.06819359958171844, 0.212962806224823, 0.17171944677829742, 0.023923302069306374, 0.1413995623588562, 0.1831594705581665, -0.027227845042943954, -0.13883548974990845, -0.02824806608259678, -0.19275878369808197, -0.30450934171676636, -0.01533134002238512, -0.019130347296595573, -0.16885384917259216, 0.05402851849794388, 0.14290930330753326, -0.024367941543459892, -0.047301534563302994, 0.050782859325408936, -0.18056267499923706, -0.04843389615416527, 0.11136592924594879, 0.0030191100668162107, 0.09544290602207184, 0.03638254478573799, -0.1775924265384674, 0.14048238098621368, -0.0045902119018137455, -0.012821780517697334, -0.009895875118672848, 0.2190624177455902, 0.06518050283193588, -0.24158093333244324, 0.07813199609518051, 0.20108895003795624, 0.029911627992987633, -0.07842379063367844, -0.15319804847240448, 0.19461286067962646, 0.14224815368652344, -0.1393205225467682, -0.008550244383513927, 0.09448916465044022, 0.06448055803775787, 0.2311716377735138, 0.06818310916423798, 0.10342150926589966, -0.09360997378826141, 0.09931270778179169, -0.16433539986610413, -0.12357130646705627, -0.12056124210357666, -0.06906692683696747, 0.09650742262601852, -0.05667673796415329, 0.017723312601447105, -0.18756216764450073, -0.03633396700024605, 0.03999226540327072, -0.06808832287788391, 0.027175024151802063, 0.05618249624967575, 0.050486430525779724, -0.17565326392650604, 0.19725440442562103, -0.20011158287525177, 0.05612190440297127, -3.2340896723326296e-05, -0.180020272731781, 0.04610849544405937, -0.18764550983905792, 0.12415186315774918, 0.12822946906089783, -1.0000083960903794e-07, 0.07636819034814835, -0.18943791091442108, -0.2045910507440567, 0.06648611277341843, 0.09671159088611603, 0.016480578109622, -0.10857221484184265, -0.00958242081105709, 0.01883896440267563, 0.11393636465072632, -0.031324610114097595, -0.05741879343986511, -0.07283942401409149, 0.016119614243507385, 0.02723017893731594, -0.1004822701215744, 0.012814975343644619, 0.012366704642772675, 0.03438109531998634, -0.07182569056749344, -0.09247828274965286, 0.06447407603263855, 0.1673264056444168, -0.18819235265254974, -0.07248468697071075, 0.012383556924760342, -0.05534396320581436, 0.01712098717689514, 0.13551899790763855, 0.054516542702913284, -0.008788923732936382, 0.01830434612929821, -0.1421400010585785, 0.11416643112897873, -0.18482056260108948, 0.007935208268463612, -0.05254556983709335, -0.05886588245630264, 0.012247557751834393, 0.006805825047194958, 0.07753364741802216, -0.028125284239649773, 0.1286158263683319, 0.14587479829788208, 0.05480772629380226, -0.12142482399940491, 0.019851751625537872, -0.17784839868545532, 0.30480247735977173, -0.03175743296742439, 0.00510010588914156, -0.0334213525056839, 0.07040385156869888, 0.0488852933049202, -0.03383816406130791, 0.038647376000881195, -0.04975834861397743, 0.0017509202007204294, 0.008922840468585491, 0.17303314805030823, -0.03695553168654442, -0.18632541596889496, 0.11362799257040024, 0.11613564938306808], "changes": {"1wk": -0.6752568519949728, "1mo": -6.404741808528732}}, {"text": "Cytokinetics Announces European Medicines Agency Validation of Marketing Authorization Application for Aficamten for the Treatment of Obstructive Hypertrophic Cardiomyopathy Cytokinetics, Incorporated Mon, Dec 23, 2024, 3:30 PM 8 min read In This Article: CYTK -2.01% Cytokinetics, Incorporated SOUTH SAN FRANCISCO, Calif., Dec. 23, 2024 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that the European Medicines Agency (EMA) has validated the Marketing Authorization Application (MAA) for aficamten , a next-in-class cardiac myosin inhibitor, for the treatment of obstructive hypertrophic cardiomyopathy (HCM). The MAA will now be reviewed by the Committee for Medicinal Products for Human Use (CHMP). \u201cWith regulatory filings for aficamten already under review in both the U.S. and China, the validation of the MAA marks an important milestone in bringing this potential medicine to even more patients with HCM worldwide,\u201d said Robert I. Blum, Cytokinetics\u2019 President and Chief Executive Officer. \u201cWe look forward to working with EMA in connection with their review of our application.\u201d The MAA is supported by the results from SEQUOIA-HCM ( S afety, E fficacy, and Q uantitative U nderstanding of O bstruction I mpact of A ficamten in HCM ), the pivotal Phase 3 clinical trial of aficamten in patients with symptomatic obstructive HCM, which were published in the New England Journal of Medicine . 1 The MAA validation follows the acceptance by the U.S. Food and Drug Administration (FDA) of the New Drug Application (NDA) for aficamten for the treatment of obstructive HCM. The FDA assigned the NDA a standard review with a Prescription Drug User Fee Act (PDUFA) target action date of September 26, 2025. About SEQUOIA-HCM SEQUOIA-HCM ( S afety, E fficacy, and Q uantitative U nderstanding of O bstruction I mpact of A ficamten in HCM ) was the pivotal Phase 3 clinical trial of aficamten in patients with symptomatic obstructive hypertrophic cardiomyopathy (HCM). The results from SEQUOIA-HCM showed that treatment with aficamten for 24 weeks significantly improved exercise capacity compared to placebo, increasing peak oxygen uptake (pVO 2 ) measured by cardiopulmonary exercise testing (CPET) by 1.8 ml/kg/min compared to baseline in patients treated with aficamten versus 0.0 ml/kg/min in patients treated with placebo (least square mean (LSM) difference [95% CI] of 1.74 mL/kg/min [1.04 - 2.44]; p=0.000002). Statistically significant improvements were observed in all 10 prespecified secondary endpoints, including Valsalva left ventricular outflow tract (LVOT) gradient, New York Heart Association (NYHA) Functional Class, Kansas City Cardiomyopathy Clinical Summary Score (KCCQ-CSS), and proportion with LVOT gradient <30 mmHg, each at 12 and 24 weeks, as well as duration of guideline eligibility for septal reduction therapy (SRT), and total workload during CPET at 24 weeks. Treatment emergent serious adverse events occurred in 5.6% and 9.3% of patients on aficamten and placebo, respectively. Core echocardiographic left ventricular ejection fraction (LVEF) was observed to be <50% in 5 patients (3.5%) on aficamten compared to 1 patient (0.7%) on placebo. There were no instances of worsening heart failure or treatment interruptions due to low LVEF. Story Continues Additional analyses from SEQUOIA-HCM have demonstrated that treatment with aficamten is associated with improvements in cardiac structure, function, and biomarkers without negatively impacting systolic function. About Aficamten Aficamten is an investigational selective, small molecule cardiac myosin inhibitor discovered following an extensive chemical optimization program that was conducted with careful attention to therapeutic index and pharmacokinetic properties and as may translate into next-in-class potential in clinical development. Aficamten was designed to reduce the number of active actin-myosin cross bridges during each cardiac cycle and consequently suppress the myocardial hypercontractility that is associated with HCM. In preclinical models, aficamten reduced myocardial contractility by binding directly to cardiac myosin at a distinct and selective allosteric binding site, thereby preventing myosin from entering a force producing state. The development program for aficamten is assessing its potential as a treatment that improves exercise capacity and relieves symptoms in patients with HCM as well as its potential long-term effects on cardiac structure and function. Aficamten was evaluated in SEQUOIA-HCM, a positive pivotal Phase 3 clinical trial in patients with symptomatic obstructive hypertrophic cardiomyopathy (HCM). Aficamten received Breakthrough Therapy Designation for the treatment of symptomatic obstructive HCM from the U.S. Food & Drug Administration (FDA) as well as the National Medical Products Administration (NMPA) in China where it is currently also under review for potential approval. Aficamten is also currently being evaluated in MAPLE-HCM, a Phase 3 clinical trial of aficamten as monotherapy compared to metoprolol as monotherapy in patients with obstructive HCM; ACACIA-HCM, a Phase 3 clinical trial of aficamten in patients with non-obstructive HCM; CEDAR-HCM, a clinical trial of aficamten in a pediatric population with obstructive HCM; and FOREST-HCM, an open-label extension clinical study of aficamten in patients with HCM. About Hypertrophic Cardiomyopathy Hypertrophic cardiomyopathy (HCM) is a disease in which the heart muscle (myocardium) becomes abnormally thick (hypertrophied). The thickening of cardiac muscle leads to the inside of the left ventricle becoming smaller and stiffer, and thus the ventricle becomes less able to relax and fill with blood. This ultimately limits the heart\u2019s pumping function, resulting in reduced exercise capacity and symptoms including chest pain, dizziness, shortness of breath, or fainting during physical activity. HCM is the most common monogenic inherited cardiovascular disorder, with approximately 280,000 patients diagnosed, however, there are an estimated 400,000-800,000 additional patients who remain undiagnosed in the U.S. 2,3,4 Two-thirds of patients with HCM have obstructive HCM (oHCM), where the thickening of the cardiac muscle leads to left ventricular outflow tract (LVOT) obstruction, while one-third have non-obstructive HCM (nHCM), where blood flow isn\u2019t impacted, but the heart muscle is still thickened. People with HCM are at high risk of also developing cardiovascular complications including atrial fibrillation, stroke and mitral valve disease. 5 People with HCM are at risk for potentially fatal ventricular arrhythmias and it is one of the leading causes of sudden cardiac death in younger people or athletes. 6 A subset of patients with HCM are at high risk of progressive disease leading to dilated cardiomyopathy and heart failure necessitating cardiac transplantation. About Cytokinetics Cytokinetics is a late-stage, specialty cardiovascular biopharmaceutical company focused on discovering, developing and commercializing muscle biology-directed drug candidates as potential treatments for debilitating diseases in which cardiac muscle performance is compromised. As a leader in muscle biology and the mechanics of muscle performance, the company is developing small molecule drug candidates specifically engineered to impact myocardial muscle function and contractility. Cytokinetics is readying for the potential commercialization of aficamten, a next-in-class cardiac myosin inhibitor following positive results from SEQUOIA-HCM, the pivotal Phase 3 clinical trial in patients with obstructive hypertrophic cardiomyopathy (HCM). Aficamten is also being evaluated in additional clinical trials enrolling patients with obstructive and non-obstructive HCM. Cytokinetics is also developing omecamtiv mecarbil , a cardiac myosin activator, in patients with heart failure with severely reduced ejection fraction (HFrEF), CK-586, a cardiac myosin inhibitor with a mechanism of action distinct from aficamten, for the potential treatment of heart failure with preserved ejection fraction (HFpEF) and CK-089, a fast skeletal muscle troponin activator with potential therapeutic application to a specific type of muscular dystrophy and other conditions of impaired skeletal muscle function. For additional information about Cytokinetics, visit www.cytokinetics.com and follow us on X , LinkedIn , Facebook and YouTube . Forward-Looking Statements This press release contains forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995 (the \u201cAct\u201d). Cytokinetics disclaims any intent or obligation to update these forward-looking statements and claims the protection of the Act\u2019s Safe Harbor for forward-looking statements. Examples of such statements include, but are not limited to, statements express or implied relating to the properties or potential benefits of aficamten or any of our other drug candidates, our ability to obtain regulatory approval for aficamten for the treatment of obstructive hypertrophic cardiomyopathy or any other indication from FDA or any other regulatory body in the United States or abroad, and the labeling or post-marketing conditions that FDA or another regulatory body may require in connection with the approval of aficamten . Such statements are based on management\u2019s current expectations, but actual results may differ materially due to various risks and uncertainties, including, but not limited to the risks related to Cytokinetics\u2019 business outlines in Cytokinetics\u2019 filings with the Securities and Exchange Commission. Forward-looking statements are not guarantees of future performance, and Cytokinetics\u2019 actual results of operations, financial condition and liquidity, and the development of the industry in which it operates, may differ materially from the forward-looking statements contained in this press release. Any forward-looking statements that Cytokinetics makes in this press release speak only as of the date of this press release. Cytokinetics assumes no obligation to update its forward-looking statements whether as a result of new information, future events or otherwise, after the date of this press release. CYTOKINETICS\u00ae and the CYTOKINETICS and C-shaped logo are registered trademarks of Cytokinetics in the U.S. and certain other countries. Contact: Cytokinetics Diane Weiser Senior Vice President, Corporate Affairs (415) 290-7757 References: Maron, MS, et al. Aficamten for Symptomatic Obstructive Hypertrophic Cardiomyopathy. N Engl J Med. DOI: 10.1056/NEJMoa2401424 CVrg: Heart Failure 2020-2029, p 44; Maron et al. 2013 DOI: 10.1016/S0140-6736(12)60397-3; Maron et al 2018 10.1056/NEJMra1710575 Symphony Health 2016-2021 Patient Claims Data DoF; Maron MS, Hellawell JL, Lucove JC, Farzaneh-Far R, Olivotto I. Occurrence of Clinically Diagnosed Hypertrophic Cardiomyopathy in the United States. Am J Cardiol. 2016; 15;117(10):1651-1654. Gersh, B.J., Maron, B.J., Bonow, R.O., Dearani, J.A., Fifer, M.A., Link, M.S., et al. 2011 ACCF/AHA guidelines for the diagnosis and treatment of hypertrophic cardiomyopathy. A report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. Journal of the American College of Cardiology and Circulation, 58, e212-260. Hong Y, Su WW, Li X. Risk factors of sudden cardiac death in hypertrophic cardiomyopathy. Current Opinion in Cardiology. 2022 Jan 1;37(1):15-21 View Comments Terms and Privacy Policy Privacy Dashboard Recommended Stories", "symbol": "CYTK", "date": "2024-12-23T12:30:00+00:00", "sentiment": {"score": 0.23175974003970623, "confidence": 0.24100790917873383, "probabilities": {"positive": 0.24100790917873383, "negative": 0.009248169139027596, "neutral": 0.7497439384460449}}, "embedding": [-0.041461050510406494, -0.1901087760925293, -0.011819805949926376, -0.02528555691242218, 0.0347098782658577, -0.03172464296221733, -0.07285867631435394, 0.35499143600463867, 0.10331974923610687, 0.013167612254619598, -0.008151620626449585, -0.0607185959815979, 0.053736962378025055, 0.1133529543876648, 0.012374446727335453, 0.09153144061565399, 0.18136948347091675, 0.05481819435954094, -0.10232125967741013, 0.2319844663143158, 0.03949674218893051, 0.028897074982523918, 0.009111810475587845, 0.20148396492004395, -0.19067546725273132, -0.08006203919649124, -0.1492110937833786, 0.019738007336854935, -0.1273392289876938, -0.05571405589580536, -0.0016441293992102146, 0.16475695371627808, 0.2679244875907898, 0.09706069529056549, 0.11332559585571289, -0.020786909386515617, -0.09855121374130249, -0.14547118544578552, -0.26969802379608154, 0.019980743527412415, 0.03728003054857254, -0.08961071074008942, -0.10522656887769699, 0.00278488383628428, 0.1241450309753418, -0.08964502811431885, 0.020887913182377815, 0.024594372138381004, -0.09660492092370987, 0.339091956615448, -0.14390656352043152, 0.013021016493439674, -0.10419314354658127, 0.11646387726068497, -0.09674733132123947, -0.12219667434692383, -0.1718730926513672, -0.0024658464826643467, 0.04723396897315979, 0.04653666540980339, -0.12192809581756592, 0.017676232382655144, -0.054086968302726746, -0.028461558744311333, 0.09884893149137497, 0.017002755776047707, -0.06046058237552643, -0.003428041934967041, 0.0588998943567276, -0.048654954880476, 0.10037039965391159, -0.23382961750030518, 0.037954848259687424, 0.1191851869225502, -0.0885765329003334, 0.02502479963004589, 0.10116495192050934, -6.433529779314995e-05, 0.013713940978050232, -0.14816415309906006, 0.09678970277309418, 0.18482595682144165, 0.05544644594192505, -0.04678552970290184, 0.056524407118558884, 0.06520503014326096, -0.11431892216205597, 0.20443633198738098, -0.019226454198360443, 0.08758841454982758, 0.1798461675643921, 0.07998009026050568, -0.097367063164711, 0.0542198121547699, 0.062014296650886536, -0.11566585302352905, 0.07161860913038254, 0.04909472167491913, 0.054664768278598785, -0.031124800443649292, 0.08829588443040848, 0.05767242982983589, -0.2730118930339813, -0.1562153548002243, 0.011724641546607018, -0.03620770573616028, 0.10504040122032166, -0.05362562835216522, 0.1541302502155304, 0.0349840447306633, -0.033356230705976486, -0.04547121375799179, -0.0936432033777237, -0.21690966188907623, -0.012098726816475391, 0.3108452558517456, -0.006607360206544399, 0.014349671080708504, 0.16639558970928192, 0.0736193060874939, 0.06723417341709137, -0.15553176403045654, 0.07646771520376205, -0.12925249338150024, 0.0016477219760417938, 0.08551846444606781, -0.1437702775001526, 8.967590732401928e-33, -0.02068035490810871, 0.010289398953318596, 0.042133674025535583, 0.018409712240099907, 0.04572571814060211, -0.06444022804498672, 0.08355648070573807, -0.04099610447883606, -0.05452684685587883, -0.18219754099845886, -0.11996830999851227, 0.03743916004896164, 0.008155952207744122, 0.009891917929053307, -0.14449945092201233, -0.0986543670296669, -0.07631758600473404, -0.07427586615085602, -0.059104129672050476, 0.02929428219795227, 0.1681220531463623, -0.050527866929769516, -0.01947867125272751, 0.01738346368074417, -0.1805831789970398, 0.028109636157751083, -0.004736277740448713, 0.15490584075450897, 0.13178275525569916, 0.04879014194011688, -0.028400180861353874, -0.1009959876537323, -0.008860979229211807, -0.19594435393810272, 0.0020224545150995255, -0.09379902482032776, -0.15144601464271545, -0.04129694774746895, -0.011758996173739433, 0.004753814544528723, -0.10937823355197906, 0.037296850234270096, -0.08676783740520477, -0.03454117104411125, 0.15775474905967712, -0.15110206604003906, -0.13515686988830566, -0.05518382042646408, -0.06397318094968796, -0.02262060157954693, 0.08662229776382446, -0.12338821589946747, 0.027012454345822334, -0.08409887552261353, -0.01765322871506214, -0.006062331609427929, -0.1837872862815857, 0.04973151534795761, -0.011247973889112473, 0.020216740667819977, 0.04571329057216644, 0.04318510368466377, 0.04929576441645622, 0.07661131024360657, -0.12994346022605896, 0.0162678062915802, -0.1836397349834442, 0.004252912476658821, -0.1871940791606903, 0.004650772549211979, 0.016731077805161476, -0.03353879228234291, 0.09692059457302094, 0.056135471910238266, 0.18111027777194977, -0.04875500500202179, 0.03760676831007004, 0.24443143606185913, -0.11850637197494507, -0.07760109007358551, -0.13468249142169952, 0.06546473503112793, -0.0786975622177124, 0.1386471837759018, -0.05486205592751503, -0.1289769560098648, 0.10679743438959122, 0.02088344097137451, -0.19764043390750885, -0.06389479339122772, 0.19777217507362366, -0.02950841560959816, 0.09833425283432007, 0.06483235955238342, -0.014680435881018639, -1.0535199141931821e-32, -0.06537918001413345, 0.09353822469711304, -0.011433316394686699, -0.20652002096176147, -0.10708656907081604, 0.10607762634754181, -0.008599451743066311, -0.12127736210823059, 0.19761419296264648, -0.11601929366588593, 0.07124102860689163, 0.03443524241447449, -0.07466208934783936, -0.03366803377866745, -0.1804322451353073, 0.20313766598701477, -0.07744862139225006, 0.008691464550793171, -0.15041840076446533, 0.14377973973751068, -0.012338124215602875, 0.02386832982301712, -0.008523736149072647, 0.08700752258300781, 0.09769655764102936, 0.07574523985385895, 0.07652631402015686, 0.03347422555088997, 0.172730952501297, -0.04259231314063072, 0.05847369506955147, -0.04964340850710869, -0.35126346349716187, 0.017347969114780426, -0.04045909643173218, -0.02258763089776039, 0.0059283338487148285, -0.07493647933006287, -0.05659026280045509, -0.009653584100306034, 0.011506680399179459, 0.002958439290523529, -2.980045974254608e-05, -0.028154637664556503, -0.0330367237329483, 0.13151314854621887, 0.1240156888961792, -0.11745308339595795, 0.1011219322681427, 0.05270153656601906, -0.037556182593107224, -0.04690363630652428, 0.07312662154436111, 0.09525071084499359, -0.07896719127893448, 0.008944246917963028, 0.09039311856031418, 0.1096700057387352, -0.09703227877616882, -0.031072072684764862, 0.08009903132915497, 0.07776778191328049, 0.07738087326288223, -0.12418660521507263, 0.1753494292497635, 0.11532840132713318, 0.17027351260185242, 0.06004563346505165, 0.11927236616611481, -0.08795095980167389, -0.05641280859708786, 0.037197865545749664, -0.14055395126342773, 0.009485278278589249, 0.03348454087972641, 0.08987589180469513, 0.07989400625228882, -0.1627940833568573, -0.264586865901947, -0.19327667355537415, 0.023014109581708908, -0.12342902272939682, -0.09414276480674744, -0.044518452137708664, -0.038413155823946, -0.0012588058598339558, 0.16825513541698456, -0.0935310423374176, -0.04190486669540405, 0.06973138451576233, -0.08733321726322174, -0.08040991425514221, 0.00882432796061039, 0.14151503145694733, -0.06019717454910278, -1.0072798772853275e-07, 0.013403812423348427, -0.1745447814464569, -0.09215942025184631, -0.10554233193397522, -0.019091662019491196, -0.025015003979206085, -0.0754542350769043, -0.01117178238928318, -0.055018290877342224, 0.014783395454287529, 0.014389431104063988, 0.18624846637248993, -0.01445071306079626, -0.12590979039669037, -0.009263883344829082, -0.10646845400333405, 0.09336051344871521, 0.028105035424232483, 0.02865477092564106, 0.1050952672958374, -0.05862826108932495, 0.023079555481672287, -0.03192462772130966, -0.01586799882352352, 0.07029673457145691, -0.044516678899526596, 0.12346382439136505, 0.06883709877729416, 0.11243003606796265, -0.03183816373348236, 0.12265097349882126, 0.08368846029043198, 0.10574120283126831, 0.06972020864486694, -0.12775711715221405, -0.1230696588754654, -0.03323673829436302, 0.03535064682364464, -0.06740639358758926, 0.2011193186044693, 0.030273286625742912, -0.023002661764621735, -0.05585194006562233, 0.00819933507591486, 0.05335203558206558, -0.15734979510307312, -0.012291165068745613, -0.018047291785478592, 0.08288905024528503, -0.02565683238208294, 0.013928504660725594, 0.04295793175697327, 0.01749458909034729, -0.006515303626656532, -0.022722724825143814, 0.0514104962348938, 0.002632671035826206, -0.0193845946341753, 0.1019100546836853, -0.1442548632621765, 0.023995086550712585, -0.0843496173620224, 0.13741056621074677, 0.04939233139157295], "changes": {"1wk": -3.248212722790591, "1mo": -6.39428195981764}}, {"text": "Why Is Cytokinetics (CYTK) Down 9.7% Since Last Earnings Report? Zacks Equity Research Fri, Dec 6, 2024, 7:31 PM 5 min read In This Article: CYTK -2.01% INSM +1.70% It has been about a month since the last earnings report for Cytokinetics (CYTK). Shares have lost about 9.7% in that time frame, underperforming the S&P 500. Will the recent negative trend continue leading up to its next earnings release, or is Cytokinetics due for a breakout? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at the most recent earnings report in order to get a better handle on the important drivers. Cytokinetics Q3 Loss Wider Than Expected, Pipeline in Focus Cytokinetics reported a net loss of $1.36 per share in the third quarter of 2024, wider than the Zacks Consensus Estimate of a loss of $1.27.\u00a0 In the year-ago quarter, the company reported a net loss of $1.35 per share. Cytokinetics is a late-stage, specialty cardiovascular biopharmaceutical company focused on discovering, developing and commercializing muscle biology-directed drug candidates as potential treatments for debilitating diseases in which cardiac muscle performance is compromised. Since the company does not have any approved product in its portfolio yet, it does not generate drug sales. Total revenues for the third quarter were $0.5 million, up from $0.4 million in the year-ago quarter. Quarter in Detail R&D expenses amounted to $84.6 million, up 2.5% year over year driven by higher personnel related expenses to progress our pipeline partially offset by the completion of clinical trials. General and administrative expenses surged 41.2% to $56.7 million, driven by investments toward commercial readiness and personnel related expenses. Cash Balance Increase As of Sept. 30, 2024, Cytokinetics had approximately $1.3 billion in cash, cash equivalents and investments, down from $1.4 billion as of Jun. 31, 2024. During the second quarter, Cytokinetics completed a public offering of 11.27 million shares of its common stock, raising approximately $563.2 million in net proceeds. In May 2024, Cytokinetics entered into a strategic funding collaboration (worth $575 million) with Royalty Pharma to support the commercialization of late-stage candidate aficamten and advance the company\u2019s expanding cardiovascular pipeline. Pipeline Updates Cytokinetics completed the rolling submission of the new drug application (NDA) for aficamten and submitted the NDA for the treatment of obstructive hypertrophic cardiomyopathy (HCM). Results from the phase III SEQUOIA-HCM study in obstructive HCM showed that treatment with aficamten in SEQUOIA-HCM was associated with improvements in cardiac structure and function, heart failure symptoms, cardiac biomarkers, and multiple assessments of clinical significance to cardiologists. Story Continues Additionally, an analysis from FOREST-HCM, the open label extension clinical study of aficamten in patients with HCM, demonstrated that patients who attempted withdrawal of standard of care medications did not experience negative impacts on the efficacy or safety of aficamten. A marketing authorization application for aficamten in the EU is planned for the fourth quarter. Corxel (formerly Ji Xing Pharmaceuticals) completed submission of the NDA for aficamten to treat obstructive HCM. The Center for Drug Evaluation of the National Medical Products Administration in China accepted the NDA. Aficamten is also currently being evaluated in MAPLE-HCM, a phase III study of aficamten as monotherapy compared to metoprolol as monotherapy in patients with obstructive HCM (enrollment completed) and ACACIA-HCM, a phase III study of aficamten in patients with non-obstructive HCM (enrolment ongoing. Other studies include CEDAR-HCM, a clinical trial of aficamten in a pediatric population with obstructive HCM. Enrollment is ongoing in CEDAR-HCM. Other pipeline candidates include omecamtiv mecarbil, a cardiac muscle activator, in patients with heart failure. Cytokinetics conducted start-up activities for COMET-HF, a confirmatory phase III multi-center, double-blind, randomized, placebo-controlled trial to assess the efficacy and safety of omecamtiv mecarbil in patients with symptomatic heart failure with severely reduced ejection fraction, expected to start shortly. Additionally, Cytokinetics is developing CK-586, a cardiac myosin inhibitor with a mechanism of action distinct from aficamten for the potential treatment of heart failure with preserved ejection fraction (HFpEF). Data from the phase I study support progression to a phase IIa study in patients with HFpEF (initiation expected in the fourth quarter). How Have Estimates Been Moving Since Then? In the past month, investors have witnessed an upward trend in estimates review. VGM Scores At this time, Cytokinetics has a poor Growth Score of F, however its Momentum Score is doing a bit better with a D. Charting a somewhat similar path, the stock was allocated a grade of F on the value side, putting it in the lowest quintile for this investment strategy. Overall, the stock has an aggregate VGM Score of F. If you aren't focused on one strategy, this score is the one you should be interested in. Outlook Estimates have been broadly trending upward for the stock, and the magnitude of these revisions looks promising. Notably, Cytokinetics has a Zacks Rank #3 (Hold). We expect an in-line return from the stock in the next few months. Performance of an Industry Player Cytokinetics belongs to the Zacks Medical - Biomedical and Genetics industry. Another stock from the same industry, Insmed (INSM), has gained 5.1% over the past month. More than a month has passed since the company reported results for the quarter ended September 2024. Insmed reported revenues of $93.43 million in the last reported quarter, representing a year-over-year change of +18.2%. EPS of -$1.27 for the same period compares with -$1.10 a year ago. For the current quarter, Insmed is expected to post a loss of $1.17 per share, indicating a change of +8.6% from the year-ago quarter. The Zacks Consensus Estimate has changed -0.1% over the last 30 days. The overall direction and magnitude of estimate revisions translate into a Zacks Rank #3 (Hold) for Insmed. Also, the stock has a VGM Score of F. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Cytokinetics, Incorporated (CYTK) : Free Stock Analysis Report Insmed, Inc. (INSM) : Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research View Comments Terms and Privacy Policy Privacy Dashboard Recommended Stories", "symbol": "CYTK", "date": "2024-12-06T16:31:15+00:00", "sentiment": {"score": -0.9233642518520355, "confidence": 0.9552149772644043, "probabilities": {"positive": 0.031850725412368774, "negative": 0.9552149772644043, "neutral": 0.012934309430420399}}, "embedding": [-0.08556795120239258, -0.005234923679381609, 0.05700003355741501, -0.06497892737388611, -0.01162097230553627, 0.021458635106682777, -0.018897000700235367, 0.30850517749786377, 0.13980935513973236, 0.11433442682027817, -0.09306220710277557, 0.03546634688973427, 0.09267251193523407, 0.055839452892541885, -0.06087925285100937, 0.0015108272200450301, 0.053440339863300323, 0.15379871428012848, -0.13408467173576355, 0.05248425155878067, -0.08507801592350006, -0.009170442819595337, 0.055485017597675323, 0.05626123398542404, 0.05782271549105644, 0.0838298350572586, -0.11914290487766266, -0.03056998923420906, -0.15885476768016815, 0.10007785260677338, -0.08704519271850586, 0.13944441080093384, 0.11680856347084045, 0.007661197334527969, 0.003434091806411743, 0.029777325689792633, -0.07128973305225372, 0.07807441800832748, 0.015177736058831215, 0.02231244370341301, -0.001946805976331234, -0.045349135994911194, -0.1219155341386795, 0.02299264818429947, 0.08468181639909744, -0.024426113814115524, 0.0041239261627197266, 0.015253670513629913, -0.0539017915725708, 0.0711870789527893, -0.11265574395656586, -0.15030032396316528, 0.11383449286222458, 0.06596352905035019, -0.07052454352378845, -0.0016956906765699387, -0.26705479621887207, -0.05389062687754631, -0.025348978117108345, 0.05478890612721443, -0.057125482708215714, 0.000823750626295805, -0.04154886677861214, 0.021582573652267456, 0.09948058426380157, -0.043404147028923035, -0.05783231556415558, 0.04057318717241287, 0.04150953143835068, -0.009919571690261364, 0.09197109937667847, -0.10860300064086914, -0.1030106395483017, -0.01589963585138321, -0.11000942438840866, 0.2432699054479599, 0.17795786261558533, 0.1728869080543518, 0.031754039227962494, -0.1717858910560608, 0.16885977983474731, -0.04007229208946228, 0.08658282458782196, 0.04730698838829994, -0.003993516322225332, 0.030045028775930405, 0.07027556002140045, 0.16838890314102173, -0.020088182762265205, 0.10802032053470612, 0.08829060196876526, 0.051115475594997406, 0.09811951220035553, -0.026119451969861984, -0.07449978590011597, -0.02794184535741806, -0.1190505176782608, 0.025564735755324364, 0.049605000764131546, 0.07121151685714722, 0.04376668110489845, 0.0606670081615448, -0.03637228161096573, -0.13016054034233093, -0.029622629284858704, -0.1418469399213791, 0.11566522717475891, -0.06101873517036438, 0.08150691539049149, 0.05619393661618233, -0.051690954715013504, -0.06303688883781433, -0.19440048933029175, -0.07232612371444702, 0.0066359215416014194, 0.26711347699165344, -0.011693449690937996, 0.08630599081516266, 0.15062357485294342, 0.08474725484848022, 0.0519239716231823, -0.06530718505382538, -0.046192243695259094, -0.04553588852286339, -0.059461869299411774, 0.09708060324192047, -0.20285382866859436, 1.1776843702662664e-32, -0.03790932521224022, 0.015994684770703316, 0.15344728529453278, -0.02533341757953167, -0.05996987223625183, -0.010359309613704681, 0.11356779932975769, -0.11978469043970108, 0.013581067323684692, -0.1987551897764206, -0.1419806331396103, 0.10535173118114471, 0.03385588154196739, -0.002000211738049984, -0.09377261251211166, -0.12318315356969833, -0.1275424063205719, 0.02134084329009056, 0.05050152540206909, -0.06283286213874817, 0.02088390663266182, -0.045694079250097275, -0.05453912168741226, 0.0687979906797409, -0.022046871483325958, 0.0003599850460886955, -0.06384962797164917, -0.027372190728783607, -0.03395586833357811, 0.02550678327679634, -0.12048009037971497, -0.02813699096441269, 0.10687054693698883, -0.12013933062553406, -0.06387390941381454, -0.03837224096059799, 0.047688309103250504, -0.10287085920572281, 0.07526279985904694, 0.03130540996789932, -0.18323230743408203, -0.05351369082927704, -0.01819750666618347, -0.15767042338848114, -0.022938143461942673, -0.025870386511087418, -0.1196846142411232, -0.04502806067466736, -0.03305938094854355, -0.011615375056862831, 0.09784531593322754, 0.03213151916861534, -0.012378952465951443, -0.0269960705190897, -0.016267996281385422, 0.05009911209344864, -0.0967123806476593, -0.07178384810686111, -0.03050101175904274, 0.05131589621305466, 0.014809273183345795, 0.11334643512964249, -0.01863069087266922, 0.028009695932269096, -0.12843048572540283, 0.17588156461715698, -0.08314985036849976, -0.04853740334510803, -0.19219642877578735, 0.25745081901550293, -0.041250843554735184, -0.04742179811000824, 0.04240419343113899, -0.10013043135404587, 0.17706218361854553, -0.011112282983958721, -0.029464442282915115, 0.11136746406555176, 0.007706064730882645, 0.06303197890520096, 0.04375181347131729, -0.040485575795173645, -0.06575573980808258, 0.06757494062185287, 0.0781097486615181, -0.07206859439611435, 0.08814428746700287, -0.03255071863532066, -0.050960686057806015, -0.019370678812265396, 0.07626736164093018, -0.13959383964538574, -0.0579797737300396, 0.23283864557743073, -0.06289514899253845, -1.2323693960240761e-32, -0.14000165462493896, 0.16148003935813904, -0.01923941820859909, -0.10782493650913239, -0.008924202062189579, 0.0933065414428711, 0.04626882076263428, -0.02605181373655796, 0.06630445271730423, 0.022409707307815552, 0.01833958551287651, -0.03266182914376259, -0.0786546990275383, 0.11130237579345703, -0.18220317363739014, -0.04449462890625, 0.015271225944161415, -0.0632799044251442, -0.06038803234696388, -0.007551960181444883, 0.05783320963382721, 0.13498124480247498, 0.017874550074338913, 0.16063079237937927, 0.008819470182061195, 0.11210038512945175, 0.0010927743278443813, 0.1489471197128296, 0.0583309531211853, -0.05976080894470215, -0.018186544999480247, 0.01882687211036682, -0.18290552496910095, -0.010626744478940964, 0.0742105096578598, 0.03743390366435051, -0.05094514787197113, -0.11433925479650497, 0.019895687699317932, -0.13571909070014954, -0.005604622885584831, -0.09263923764228821, 0.06979420781135559, 0.07792244851589203, 0.08794043958187103, -0.036598607897758484, 0.16271600127220154, -0.07125639170408249, 0.12106572091579437, 0.08555791527032852, 0.015917036682367325, 0.009145475924015045, -0.0206020288169384, 0.1398778259754181, -0.11146488785743713, 0.09901616722345352, 0.10200382024049759, 0.049154266715049744, -0.13687120378017426, -0.03238200768828392, 0.0013203725684434175, -0.018758242949843407, -0.003839646466076374, 0.012181954458355904, 0.11566919088363647, 0.00421330938115716, 0.15376445651054382, 0.06993602961301804, 0.04920371621847153, -0.08338437974452972, 0.014298271387815475, 0.009960017167031765, 0.022423826158046722, -0.08249001204967499, 0.008831014856696129, 0.1887822300195694, -0.021598368883132935, -0.19062775373458862, -0.12969084084033966, 0.018390418961644173, 0.03499419614672661, -0.016974477097392082, 0.0478556826710701, -0.03680023178458214, -0.043831415474414825, 0.012552374042570591, 0.10328824818134308, 0.06365957111120224, -0.06029659882187843, 0.017554763704538345, -0.06967897713184357, -0.1073671281337738, -0.021566273644566536, 0.16594409942626953, 0.06996802240610123, -1.0073904377350118e-07, 0.11102111637592316, -0.05779210478067398, -0.08218474686145782, -0.0905071496963501, 0.08191676437854767, -0.13734684884548187, -0.060951970517635345, 0.04360451549291611, 0.02994394861161709, 0.10651203244924545, 0.04147879779338837, 0.10423516482114792, -0.12032726407051086, 0.046432919800281525, -0.03837234526872635, -0.035774409770965576, -0.17105315625667572, 0.009857346303761005, -0.02149706706404686, -0.07357518374919891, -0.05277678370475769, -0.003376239910721779, -0.05178628861904144, -0.08318784832954407, -0.01905416138470173, -0.13367582857608795, -0.040195196866989136, 0.12232635915279388, -0.030059974640607834, -0.04461143910884857, 0.07250213623046875, -0.0009972043335437775, 0.05009351670742035, 0.08619669824838638, -0.16605323553085327, -0.13902127742767334, 0.02115924097597599, -0.014212029054760933, 0.031347744166851044, 0.09560292959213257, -0.11676548421382904, -0.03350376337766647, 0.016371123492717743, 0.06973341107368469, -0.07150343060493469, -0.10780803859233856, -0.10516777634620667, -0.0049907611683011055, 0.07123410701751709, -0.2053319662809372, -0.002084663137793541, -0.004836700391024351, -0.032379306852817535, -0.08634014427661896, -0.0027050860226154327, 0.050380513072013855, -0.1455843448638916, 0.017563074827194214, -0.10530689358711243, -0.14209505915641785, -0.10464566200971603, -0.24791494011878967, 0.10577044636011124, 0.12601667642593384], "changes": {"1wk": -4.5329623235758625, "1mo": -3.139714487570719}}, {"text": "PREMIUM RBC Raises Price Target on Cytokinetics to $82 From $80, Keeps Outperform, Speculative Risk MT Newswires Wed, Dec 18, 2024, 3:35 PM In This Article: CYTK -2.01% Cytokinetics (CYTK) has an average rating of overweight and mean price target of $80.94, according t PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premium news articles. Upgrade Already have a subscription? Sign in Terms and Privacy Policy Privacy Dashboard Recommended Stories", "symbol": "CYTK", "date": "2024-12-18T12:35:55+00:00", "sentiment": {"score": 0.09006308950483799, "confidence": 0.10113531351089478, "probabilities": {"positive": 0.10113531351089478, "negative": 0.011072224006056786, "neutral": 0.8877924680709839}}, "embedding": [-0.19833901524543762, -0.05586572736501694, -0.08973602950572968, 0.15805216133594513, 0.1479131281375885, 0.0830150917172432, 0.07325638830661774, 0.3403158485889435, 0.09386222809553146, 0.06242576241493225, -0.0391397550702095, 0.024182111024856567, 0.11324841529130936, -0.06126416102051735, 0.05373724550008774, 0.006547157187014818, 0.27047088742256165, 0.1494067758321762, -0.0692884624004364, -0.03492984548211098, -0.2004324495792389, -0.02748004160821438, 0.10358519107103348, 0.10588960349559784, 0.14486083388328552, -0.13173852860927582, -0.022902587428689003, 0.010332737118005753, -0.0610070563852787, 0.11469022184610367, -0.06844828277826309, -0.08146820962429047, 0.11279282718896866, -0.00916348583996296, 0.03413368761539459, -0.15605714917182922, -0.05421173572540283, -0.01742461510002613, -0.0928603783249855, -0.012341385707259178, 0.155385822057724, -0.03919966518878937, -0.3575141131877899, 0.09358607232570648, 0.0506923645734787, 0.04191553220152855, 0.02565421164035797, 0.1605215221643448, -0.042483750730752945, 0.033936500549316406, -0.00040483250631950796, -0.0957842692732811, -0.00866021029651165, -0.02846696227788925, -0.06488540023565292, -0.023272745311260223, -0.32499945163726807, -0.06970039010047913, 0.20634110271930695, 0.04304724559187889, -0.12076663225889206, -0.06075853854417801, -0.09586832672357559, 0.007518275640904903, 0.05266208201646805, -0.11230707913637161, -0.10341216623783112, 0.09607452154159546, 0.13225087523460388, -0.12406571209430695, -0.018295958638191223, 0.03891248628497124, -0.031914085149765015, 0.0018963896436616778, 0.02704540826380253, 0.2532564103603363, 0.13384030759334564, -0.07053101807832718, -0.07884024828672409, -0.11931651085615158, 0.056973833590745926, -0.14508101344108582, 0.1324094980955124, 0.07290046662092209, 0.10479690879583359, -0.07773081213235855, 0.1350535750389099, 0.1410333514213562, -0.0911005437374115, 0.09526712447404861, 0.19682542979717255, -0.0281887948513031, 0.1129932776093483, -0.0294408667832613, -0.13230009377002716, -0.06159786134958267, -0.1626712530851364, -0.07679778337478638, -0.13098302483558655, 0.028110308572649956, -0.06410795450210571, 0.005609522107988596, 0.023832613602280617, 0.046085041016340256, -0.01351194828748703, -0.2730422616004944, -0.04887811839580536, 0.06413111835718155, 0.16979676485061646, 0.07805168628692627, -0.08716569095849991, -0.037997614592313766, -0.11190404742956161, -0.18509943783283234, -0.18196922540664673, 0.21391524374485016, 0.003046769183129072, -0.1561129093170166, 0.08750870823860168, -0.004545650910586119, 0.04756215587258339, -0.10632817447185516, -0.13464994728565216, 0.06354265660047531, -0.0446951687335968, 0.0551937036216259, -0.1421276032924652, 1.476194328096672e-32, -0.027369871735572815, 0.1152317225933075, 0.15145012736320496, -0.21999745070934296, -0.20293888449668884, 0.14917276799678802, 0.07093445956707001, -0.22288426756858826, 0.0866972804069519, -0.11385774612426758, -0.11604434996843338, 0.1300140917301178, 0.08468933403491974, 0.06171111389994621, -0.22934114933013916, -0.18005114793777466, -0.22959129512310028, 0.06280988454818726, 0.09531932324171066, 0.1901644915342331, -0.05823168531060219, -0.11031549423933029, -0.11307106912136078, -0.07133728265762329, -0.050995778292417526, 0.045175548642873764, 0.061956971883773804, -0.1115073412656784, 0.16315047442913055, 0.08093148469924927, -0.2030516266822815, 0.08648243546485901, 0.09587682038545609, -0.03528500720858574, -0.027799788862466812, 0.03685785457491875, 0.016152398660779, -0.13888268172740936, -0.019003774970769882, -0.13142360746860504, -0.142154723405838, -0.04244440048933029, -0.017717843875288963, -0.04569539427757263, 0.12358494848012924, 0.0009757219231687486, -0.09918621182441711, -0.06644780188798904, -0.093390092253685, -0.10875499248504639, -0.011544425040483475, 0.07025888562202454, -0.12080547213554382, 0.1402190923690796, -0.08942919969558716, -0.08093041181564331, -0.03753932937979698, -0.04349976405501366, 0.059397559612989426, 0.034660711884498596, 0.1880999654531479, 0.0351133868098259, -0.016795454546809196, -0.0011303810169920325, -0.011383065953850746, 0.16552385687828064, -0.27600347995758057, -0.10891231894493103, -0.24925971031188965, 0.29495924711227417, 0.25599610805511475, 0.13098891079425812, 0.17934802174568176, -0.08257011324167252, -0.09886695444583893, 0.0367630235850811, -0.02670532651245594, 0.07876025885343552, 0.10299652069807053, 0.08029662072658539, -0.0353073887526989, -0.08213787525892258, 0.08285853266716003, -0.0602080337703228, 0.12184249609708786, -0.1101784035563469, -0.1424848735332489, -0.007215380668640137, -0.15595996379852295, -0.07349435985088348, 0.13544511795043945, -0.07479491084814072, -0.13776536285877228, 0.20785310864448547, -0.07398472726345062, -1.357450590754008e-32, -0.12301484495401382, 0.17996233701705933, 0.031771812587976456, 0.03767773509025574, 0.039128970354795456, -0.0143605200573802, -0.09625101089477539, 0.06870908290147781, 0.18188537657260895, 0.16793200373649597, 0.0019645399879664183, 0.005805645138025284, -0.14873851835727692, 0.3035920560359955, -0.012640148401260376, -0.06498951464891434, -0.05903271958231926, 0.010103029198944569, -0.09434118866920471, 0.024853847920894623, -0.2439328134059906, 0.10857130587100983, 0.00731666712090373, 0.3380547761917114, 0.12533213198184967, -0.017256857827305794, -0.013148820027709007, 0.2437344491481781, 0.018735481426119804, -0.10972516238689423, -0.14971549808979034, 0.08083132654428482, -0.06081061437726021, -0.004191494546830654, -0.04263253137469292, 0.04551463946700096, 0.09619095176458359, 0.045184969902038574, 0.08152128010988235, -0.07311560213565826, 0.04021265730261803, -0.18007183074951172, -0.10376980900764465, -0.04450172930955887, 0.1391768604516983, 0.062420085072517395, 0.14007093012332916, 0.03819367662072182, 0.18284036219120026, 0.04869333282113075, 0.022232459858059883, 0.0007720275316387415, 0.07794604450464249, 0.3303287625312805, -0.23827457427978516, 0.010532365180552006, 0.07202516496181488, 0.16313289105892181, 0.026035193353891373, -0.12739351391792297, 0.12812931835651398, 0.18732202053070068, -0.07139600813388824, 0.042455367743968964, 0.05245090276002884, -0.020759698003530502, 0.22292354702949524, 0.037954069674015045, 0.03525250405073166, -0.07140633463859558, -0.08584155887365341, -0.054435260593891144, 0.01031047385185957, -0.07725122570991516, -0.036954887211322784, 0.03481948375701904, 0.07535190880298615, 0.015839949250221252, -0.035050828009843826, -0.0039621638134121895, -0.025290800258517265, -0.05642823502421379, 0.030049603432416916, -0.06995498389005661, 0.041042208671569824, -0.06586626172065735, 0.0374624989926815, 0.12088824808597565, -0.1681966781616211, 0.12292211502790451, -0.24158424139022827, -0.04159439727663994, -0.026161763817071915, 0.14340969920158386, 0.013787561096251011, -9.94118352082296e-08, 0.12732960283756256, -0.04900066927075386, -0.08136805891990662, 0.04877030476927757, 0.14041781425476074, -0.0011694884160533547, -0.10376914590597153, 0.04183308780193329, -0.06765352189540863, 0.16833236813545227, 0.011386771686375141, -0.0032188924960792065, -0.03569696843624115, -0.09978172928094864, 0.009083852171897888, -0.02103928104043007, -0.02409765124320984, 0.03914536535739899, 0.07861363887786865, -0.029039347544312477, 0.023726418614387512, 0.13386008143424988, 0.04961507022380829, -0.09947347640991211, -0.11372397094964981, -0.03396299481391907, -0.06417723745107651, 0.11156049370765686, 0.1020103171467781, -0.03222109004855156, 0.06726811081171036, 0.00849185697734356, 0.017897162586450577, 0.023619621992111206, -0.05013309419155121, 0.02561982162296772, -0.07705630362033844, 0.030527351424098015, 0.025449402630329132, 0.04812626168131828, -0.02369527891278267, -0.07793004810810089, -0.04447418078780174, -0.02011929079890251, -0.04969479516148567, -0.024201782420277596, -0.20550483465194702, -0.174560546875, 0.10188611596822739, -0.15202312171459198, 0.05837510526180267, 0.011038022115826607, 0.06521287560462952, -0.0685538575053215, 0.06675344705581665, -0.001236919779330492, -0.0768040269613266, -0.03656692057847977, -0.04647416993975639, 0.08593528717756271, -0.004048684611916542, -0.3331744074821472, -0.021052120253443718, 0.21011710166931152], "changes": {"1wk": 4.680755263969477, "1mo": 1.3589323982333246}}, {"text": "Cytokinetics Initiates Confirmatory Study on Heart Failure Drug Zacks Equity Research Wed, Dec 4, 2024, 8:30 PM 4 min read In This Article: CYTK -2.01% Cytokinetics, Incorporated CYTK announced that the late-stage COMET-HF study on pipeline candidate, omecamtiv mecarbil, has started. COMET-HF (Confirmation of Omecamtiv Mecarbil Efficacy Trial in Heart Failure) is a confirmatory phase III study of omecamtiv mecarbil in patients with symptomatic heart failure (HF) with severely reduced ejection fraction. Year to date, Cytokinetics\u2019 shares have lost 38.3% compared with the industry\u2019s 8.3% decline. Zacks Investment Research Image Source: Zacks Investment Research More on CYTK\u2019s COMET-HF Study Omecamtiv mecarbil is a novel investigational selective cardiac myosin activator in development for the potential treatment of HF with severely reduced ejection fraction. The phase III COMET-HF study is being conducted in collaboration with Duke Clinical Research Institute, a leading academic research organization. The study is open to enrollment. The multi-center, double-blind, randomized, placebo-controlled study is designed to assess the efficacy and safety of omecamtiv mecarbil in patients with symptomatic HF with severely reduced ejection fraction. The primary endpoint of COMET-HF is the time to first event in the primary composite endpoint of cardiovascular death, first heart failure event, left ventricular assist device (LVAD) implantation or cardiac transplantation, or stroke. Secondary endpoints will evaluate the risk of individual components, including heart failure hospitalization, cardiovascular death, and stroke, as well as the risk of irreversible morbidity/mortality based on the composite endpoint of cardiovascular death, LVAD or cardiac implantation, or stroke. The study is expected to randomize approximately 1,800 patients in two arms equally to receive omecamtiv mecarbil or placebo. Eligible patients will enter a two-week run-in period, following which all patients will undergo a two-week washout period before being randomized to receive omecamtiv mecarbil, up to a maximum dose of 50 mg twice daily based on the plasma concentration of omecamtiv mecarbil during the run-in period, or placebo. Patients will continue to receive omecamtiv mecarbil or placebo twice daily until at least 850 primary composite endpoint events have occurred in the trial. However, patients who are intolerant to omecamtiv mecarbil, are non-adherent, or have either undetectable or excessive plasma concentrations of omecamtiv mecarbil will not be eligible for randomization. CYTK\u2019s Pipeline Progress Cytokinetics recently announced that the FDA has accepted the company\u2019s new drug application (NDA) for lead pipeline candidate, aficamten. Leer m\u00e1s Aficamten is a next-in-class cardiac myosin inhibitor. The NDA is seeking approval for the candidate for the treatment of obstructive hypertrophic cardiomyopathy. The regulatory body assigned the NDA a standard review and set a target action date of Sept. 26, 2025. The FDA also informed the company that it is not planning to hold an advisory committee meeting to discuss the application. A potential approval and the successful development of the candidate should be a significant boost for this late-stage, specialty cardiovascular biopharmaceutical company, CYTK, as it currently does not have any approved product in its portfolio. Pharma giant Bayer AG BAYRY recently announced that it will acquire rights to aficamten in Japan. Per the financial terms of the agreement, Cytokinetics will receive an upfront payment of \u20ac50 million and an additional \u20ac90 million upon achieving milestones through commercial launch, including \u20ac20 million, which are near-term. In addition, Cytokinetics is eligible to receive up to \u20ac490 million in commercial milestone payments upon achieving certain sales milestones by Bayer and tiered royalties on net sales of aficamten in Japan. CYTK\u2019s Zacks Rank and Stocks to Consider Cytokinetics currently carries a Zacks Rank #3 (Hold). A couple of better-ranked stocks in the biotech sector are Spero Therapeutics SPRO and Castle Biosciences, Inc . CSTL, both carrying a Zacks Rank #1 (Strong Buy) at present. You can see the complete list of today\u2019s Zacks #1 Rank stocks here . In the past 60 days, estimates for Spero Therapeutics\u2019 2024 loss per share have narrowed from $1.59 to $1.29. Estimates for 2025 loss per share have narrowed from $1.54 to 79 cents. Spero Therapeutics\u2019 earnings beat estimates in two of the trailing four quarters and missed the mark on the other two occasions, delivering an average surprise of 94.42%. In the past 60 days, estimates for Castle Biosciences\u2019 2024 loss per share have narrowed from 58 cents to 8 cents. Loss per share estimates for 2025 have narrowed from $2.13 to $1.88 during the same time frame. Year to date, shares of CSTL have surged 42.6%. CSTL\u2019s earnings beat estimates in each of the trailing four quarters, the average surprise being 172.72%. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Bayer Aktiengesellschaft (BAYRY) : Free Stock Analysis Report Cytokinetics, Incorporated (CYTK) : Free Stock Analysis Report Spero Therapeutics, Inc. (SPRO) : Free Stock Analysis Report Castle Biosciences, Inc. (CSTL) : Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research Ver comentarios Condiciones y Pol\u00edtica de privacidad Privacy Dashboard Historias recomendadas", "symbol": "CYTK", "date": "2024-12-04T17:30:00+00:00", "sentiment": {"score": -0.028545692563056946, "confidence": 0.07699401676654816, "probabilities": {"positive": 0.04844832420349121, "negative": 0.07699401676654816, "neutral": 0.874557614326477}}, "embedding": [0.0482478030025959, 0.07791603356599808, 0.07425804436206818, -0.06744923442602158, 0.060825325548648834, -0.08344550430774689, -0.12691675126552582, 0.33528590202331543, 0.09702470898628235, 0.04557862877845764, -0.05408414080739021, -0.01004350371658802, 0.08020783960819244, 0.08632926642894745, -0.014940712600946426, 0.04535091295838356, 0.18636342883110046, 0.1495671421289444, -0.10333679616451263, 0.09525784850120544, 0.034178946167230606, -0.037356484681367874, -0.0009680408984422684, 0.09207427501678467, -0.0623617023229599, 0.01514873094856739, -0.23209676146507263, -0.027852807193994522, -0.1148570328950882, 0.02330062910914421, 0.032519806176424026, 0.09849576652050018, 0.12276214361190796, 0.057807572185993195, -0.03733517974615097, 0.05312633141875267, -0.12578418850898743, 0.02030208520591259, -0.1709604263305664, -0.006935282610356808, 0.026612017303705215, -0.12371756136417389, -0.036215003579854965, 0.08560004830360413, 0.16144061088562012, -0.10174034535884857, -0.0944289118051529, -0.008780303411185741, -0.04724225401878357, 0.22323164343833923, -0.12487275153398514, 0.006229773163795471, 0.0890212431550026, 0.11167864501476288, -0.08180589973926544, -0.015853678807616234, -0.22259873151779175, 0.03374190628528595, 0.12256072461605072, -0.03142361715435982, -0.08224627375602722, 0.03836031258106232, -0.04042382538318634, -0.08033975213766098, 0.009929530322551727, 0.035202424973249435, -0.05126199871301651, -0.12773844599723816, 0.02984817698597908, 0.032044511288404465, 0.10342983901500702, -0.09347037971019745, -0.07320144027471542, 0.0696696937084198, -0.034168846905231476, 0.202397882938385, 0.10462319850921631, 0.033735424280166626, -0.036993592977523804, 0.01580156944692135, 0.08304562419652939, 0.05750114470720291, 0.04796185716986656, -0.10272803902626038, -0.01828688010573387, 0.15152283012866974, -0.08161745965480804, 0.2183229625225067, -0.06123591959476471, 0.013436523266136646, 0.08285132050514221, 0.01788974553346634, 0.007236689329147339, 0.036224402487277985, 0.10721935331821442, -0.11354957520961761, -0.019083481281995773, 0.045930907130241394, 0.07869390398263931, 0.044184040278196335, 0.1166372001171112, -0.028784602880477905, -0.17678740620613098, -0.0539284273982048, -0.037253353744745255, -0.059032052755355835, 0.047391366213560104, -0.1627623587846756, 0.1462453007698059, -0.009831195697188377, -0.012219546362757683, -0.08074163645505905, 0.011633578687906265, -0.06213084235787392, -0.04071959853172302, 0.2967178523540497, -0.10759852081537247, 0.09324024617671967, 0.2335735559463501, 0.06709501147270203, 0.140822172164917, -0.15007469058036804, 0.12568415701389313, -0.12199956178665161, 0.010474136099219322, 0.09010849893093109, 0.0011234208941459656, 1.5673099809015785e-32, 0.013453269377350807, -0.05172001197934151, 0.16514110565185547, 0.045551445335149765, -0.010086709633469582, -0.12234819680452347, 0.0824478343129158, -0.06552781164646149, -0.008946997113525867, -0.16337352991104126, -0.005773607641458511, -0.03791312873363495, -0.014783894643187523, 0.06452858448028564, -0.2725086808204651, -0.04542618244886398, -0.05990142002701759, -0.041007522493600845, 0.0008197249844670296, 0.02180645614862442, 0.012015508487820625, -0.09210404753684998, -0.11472912132740021, -0.03611236438155174, -0.0612129345536232, 0.1450325846672058, -0.02733772061765194, 0.11474327743053436, -0.042720843106508255, 0.05808974802494049, -0.08549053966999054, -0.049657437950372696, -0.012720488011837006, -0.15320086479187012, -0.1782437115907669, -0.10869815200567245, -0.07045470178127289, -0.03662830591201782, -0.019032403826713562, -0.03464701771736145, -0.19536563754081726, 0.023948291316628456, -0.024086082354187965, -0.14083117246627808, 0.1468428075313568, -0.1914900243282318, 0.06417019665241241, -0.053535617887973785, -0.05421558767557144, -0.022497253492474556, 0.05557495355606079, -0.08217595517635345, 0.005510859191417694, -0.08022062480449677, 0.0009070336818695068, 0.05841519683599472, -0.08268965780735016, 0.030444884672760963, 0.07134135812520981, 0.0341150164604187, -0.08789268136024475, 0.040775515139102936, -0.06818031519651413, 0.10201303660869598, -0.06341854482889175, 0.12941808998584747, -0.12411105632781982, -0.160636305809021, -0.07370689511299133, 0.18482232093811035, 0.08303650468587875, -0.0804106742143631, 0.01402711495757103, -0.0053894598968327045, 0.06017335131764412, 0.03557923063635826, 0.019096042960882187, 0.265388160943985, 0.015293546952307224, -0.07812993228435516, -0.02758381888270378, -0.03435468673706055, -0.0832664966583252, 0.06929647922515869, 0.017627794295549393, -0.03390861302614212, 0.06378917396068573, -0.06356285512447357, -0.1980312615633011, -0.05178704112768173, 0.09469585120677948, -0.10680148005485535, 0.0610964298248291, 0.15607282519340515, 0.002822763752192259, -1.4754334893781024e-32, -0.14083442091941833, 0.13226643204689026, 0.013135094195604324, -0.04282087832689285, 0.0611628033220768, 0.11485220491886139, 0.10485581308603287, -0.16159866750240326, 0.13499772548675537, -0.10228249430656433, -0.006030092015862465, -0.009846396744251251, -0.03629245236515999, 0.026988856494426727, -0.16845092177391052, 0.11421546339988708, -0.057061050087213516, -0.0864320769906044, -0.1330556869506836, 0.21415555477142334, 0.04534142464399338, 0.0618063285946846, -0.054064638912677765, 0.1094932109117508, 0.07088450342416763, 0.05696316808462143, 0.11130508780479431, 0.04937439039349556, 0.12676188349723816, -0.1679517924785614, 0.01467172335833311, 0.006588113959878683, -0.17758223414421082, -0.012118724174797535, 0.020376233384013176, -0.01391800306737423, -0.015269853174686432, 0.03911682218313217, -0.015021304599940777, -0.1401873230934143, -0.03903050348162651, 0.004062301479279995, -0.02684638276696205, -0.07679054141044617, -0.026466161012649536, 0.11849796026945114, 0.17481356859207153, -0.044095855206251144, 0.1262425184249878, 0.07496299594640732, -0.12435182929039001, 0.06471697241067886, -0.04611129313707352, 0.15321961045265198, -0.0080681461840868, 0.03575439378619194, 0.1425914615392685, 0.03983418643474579, -0.09015362709760666, -0.05518307536840439, -0.00446303328499198, 0.029407646507024765, 0.07426225394010544, 0.02948949672281742, 0.13591545820236206, 0.05156564712524414, 0.11161494255065918, 0.13067559897899628, -0.011241545900702477, 0.006028691306710243, 0.040702201426029205, 0.028889650478959084, 0.078252874314785, -0.047952957451343536, 0.0769047662615776, 0.06882937252521515, -0.013002381660044193, -0.14302770793437958, -0.14772281050682068, -0.055977433919906616, -0.09116705507040024, -0.10462875664234161, -0.08944395184516907, -0.0683722272515297, -0.02205679379403591, 0.03995566815137863, 0.07758035510778427, 0.006532616447657347, 0.03683559596538544, 0.07720473408699036, -0.09902701526880264, 0.12048158049583435, -0.1596107929944992, 0.11127519607543945, 0.012939859181642532, -1.0057146937469952e-07, 0.10542245209217072, -0.1650368571281433, -0.07824179530143738, -0.15135322511196136, -0.16565972566604614, -0.17274796962738037, 0.0030939425341784954, 0.0472395122051239, -0.15451835095882416, 0.08158884197473526, 0.036290243268013, 0.15439367294311523, 0.0020401678048074245, -0.13966387510299683, -0.038726672530174255, -0.11696888506412506, 0.11158035695552826, 0.005760197062045336, -0.01688113808631897, -0.01531373243778944, -0.07880204916000366, -0.0718376636505127, 0.13005560636520386, -0.17810919880867004, 0.0015446587931364775, -0.08418963104486465, 0.12511670589447021, 0.1519753485918045, 0.0037027718499302864, -0.08245310187339783, -0.07925911247730255, 0.024156413972377777, 0.07134803384542465, 0.04688195139169693, -0.040550779551267624, -0.02901867963373661, 0.029812918975949287, 0.028126686811447144, 0.0014482360566034913, 0.08296333998441696, -0.01688990741968155, -0.07090601325035095, 0.021289093419909477, -0.0009680092334747314, -0.04088738560676575, -0.07299666851758957, -0.00861410703510046, -0.08047357201576233, 0.0315886065363884, -0.12509450316429138, -0.03883294761180878, -0.055430490523576736, -0.08590525388717651, -0.07614356279373169, 0.07805559039115906, 0.149397075176239, -0.034188926219940186, 0.029661118984222412, 0.05840577930212021, -0.13554124534130096, 0.0874079242348671, -0.04353862255811691, 0.03908674418926239, -0.056864138692617416], "changes": {"1wk": 0.5154681667512823, "1mo": -2.141153936878859}}, {"text": "FDA Accepts Cytokinetics' Application for Cardiovascular Drug Zacks Equity Research Tue, Dec 3, 2024, 9:37 PM 4 min read In This Article: CYTK -2.01% BAYN.DE +0.95% Cytokinetics, Incorporated CYTK announced that the FDA has accepted the company\u2019s new drug application (NDA) for lead pipeline candidate, aficamten. Aficamten is a next-in-class cardiac myosin inhibitor. The NDA is seeking approval of the candidate for the treatment of obstructive hypertrophic cardiomyopathy (HCM). Year to date, Cytokinetics\u2019 shares have lost 39.5% compared with the industry\u2019s 7% decline. Zacks Investment Research Image Source: Zacks Investment Research CYTK\u2019s NDA Acceptance The regulatory body assigned a standard review to the NDA and set a target action date of Sept. 26, 2025. The FDA also informed the company that it is not planning to hold an advisory committee meeting to discuss the application. The NDA is supported by the results from the phase III SEQUOIA-HCM (Safety, Efficacy, and Quantitative Understanding of Obstruction Impact of Aficamten in HCM) study on aficamten in patients with symptomatic obstructive HCM. Results from SEQUOIA-HCM showed that treatment with aficamten for 24 weeks significantly improved exercise capacity compared to placebo, increasing peak oxygen uptake measured by cardiopulmonary exercise testing by 1.8 ml/kg/min compared to baseline in patients treated with aficamten versus 0.0 ml/kg/min in patients treated with placebo. Statistically significant improvements were observed in all 10 prespecified secondary endpoints. Treatment-emergent serious adverse events occurred in 5.6% and 9.3% of patients on aficamten and placebo, respectively. Core echocardiographic left ventricular ejection fraction (LVEF) was less than 50% in five patients on aficamten compared to one on placebo. There were no instances of worsening heart failure or treatment interruptions due to low LVEF. Additional analyses from SEQUOIA-HCM have demonstrated that treatment with aficamten is associated with favorable cardiac remodeling as well as improvements in cardiac structure, function and biomarkers without negatively impacting systolic function. We remind investors that the FDA had granted orphan drug designation to aficamten for the treatment of symptomatic HCM in January 2021. It also granted Breakthrough Therapy Designation in December 2021 for treating obstructive HCM. A potential approval and the successful development of the candidate will be a significant boost for late-stage, specialty cardiovascular biopharmaceutical company, CYTK, as it currently does not have any approved product in its portfolio. CYTK\u2019s Pipeline Progress Aficamten is also currently being evaluated in MAPLE-HCM, a phase III clinical trial assessing aficamten as monotherapy compared to metoprolol as monotherapy in patients with obstructive HCM. FOREST-HCM is an open-label extension clinical study of aficamten in patients with HCM. Story Continues Meanwhile, Bayer AG BAYRY will acquire rights to aficamten in Japan. As per the joint development plan, Bayer plans to conduct a phase III study in Japanese patients with obstructive HCM. On the other hand, Cytokinetics will expand ACACIA-HCM, the ongoing global late-stage study of aficamten in patients with non-obstructive HCM, into Japan. This study is intended to support the potential marketing authorization of aficamten in Japan for Bayer. CYTK will also expand CEDAR-HCM, its ongoing study for pediatric patients with obstructive HCM. Per the financial terms of the agreement, Cytokinetics will receive an upfront payment of \u20ac50 million and an additional \u20ac90 million upon achieving milestones through commercial launch, including \u20ac20 million, which are near-term. In addition, Cytokinetics is eligible to receive up to \u20ac490 million in commercial milestone payments upon achieving certain sales milestones by Bayer and tiered royalties on net sales of aficamten in Japan. Zacks Rank and Stocks to Consider Cytokinetics currently carries a Zacks Rank #3 (Hold). A couple of better-ranked stocks in the biotech sector are Spero Therapeutics SPRO and Castle Biosciences, Inc . CSTL, both carrying a Zacks Rank #1 (Strong Buy) at present. You can see the complete list of today\u2019s Zacks #1 Rank stocks here . In the past 60 days, estimates for Spero Therapeutics\u2019 2024 loss per share have narrowed from $1.59 to $1.13. Estimates for 2025 loss per share have narrowed from $1.54 to 54 cents. Spero Therapeutics\u2019 earnings beat estimates in two of the trailing four quarters and missed the mark on the other two occasions, delivering an average surprise of 94.42%. In the past 60 days, estimates for Castle Biosciences\u2019 2024 loss per share have narrowed from 58 cents to 8 cents. Loss per share estimates for 2025 have narrowed from $2.13 to $1.88 during the same time frame. Year to date, shares of CSTL have surged 44.6%. CSTL\u2019s earnings beat estimates in each of the trailing four quarters, the average surprise being 172.72%. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Bayer Aktiengesellschaft (BAYRY) : Free Stock Analysis Report Cytokinetics, Incorporated (CYTK) : Free Stock Analysis Report Spero Therapeutics, Inc. (SPRO) : Free Stock Analysis Report Castle Biosciences, Inc. (CSTL) : Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research View Comments Terms and Privacy Policy Privacy Dashboard Recommended Stories", "symbol": "CYTK", "date": "2024-12-03T18:37:00+00:00", "sentiment": {"score": 0.35368308424949646, "confidence": 0.6572156548500061, "probabilities": {"positive": 0.6572156548500061, "negative": 0.30353257060050964, "neutral": 0.03925173729658127}}, "embedding": [0.016639983281493187, -0.0836048275232315, 0.005849407985806465, -0.052069298923015594, 0.05240293964743614, -0.02000093273818493, -0.1748497486114502, 0.3074178695678711, 0.05915876477956772, -0.059677571058273315, -0.08794017136096954, -0.00889468751847744, 0.04895338416099548, 0.05848024785518646, -0.012368476018309593, -0.04049457982182503, 0.20948375761508942, 0.045209892094135284, -0.10131470859050751, 0.13976213335990906, -0.025511499494314194, 0.05229632928967476, 0.012416891753673553, 0.15544280409812927, -0.10096372663974762, -0.02147558704018593, -0.1780361533164978, -0.03669127821922302, -0.12203624844551086, 0.013896909542381763, 0.02926223911345005, 0.06868535280227661, 0.2583797872066498, 0.10932472348213196, -0.00012584403157234192, -0.01750759221613407, -0.07321523129940033, -0.04422090947628021, -0.22894462943077087, -0.015229255892336369, -0.02948712185025215, -0.06116223335266113, -0.12273440510034561, 0.05451115965843201, 0.14348474144935608, -0.06400567293167114, -0.008247371762990952, -0.04978800565004349, -0.11957526952028275, 0.19777563214302063, -0.14285308122634888, -0.02614295668900013, 0.0018784664571285248, 0.13445128500461578, -0.07883219420909882, -0.016934193670749664, -0.18459466099739075, -0.06885239481925964, 0.009151068516075611, -0.05631345883011818, -0.041114505380392075, 0.012282900512218475, -0.05893588438630104, 0.004929671064019203, -0.031016046181321144, 0.035970717668533325, -0.032619208097457886, 0.035452090203762054, 0.0763799250125885, -0.06381869316101074, 0.18705475330352783, -0.1363164633512497, 0.027123944833874702, 0.04227660596370697, -0.1371232569217682, 0.0789014920592308, 0.09343969821929932, 0.009069018065929413, -0.08646970987319946, -0.10994082689285278, 0.07640689611434937, 0.1146959438920021, 0.0006216783076524734, -0.023315027356147766, 0.007831782102584839, 0.042345236986875534, -0.07890822738409042, 0.20130378007888794, -0.03041040524840355, 0.07229495048522949, 0.21319317817687988, 0.07787344604730606, 0.028797755017876625, 0.051838770508766174, 0.036875490099191666, -0.09676662087440491, -0.06290774047374725, 0.07008317112922668, 0.004484126344323158, -0.041951898485422134, 0.12286851555109024, 0.08303043991327286, -0.26183074712753296, -0.08847790211439133, 0.05062957853078842, -0.04577498137950897, 0.14190897345542908, -0.1152811050415039, 0.17532208561897278, 0.053580883890390396, 0.04580635949969292, -0.05903959274291992, -0.09901351481676102, -0.05088212713599205, 0.03946235030889511, 0.29668760299682617, 0.02712026983499527, 0.04826587438583374, 0.09370431303977966, 0.11253608763217926, 0.10289336740970612, -0.1483364999294281, 0.05786438658833504, -0.1392160952091217, -0.06402061134576797, 0.13263821601867676, -0.14196434617042542, 1.1208501734931688e-32, 0.026684055104851723, -0.027478855103254318, 0.13899770379066467, 0.033379003405570984, 0.05589861795306206, -0.08049062639474869, 0.09619124233722687, -0.045630455017089844, -0.0017594490200281143, -0.1422523856163025, -0.13146033883094788, 0.032791897654533386, -0.0013379768934100866, 0.05241718515753746, -0.20039600133895874, -0.08924207091331482, -0.11826366931200027, -0.032497137784957886, -0.02911433018743992, 0.051494695246219635, 0.0854848325252533, -0.11499899625778198, -0.12587879598140717, 0.0022604642435908318, -0.11460843682289124, 0.04662177339196205, -0.012932438403367996, 0.111703060567379, -0.009459994733333588, 0.02519192546606064, -0.061766427010297775, -0.10881909728050232, 0.051678676158189774, -0.140677809715271, 0.012730669230222702, -0.11446711421012878, -0.06264880299568176, -0.016729939728975296, 0.05338965356349945, 0.02482299879193306, -0.17478075623512268, 0.05386463925242424, -0.0781371220946312, -0.08493787050247192, 0.20124605298042297, -0.1572730541229248, -0.08864664286375046, -0.003942148759961128, -0.11275366693735123, 0.04870779439806938, 0.05753464996814728, -0.06700495630502701, 0.02520916983485222, -0.06991878896951675, -0.026579992845654488, 0.02897796779870987, -0.08404535800218582, 0.02383601665496826, 0.0005283942446112633, 0.02652430161833763, 0.03914080560207367, 0.09404580295085907, 0.015362376347184181, 0.0374554805457592, -0.12383364140987396, 0.13661299645900726, -0.11381499469280243, -0.08089698851108551, -0.23592925071716309, 0.09575635939836502, -0.02290727198123932, -0.027098990976810455, 0.010068731382489204, 0.042887911200523376, 0.20486697554588318, -0.013628819957375526, -0.04393182322382927, 0.22529104351997375, -0.06799283623695374, -0.0917152389883995, -0.0030989954248070717, 0.03666285425424576, -0.08463229238986969, 0.050730105489492416, 0.034681286662817, -0.12799739837646484, 0.11064717173576355, -0.028590025380253792, -0.1720469892024994, -0.05297709256410599, 0.1723766028881073, -0.016502954065799713, 0.04430771619081497, 0.10184574872255325, -0.00017944537103176117, -1.2520919137105694e-32, -0.07504619657993317, 0.12967520952224731, -0.006207408849149942, -0.15162605047225952, 0.01587700843811035, 0.07596195489168167, 0.05095084756612778, -0.08701621741056442, 0.23469187319278717, -0.16545085608959198, 0.05688249692320824, 0.03674029931426048, -0.029152870178222656, 0.05177665129303932, -0.1300967037677765, 0.1441771388053894, -0.0635073333978653, -0.07106144726276398, -0.16762423515319824, 0.07230093330144882, 0.05129355937242508, -0.06299728900194168, -0.04338516667485237, 0.1606786996126175, 0.06314203888177872, 0.09811203181743622, 0.040392857044935226, 0.05648867413401604, 0.11686386168003082, -0.1288997232913971, 0.0597415491938591, -0.004933531861752272, -0.2705906629562378, -0.013992046937346458, -0.008830157108604908, 0.05575689673423767, -0.05619630962610245, 0.0024093147367239, -0.025744622573256493, -0.1095566600561142, -0.002602590247988701, 0.07013183832168579, 0.06768345832824707, 0.0554991215467453, -0.10080765187740326, 0.006042282097041607, 0.13452666997909546, -0.17272675037384033, 0.02592545561492443, -0.0034731070045381784, -0.07388413697481155, -0.007221058942377567, 0.0758945420384407, 0.18509919941425323, 0.041785307228565216, 0.02856452576816082, 0.13405629992485046, 0.14458085596561432, -0.16134466230869293, 0.017592759802937508, 0.04540491849184036, 0.07221567630767822, 0.07099565118551254, -0.07623841613531113, 0.13097535073757172, -0.03258258476853371, 0.14807747304439545, 0.06431132555007935, 0.1211932972073555, -0.06100164353847504, -0.04790513962507248, 0.03931301087141037, -0.04640420526266098, -0.018538549542427063, -0.05614657700061798, 0.12409419566392899, 0.05669012293219566, -0.17952555418014526, -0.23803550004959106, -0.07415503263473511, 0.01912350207567215, -0.11743089556694031, -0.05329958721995354, -0.07744938135147095, -0.06784818321466446, 0.04452816769480705, 0.14757047593593597, -0.06731843948364258, -0.03465120494365692, 0.05561365187168121, -0.04105601832270622, -0.018003590404987335, -0.059654489159584045, 0.1547093242406845, 0.010206515900790691, -1.0081963353059109e-07, -0.023574361577630043, -0.14638687670230865, -0.05183093994855881, -0.11942112445831299, -0.05199825018644333, -0.09605904668569565, -0.00469058845192194, -0.0037110222037881613, -0.11415424942970276, 0.01970910280942917, 0.15470600128173828, 0.10091415047645569, -0.06442173570394516, -0.12267622351646423, -0.007211762014776468, -0.12055596709251404, 0.04068341106176376, 0.01795968785881996, 0.03918057680130005, 0.1639736294746399, 0.017743436619639397, -0.02016516402363777, -0.028097782284021378, -0.1689988076686859, 0.07932662963867188, -0.10855348408222198, 0.10118760168552399, 0.11147540807723999, 0.08248543739318848, -0.07876083254814148, 0.09126713871955872, -0.009077854454517365, 0.10872039198875427, 0.12131170183420181, -0.07765238732099533, -0.10217203199863434, 0.039124228060245514, 0.024535588920116425, -0.04955246299505234, 0.1496150642633438, -0.049616407603025436, -0.022888485342264175, -0.015008963644504547, -0.0009749345481395721, 0.019962646067142487, -0.12712037563323975, 0.00040522683411836624, -0.04545430839061737, 0.0761183351278305, -0.079724982380867, 0.04066542536020279, 0.045082464814186096, -0.003209545277059078, -0.014698002487421036, 0.022572223097085953, 0.10506774485111237, -0.15040871500968933, 0.01913423091173172, 0.008139118552207947, -0.11315648257732391, -0.08837459981441498, -0.1317363977432251, 0.06595687568187714, 0.06705319136381149], "changes": {"1wk": -1.863714066694774, "1mo": -5.008732479959878}}, {"text": "Cytokinetics (CYTK) Reports Q3 Loss, Lags Revenue Estimates Zacks Equity Research Thu, Nov 7, 2024, 1:05 AM 3 min read In This Article: CYTK -2.01% Cytokinetics (CYTK) came out with a quarterly loss of $1.36 per share versus the Zacks Consensus Estimate of a loss of $1.27. This compares to loss of $1.35 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of -7.09%. A quarter ago, it was expected that this biopharmaceutical company would post a loss of $1.02 per share when it actually produced a loss of $1.31, delivering a surprise of -28.43%. Over the last four quarters, the company has not been able to surpass consensus EPS estimates. Cytokinetics , which belongs to the Zacks Medical - Biomedical and Genetics industry, posted revenues of $0.46 million for the quarter ended September 2024, missing the Zacks Consensus Estimate by 54.87%. This compares to year-ago revenues of $0.38 million. The company has not been able to beat consensus revenue estimates over the last four quarters. The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call. Cytokinetics shares have lost about 37.1% since the beginning of the year versus the S&P 500's gain of 21.2%. What's Next for Cytokinetics? While Cytokinetics has underperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock? There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's earnings outlook. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately. Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions. Ahead of this earnings release, the estimate revisions trend for Cytokinetics: mixed. While the magnitude and direction of estimate revisions could change following the company's just-released earnings report, the current status translates into a Zacks Rank #3 (Hold) for the stock. So, the shares are expected to perform in line with the market in the near future. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here. It will be interesting to see how estimates for the coming quarters and current fiscal year change in the days ahead. The current consensus EPS estimate is -$1.28 on $14.71 million in revenues for the coming quarter and -$5.20 on $13.07 million in revenues for the current fiscal year. Story Continues Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well. In terms of the Zacks Industry Rank, Medical - Biomedical and Genetics is currently in the top 38% of the 250 plus Zacks industries. Our research shows that the top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1. One other stock from the same industry, Eton Pharmaceuticals, Inc. (ETON), is yet to report results for the quarter ended September 2024. This company is expected to post quarterly loss of $0.01 per share in its upcoming report, which represents a year-over-year change of +50%. The consensus EPS estimate for the quarter has remained unchanged over the last 30 days. Eton Pharmaceuticals, Inc.'s revenues are expected to be $9.9 million, up 40.8% from the year-ago quarter. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Cytokinetics, Incorporated (CYTK) : Free Stock Analysis Report Eton Pharmaceuticals, Inc. (ETON) : Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research View Comments Terms and Privacy Policy Privacy Dashboard Recommended Stories", "symbol": "CYTK", "date": "2024-11-06T22:05:02+00:00", "sentiment": {"score": -0.7633616477251053, "confidence": 0.8099889159202576, "probabilities": {"positive": 0.04662726819515228, "negative": 0.8099889159202576, "neutral": 0.14338386058807373}}, "embedding": [-0.1675519347190857, 0.07514446973800659, 0.04691324383020401, 0.02942950278520584, -0.007987359538674355, -0.00857068132609129, -0.05918988585472107, 0.2364545315504074, 0.19228553771972656, 0.12897032499313354, -0.12417006492614746, 0.05087606981396675, 0.06920626759529114, -0.036095067858695984, -0.12730619311332703, -0.0308607816696167, 0.04696936160326004, 0.14079482853412628, -0.12457272410392761, -0.014029903337359428, -0.0652763694524765, 0.011767243966460228, 0.09533095359802246, 0.10225439071655273, 0.13141338527202606, 0.04263093322515488, -0.12317367643117905, 0.05481848865747452, -0.15304547548294067, 0.0036349203437566757, -0.1292264312505722, 0.12636709213256836, 0.11477968096733093, -0.020684007555246353, -0.04035183787345886, -0.031255025416612625, -0.010382897220551968, 0.06639713048934937, 0.10748535394668579, -0.021818052977323532, 0.007270369678735733, 0.03680598363280296, -0.22454312443733215, 0.023895593360066414, 0.011297138407826424, -0.03585432469844818, 0.014033790677785873, -0.0032358188182115555, -0.03004366159439087, 0.026713378727436066, -0.1330152302980423, -0.10273844003677368, 0.115817591547966, 0.09459352493286133, -0.10536806285381317, 0.03498657047748566, -0.20073440670967102, -0.06676025688648224, 0.06742417067289352, 0.08922676742076874, -0.004793532192707062, -0.008889306336641312, 0.0064506325870752335, 0.052202410995960236, 0.16603687405586243, -0.06263943016529083, -0.010369661264121532, 0.060219962149858475, -0.06373544782400131, 0.0028317347168922424, 0.06377723813056946, -0.054209232330322266, -0.13383865356445312, 0.04289448261260986, -0.15912002325057983, 0.13154062628746033, 0.16323614120483398, 0.11816500127315521, 0.03062007762491703, -0.09580574929714203, 0.11210241168737411, -0.07184416800737381, 0.027062341570854187, 0.009142542257905006, 0.025750167667865753, -0.05547817796468735, 0.08971461653709412, 0.21606969833374023, 0.008432973176240921, 0.1056978851556778, 0.021738218143582344, -0.020494243130087852, 0.06967828422784805, -0.008827297948300838, 0.03629875183105469, 0.03089636191725731, -0.04461466521024704, -0.09349705278873444, 0.08427274227142334, 0.07503557205200195, 0.05955485254526138, 0.1292615532875061, -0.058476150035858154, -0.12496131658554077, 0.03958631679415703, -0.14031755924224854, 0.069923996925354, -0.06632217764854431, 0.09137819707393646, 0.09382885694503784, -0.04589322209358215, 0.011384054087102413, -0.22948262095451355, -0.05970853567123413, -0.044174179434776306, 0.15326917171478271, 0.042334213852882385, 0.12700361013412476, 0.10855327546596527, 0.11250057816505432, 0.07544843852519989, -0.02921665832400322, -0.04489218816161156, -0.01711346209049225, 0.022616257891058922, 0.15432024002075195, -0.17953011393547058, 9.321485061660485e-33, 0.024368781596422195, 0.07360842078924179, 0.11211086809635162, -0.09239181876182556, -0.06937769055366516, 0.025850636884570122, 0.09014561027288437, -0.12994815409183502, 0.06417252868413925, -0.17203108966350555, -0.16127634048461914, 0.08014590293169022, 0.0013688374310731888, -0.1136993020772934, -0.06264990568161011, -0.11783485114574432, -0.13571563363075256, -0.007818028330802917, 0.027654536068439484, -0.025454742833971977, 0.012876460328698158, -0.08910243958234787, -0.08893004804849625, 0.003032407257705927, 0.015251221135258675, 0.03319479897618294, -0.05208948627114296, -0.004555085673928261, -0.10138901323080063, 0.046908169984817505, -0.0881495475769043, 0.0146489217877388, 0.0670078694820404, -0.12767702341079712, -0.06541986018419266, -0.08714407682418823, 0.008455545641481876, -0.07282468676567078, 0.12589016556739807, 0.01104077510535717, -0.16056010127067566, -0.024083290249109268, -0.07912548631429672, -0.19570392370224, -0.050479352474212646, -0.004475739784538746, -0.10925278067588806, 0.0013392595574259758, -0.02326240763068199, -0.022459177300333977, 0.0502161867916584, 0.04195524752140045, -0.033660683780908585, -0.08329117298126221, -0.027419067919254303, 0.07029084116220474, -0.04802127182483673, -0.16220420598983765, -0.010416940785944462, 0.07978440076112747, 0.09351122379302979, 0.19342079758644104, 0.034601841121912, -0.008341282606124878, -0.14007431268692017, 0.19182828068733215, -0.11633678525686264, 0.01988999731838703, -0.22993896901607513, 0.27882224321365356, 0.013419089838862419, -0.03694036230444908, 0.08397623896598816, -0.09585645794868469, 0.19374190270900726, -0.029418013989925385, -0.013298923149704933, 0.009318260475993156, 0.05666861683130264, 0.04563916474580765, 0.07938061654567719, -0.11908017098903656, -0.045612458139657974, 0.0065167914144694805, 0.06851087510585785, -0.09211097657680511, 0.07525917142629623, 0.03311704471707344, -0.004565706942230463, -0.04821483790874481, 0.1013026088476181, -0.18006426095962524, -0.0693550854921341, 0.2028757780790329, -0.09940864890813828, -1.0320547995999917e-32, -0.11104682087898254, 0.16976943612098694, -0.042976222932338715, -0.026074063032865524, -0.05954761430621147, 0.00218644249252975, 0.04289323836565018, 0.10604587942361832, 0.013339124619960785, -0.01514899730682373, 0.00215885229408741, 0.03837578743696213, -0.14771059155464172, 0.1404038965702057, -0.15771979093551636, 0.012234611436724663, 0.062071964144706726, -0.08932524919509888, 0.00966298021376133, -0.05227045714855194, -0.0091492785140872, 0.14972445368766785, -0.03996593505144119, 0.1862107217311859, 0.020098308101296425, 0.07360532134771347, -0.01352160144597292, 0.22721511125564575, 0.013076244853436947, -0.08593910932540894, -0.014505237340927124, -0.016106203198432922, -0.11091042309999466, -0.004583955742418766, 0.11604645103216171, -0.00760384276509285, -0.052026186138391495, -0.15504612028598785, 0.03795555979013443, -0.0629318580031395, 0.08108898252248764, -0.05116016045212746, 0.037009380757808685, 0.04493570700287819, 0.09451672434806824, 0.04978810250759125, 0.12278816103935242, -0.010333003476262093, 0.22733503580093384, 0.11797459423542023, 0.04546944797039032, 0.045838192105293274, -0.07546299695968628, 0.24598482251167297, -0.12655073404312134, 0.08292211592197418, -0.030441677197813988, 0.07199829071760178, -0.11880514025688171, -0.007064393721520901, -0.009402146562933922, 0.04716072976589203, -0.00747350137680769, 0.07910306751728058, 0.0704750195145607, 0.002017310820519924, 0.049723800271749496, 0.050456613302230835, 0.10276243090629578, -0.03430546820163727, 0.032021746039390564, -0.05992002412676811, 0.06488889455795288, -0.16272027790546417, 0.04524904489517212, 0.2576180100440979, -0.06669246405363083, -0.17735999822616577, -0.1291407346725464, -0.016053220257163048, 0.11311083287000656, 0.042463768273591995, 0.04932435601949692, -0.039340391755104065, -0.09719616919755936, 0.026306703686714172, 0.050181932747364044, 0.061712514609098434, -0.061731111258268356, -0.024822944775223732, -0.07059478759765625, -0.15914522111415863, -0.10916081070899963, 0.12906412780284882, 0.08434873819351196, -9.986200666389777e-08, 0.11228027939796448, -0.08055771142244339, -0.012302127666771412, -0.05726887285709381, 0.13511906564235687, -0.08576591312885284, -0.04605425149202347, -0.009355546906590462, 0.060202136635780334, 0.07231761515140533, 0.05119060352444649, 0.029867390170693398, -0.17400045692920685, 0.044078029692173004, -0.0468326061964035, 0.021791644394397736, -0.13068386912345886, -0.009371085092425346, 0.009392103180289268, -0.13415595889091492, -0.08317972719669342, 0.02192007750272751, -0.0015281280502676964, -0.14628121256828308, 0.0230867937207222, -0.07665213942527771, -0.10242671519517899, 0.03787694126367569, -0.013640652410686016, -0.04061406850814819, 0.11394629627466202, -0.013034520670771599, 0.05350540205836296, 0.09669730067253113, -0.15253113210201263, -0.07329893857240677, -0.021184012293815613, -0.0223306342959404, 0.09350107610225677, 0.037987399846315384, -0.08465416729450226, -0.044724613428115845, -0.031413689255714417, 0.06100885942578316, -0.07877597957849503, -0.09735940396785736, -0.08879395574331284, -0.0054106395691633224, 0.009650428779423237, -0.2817259430885315, 0.10220542550086975, -0.07337146997451782, 0.01825530081987381, -0.01322772167623043, 0.10395340621471405, 0.03282686695456505, -0.1859380304813385, 0.005831258837133646, -0.13600298762321472, -0.12005948275327682, -0.021866487339138985, -0.2240493893623352, 0.05782580375671387, 0.14372768998146057], "changes": {"1wk": 0.8288271792300113, "1mo": -8.180181829778997}}, {"text": "Cytokinetics Announces Sanofi Acquired Rights to Develop and Commercialize Aficamten in Greater China Cytokinetics, Incorporated Fri, Dec 20, 2024, 8:00 AM 7 min read In This Article: CYTK -2.01% Cytokinetics, Incorporated SOUTH SAN FRANCISCO, Calif., Dec. 20, 2024 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated\u00a0(Nasdaq: CYTK) today announced that Sanofi will acquire exclusive rights to develop and commercialize aficamten from Corxel Pharmaceuticals (CORXEL) for the treatment of patients with obstructive and non-obstructive hypertrophic cardiomyopathy (HCM) in Greater China. Aficamten is a next-in-class cardiac myosin inhibitor for the potential treatment of patients with HCM. In 2020, CORXEL (formerly Ji Xing) acquired the rights to develop and commercialize aficamten in Greater China (including the Chinese mainland, Hong Kong SAR and Macau SAR, and Taiwan) from Cytokinetics in accordance with Cytokinetics\u2019 global registration programs. Aficamten received Breakthrough Therapy Designation for the treatment of symptomatic obstructive hypertrophic cardiomyopathy (oHCM) from The Center for Drug Evaluation of the China National Medical Products Administration which recently accepted the New Drug Application for aficamten tablets for\u00a0the treatment of oHCM for Priority Review. Sanofi will now acquire CORXEL\u2019s rights relating to aficamten in Greater China for an undisclosed amount. Cytokinetics\u00a0remains eligible to receive up to $150 million in development and commercial milestone payments from Sanofi as well as royalties in the low-to-high teens on future sales of aficamten in Greater China. Cytokinetics is now also eligible to receive additional undisclosed payments in connection with the execution of the agreement between Sanofi and CORXEL. \u201cWe have enjoyed a productive collaboration with CORXEL and appreciate all they have done to advance aficamten in Greater China,\u201d said Robert I. Blum, Cytokinetics\u2019 President and CEO. \u201cWe now look forward to partnering with Sanofi with shared objective to leverage their cardiovascular expertise and expand the reach of aficamten to patients suffering from HCM throughout Greater China.\u201d About Aficamten Aficamten is an investigational selective, small molecule cardiac myosin inhibitor discovered following an extensive chemical optimization program that was conducted with careful attention to therapeutic index and pharmacokinetic properties and as may translate into next-in-class potential in clinical development. Aficamten was designed to reduce the number of active actin-myosin cross bridges during each cardiac cycle and consequently suppress the myocardial hypercontractility that is associated with hypertrophic cardiomyopathy (HCM). In preclinical models, aficamten reduced myocardial contractility by binding directly to cardiac myosin at a distinct and selective allosteric binding site, thereby preventing myosin from entering a force producing state. Story Continues The development program for aficamten is assessing its potential as a treatment that improves exercise capacity and relieves symptoms in patients with HCM as well as its potential long-term effects on cardiac structure and function . Aficamten was evaluated in SEQUOIA-HCM (Safety, Efficacy, and Quantitative Understanding of Obstruction Impact of Aficamten in HCM), a positive pivotal Phase 3 clinical trial in patients with symptomatic obstructive hypertrophic cardiomyopathy (HCM). Aficamten received Breakthrough Therapy Designation for the treatment of symptomatic obstructive HCM from the U.S. Food & Drug Administration (FDA). The FDA recently accepted the company\u2019s New Drug Application (NDA) for aficamten, for the treatment of obstructive hypertrophic cardiomyopathy and assigned the NDA a Prescription Drug User Fee Act target action date of\u00a0September 26, 2025. Cytokinetics also recently submitted a Marketing Authorization Application for aficamten to the European Medicines Agency. Aficamten is also currently being evaluated in MAPLE-HCM, a Phase 3 clinical trial of aficamten as monotherapy compared to metoprolol as monotherapy in patients with obstructive HCM, ACACIA-HCM, a Phase 3 clinical trial of aficamten in patients with non-obstructive HCM, and CEDAR-HCM, a clinical trial of aficamten in a pediatric population with obstructive HCM, and FOREST-HCM, an open-label extension clinical study of aficamten in patients with HCM. About Hypertrophic Cardiomyopathy Hypertrophic cardiomyopathy (HCM) is a disease in which the heart muscle (myocardium) becomes abnormally thick (hypertrophied). The thickening of cardiac muscle leads to the inside of the left ventricle becoming smaller and stiffer, and thus the ventricle becomes less able to relax and fill with blood. This ultimately limits the heart\u2019s pumping function, resulting in reduced exercise capacity and symptoms including chest pain, dizziness, shortness of breath, or fainting during physical activity. HCM is the most common monogenic inherited cardiovascular disorder, with approximately 280,000 patients diagnosed, however, there are an estimated 400,000-800,000 additional patients who remain undiagnosed in the U.S. 1,2,3 Two-thirds of patients with HCM have obstructive HCM, in which the thickening of the cardiac muscle leads to left ventricular outflow tract obstruction, while one-third have non-obstructive HCM, in which blood flow isn\u2019t impacted, but the heart muscle is still thickened. People with HCM are at high risk of also developing cardiovascular complications including atrial fibrillation, stroke and mitral valve disease. 4 People with HCM are at risk for potentially fatal ventricular arrhythmias and it is one of the leading causes of sudden cardiac death in younger people or athletes. 5 A subset of patients with HCM are at high risk of progressive disease leading to dilated cardiomyopathy and heart failure necessitating cardiac transplantation. About Cytokinetics Cytokinetics is a late-stage, specialty cardiovascular biopharmaceutical company focused on discovering, developing and commercializing muscle biology-directed drug candidates as potential treatments for debilitating diseases in which cardiac muscle performance is compromised. As a leader in muscle biology and the mechanics of muscle performance, the company is developing small molecule drug candidates specifically engineered to impact myocardial muscle function and contractility. Cytokinetics is readying for the potential commercialization of aficamten, a next-in-class cardiac myosin inhibitor following positive results from SEQUOIA-HCM, the pivotal Phase 3 clinical trial in patients with obstructive hypertrophic cardiomyopathy (HCM). Aficamten is also being evaluated in additional clinical trials enrolling patients with obstructive and non-obstructive HCM. Cytokinetics is also developing omecamtiv mecarbil , a cardiac myosin activator, in patients with heart failure with severely reduced ejection fraction (HFrEF), CK-586, a cardiac myosin inhibitor with a mechanism of action distinct from aficamten, for the potential treatment of heart failure with preserved ejection fraction (HFpEF) and CK-089, a fast skeletal muscle troponin activator with potential therapeutic application to a specific type of muscular dystrophy and other conditions of impaired skeletal muscle function. For additional information about Cytokinetics, visit www.cytokinetics.com and follow us on X , LinkedIn , Facebook and YouTube . Forward-Looking Statements This press release contains forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995 (the \u201cAct\u201d).\u00a0Cytokinetics\u00a0disclaims any intent or obligation to update these forward-looking statements and claims the protection of the Act's Safe Harbor for forward-looking statements. Such statements are based on management\u2019s current expectations, but actual results may differ materially due to various risks and uncertainties, including, but not limited to, potential difficulties or delays in the development, testing, regulatory approvals for trial commencement, progression or product sale or manufacturing, or production of Cytokinetics\u2019 drug candidates that could slow or prevent clinical development or product approval; patient enrollment for or conduct of clinical trials may be difficult or delayed; Cytokinetics\u2019 drug candidates may have adverse side effects or inadequate therapeutic efficacy; the FDA or foreign regulatory agencies may delay or limit Cytokinetics\u2019 ability to conduct clinical trials;\u00a0Cytokinetics\u00a0may be unable to obtain or maintain patent or trade secret protection for its intellectual property; standards of care may change, rendering Cytokinetics\u2019 drug candidates obsolete; competitive products or alternative therapies may be developed by others for the treatment of indications Cytokinetics\u2019 drug candidates and potential drug candidates may target; and risks and uncertainties relating to the timing and receipt of payments from its partners. For further information regarding these and other risks related to Cytokinetics\u2019 business, investors should consult Cytokinetics\u2019 filings with the\u00a0Securities and Exchange Commission, particularly under the caption \u201cRisk Factors\u201d in Cytokinetics\u2019 latest Quarterly Report on Form 10-Q. CYTOKINETICS \u00ae and the C-shaped logo are registered trademarks of\u00a0Cytokinetics\u00a0in the\u00a0U.S.\u00a0and certain other countries. References CVrg: Heart Failure 2020-2029, p 44; Maron et al. 2013 DOI: 10.1016/S0140-6736(12)60397-3; Maron et al 2018 10.1056/NEJMra1710575 Symphony Health 2016-2021 Patient Claims Data DoF; Maron MS, Hellawell JL, Lucove JC, Farzaneh-Far R, Olivotto I. Occurrence of Clinically Diagnosed Hypertrophic Cardiomyopathy in the United States. Am J Cardiol. 2016; 15;117(10):1651-1654. Gersh, B.J., Maron, B.J., Bonow, R.O., Dearani, J.A., Fifer, M.A., Link, M.S., et al. 2011 ACCF/AHA guidelines for the diagnosis and treatment of hypertrophic cardiomyopathy. A report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. Journal of the American College of Cardiology and Circulation, 58, e212-260. Hong Y, Su WW, Li X. Risk factors of sudden cardiac death in hypertrophic cardiomyopathy. Current Opinion in Cardiology. 2022 Jan 1;37(1):15-21 Contact: Cytokinetics Diane Weiser Senior Vice President, Corporate Affairs (415) 290-7757 View Comments Terms and Privacy Policy Privacy Dashboard Recommended Stories", "symbol": "CYTK", "date": "2024-12-20T05:00:00+00:00", "sentiment": {"score": 0.6951589756645262, "confidence": 0.7029334902763367, "probabilities": {"positive": 0.7029334902763367, "negative": 0.007774514611810446, "neutral": 0.28929194808006287}}, "embedding": [-0.050431810319423676, -0.061718329787254333, 0.009586259722709656, -0.10419169068336487, 0.06390254199504852, -0.03975546732544899, 0.025771064683794975, 0.242355078458786, 0.07901321351528168, -0.051244139671325684, 0.03047494776546955, -0.0746791660785675, 0.07495605945587158, 0.16000914573669434, 0.017849041149020195, -0.010741998441517353, 0.11020451784133911, 0.04171889275312424, -0.06533525884151459, 0.0939214751124382, -0.03636512905359268, -0.033247385174036026, 0.018782146275043488, 0.01909080147743225, -0.14909100532531738, -0.030388813465833664, -0.15232616662979126, -0.041425593197345734, -0.02724616229534149, -0.011593271046876907, 0.012707218527793884, 0.23656760156154633, 0.17466533184051514, 0.022980548441410065, 0.05417221784591675, -0.008179422467947006, 0.012173138558864594, -0.16890749335289001, -0.21263346076011658, 0.007092582061886787, 0.04657616838812828, -0.04145187884569168, -0.015139807015657425, -0.04925934225320816, 0.08663177490234375, -0.0744757354259491, 0.010148824192583561, -0.021497022360563278, -0.0731004923582077, 0.21923726797103882, -0.12754042446613312, -0.04415450990200043, -0.009329838678240776, 0.11452502012252808, -0.09199413657188416, 0.06190226227045059, -0.16636887192726135, -0.052052296698093414, -0.001900950213894248, -0.04152901470661163, -0.08622527122497559, 0.003447894938290119, 0.040935397148132324, 0.036560509353876114, -0.0017776531167328358, 0.0956118255853653, 0.007272473070770502, 0.04070540890097618, 0.1319316327571869, -0.07796642184257507, 0.12652897834777832, -0.13364186882972717, 0.020615283399820328, 0.21550168097019196, -0.14271239936351776, 0.12109158933162689, 0.11135049164295197, -0.0031381184235215187, 0.08198048919439316, -0.18082791566848755, 0.09474307298660278, 0.16382084786891937, 0.16675624251365662, -0.045377105474472046, 0.05747314542531967, 0.09207233786582947, 0.03464241325855255, 0.16996321082115173, 0.07206660509109497, 0.05247509479522705, 0.16235259175300598, 0.10621543973684311, 0.003956343047320843, 0.0664428174495697, 0.03521190956234932, -0.16351419687271118, 0.07487460970878601, 0.05684386193752289, -0.045035798102617264, -0.04508534073829651, 0.07305504381656647, -0.0179551113396883, -0.11357854306697845, -0.05641499161720276, 0.05036377161741257, -0.08638255298137665, 0.038745198398828506, -0.012397205457091331, 0.15663114190101624, 0.010330150835216045, -0.1192626953125, 0.02086927741765976, -0.14061063528060913, -0.18090619146823883, -0.024127423763275146, 0.3328655958175659, -0.02962512895464897, 0.007855089381337166, 0.18527185916900635, -0.02373521775007248, 0.10798954963684082, -0.1414032131433487, -0.14152660965919495, -0.1558282971382141, 0.020655393600463867, 0.061236679553985596, -0.2195206880569458, 1.265644628891581e-32, -0.032926879823207855, 0.14113791286945343, 0.10803717374801636, 0.07231701910495758, -0.01674741506576538, -0.036393068730831146, 0.0979142040014267, 0.041306689381599426, -0.12329968810081482, -0.18631964921951294, -0.19934126734733582, 0.0355323851108551, -0.02571279928088188, 0.08727197349071503, -0.017941448837518692, -0.2004103660583496, -0.11609672755002975, -0.05652192234992981, 0.04302896559238434, 0.03181719779968262, 0.13353508710861206, 0.00036606891080737114, -0.05921409651637077, 0.0319075845181942, -0.0822007954120636, 0.09055701643228531, -0.029683006927371025, 0.07838018238544464, 0.16436472535133362, 0.02416367642581463, -0.06535714119672775, -0.03883006423711777, 0.08642290532588959, -0.07959587872028351, -0.03494228422641754, -0.007139042019844055, -0.10798510909080505, -0.11509396135807037, -0.07149353623390198, 0.08497338742017746, -0.010127986781299114, 0.042274538427591324, -0.1793796271085739, -0.10856714844703674, 0.2163030207157135, -0.17613351345062256, -0.17472350597381592, -0.11464371532201767, -0.07746253907680511, -0.06912107765674591, 0.007465851493179798, 0.07892546057701111, -0.1116797924041748, -0.01011448260396719, 0.013156503438949585, 0.04352342337369919, -0.13072046637535095, -0.050217874348163605, -0.03877630457282066, 0.041836775839328766, -0.02077566459774971, -0.020823359489440918, 0.03525285795331001, 0.17641861736774445, -0.08134406805038452, 0.10672284662723541, -0.016082245856523514, -0.13644888997077942, -0.249341681599617, 0.08144651353359222, -0.04796181991696358, -0.03391251713037491, 0.09870558977127075, -0.04197590798139572, 0.16057756543159485, 0.00813961774110794, -0.0741017758846283, 0.09297209978103638, -0.05233611539006233, -0.11404410004615784, -0.12438899278640747, 0.07377362251281738, -0.0020881579257547855, 0.15575584769248962, -0.0062891822308301926, -0.10187079012393951, 0.0818416178226471, 0.09444944560527802, -0.18665385246276855, -0.043963219970464706, 0.11146775633096695, -0.06334191560745239, 0.06905611604452133, 0.06513545662164688, -0.14114665985107422, -1.2118767826010004e-32, -0.07070602476596832, 0.04211345314979553, -0.006656171754002571, -0.15017768740653992, -0.14270438253879547, 0.11731919646263123, 0.10136507451534271, -0.08679813891649246, 0.15805241465568542, -0.12468250840902328, 0.044727616012096405, -0.010954420082271099, 0.011420255526900291, 0.060741931200027466, -0.16569291055202484, 0.16247312724590302, 0.027373194694519043, 0.0334349200129509, -0.17269673943519592, 0.10539402067661285, 0.06593453884124756, 0.03297635167837143, 0.06427890807390213, 0.12871702015399933, 0.011842326261103153, 0.1357133984565735, 0.21076664328575134, 0.013501154258847237, 0.0704084187746048, -0.1444312334060669, -0.04679079353809357, -0.06788091361522675, -0.29836946725845337, -0.023013323545455933, -0.060345351696014404, -0.02061675302684307, -0.0708177238702774, -0.04380408674478531, -0.05294130742549896, -0.10211394727230072, -0.10552112013101578, -0.1063639223575592, -0.01780160889029503, 0.062333472073078156, -0.05084025114774704, 0.045946069061756134, 0.11301945149898529, -0.16036371886730194, 0.13075196743011475, 0.12215513736009598, -0.10428158193826675, -0.07066255807876587, 0.0430796854197979, 0.06249285861849785, -0.18975195288658142, -0.010550851933658123, 0.08914043009281158, 0.05694921314716339, -0.06597426533699036, -0.10208640992641449, 0.06805939972400665, 0.10234339535236359, 0.10286648571491241, -0.03550741821527481, 0.14622732996940613, 0.15399743616580963, 0.2852835953235626, 0.08057758212089539, 0.13296949863433838, -0.17084290087223053, 0.044062357395887375, 0.07549309730529785, -0.12399482727050781, 0.07826940715312958, 0.004821284674108028, 0.12373422086238861, -0.040264349430799484, -0.15967461466789246, -0.23538821935653687, -0.1400444209575653, 0.03954397141933441, -0.165328711271286, 0.05095546692609787, -0.036428939551115036, 0.005257292650640011, -0.01270976196974516, 0.07364298403263092, -0.11398377269506454, 0.08359523117542267, 0.041084807366132736, -0.12862542271614075, -0.03673766925930977, -0.07747548818588257, 0.051836028695106506, -0.01021479070186615, -1.0099256542162038e-07, -0.019907178357243538, -0.17618891596794128, -0.21393947303295135, -0.09295159578323364, -0.1062949150800705, -0.018831351771950722, -0.04635262116789818, -0.020306304097175598, 0.05326845496892929, 0.050292178988456726, 0.04062913358211517, 0.1741529405117035, -0.03747134283185005, -0.06751318275928497, -0.060241006314754486, -0.08591362833976746, -0.049965403974056244, -0.01116475835442543, 0.007910597138106823, 0.0001650883350521326, -0.14941805601119995, 0.07824121415615082, 0.06020722538232803, -0.04472982510924339, 0.044436123222112656, -0.048007287085056305, 0.061460405588150024, 0.11381193995475769, 0.10788211971521378, -0.010128842666745186, 0.03137354925274849, 0.052609965205192566, 0.10267093777656555, 0.1445339322090149, -0.08165837824344635, -0.14732006192207336, 0.0047816080041229725, 0.029990965500473976, -0.010712374933063984, 0.09651024639606476, 0.0395447239279747, -0.02647482231259346, -0.02153000980615616, 0.0405692532658577, 0.06144269183278084, -0.2182413637638092, -0.011175144463777542, -0.12368634343147278, 0.1795041859149933, -0.03532981500029564, 0.03468898683786392, 0.08709758520126343, -0.00405007554218173, -0.03250688314437866, -0.06249336153268814, 0.10727007687091827, -0.09856724739074707, -0.022602980956435204, 0.06861233711242676, 0.05978929251432419, -0.09378992766141891, -0.1652669608592987, 0.14941547811031342, 0.05067907273769379], "changes": {"1wk": -0.6752568519949728, "1mo": -6.404741808528732}}]